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DISSECTING THE ROLES OF TRIM24 IN REGULATION OF HEPATIC LIPID 
 
METABOLISM AND INFLAMMATION 
 
Lindsey Cauthen Minter, B.S., B.A. 
 
Advisory Professor: Michelle C. Barton, Ph.D.  
 
      In this dissertation, I report the characterization of a new mouse model that 
recapitulates development of hepatocellular carcinoma (HCC) following 
spontaneous hepatic lipid accumulation, inflammation, and damage of liver 
tissue, due to complete loss of Trim24 expression. In human HCC and other 
cancers, TRIM24 expression is aberrantly high, while deletion of TRIM24 in the 
mouse has been shown to act as a liver specific tumor suppressor. The 
hypothesis tested here was that TRIM24, the E3 ubiquitin ligase of p53, regulates 
genes that impact hepatic lipid inflammation and metabolism. I further dissected 
whether TRIM24 regulates immune cell populations that are commonly 
misregulated in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic 
steatohepatitis (NASH). In the first part of my dissertation, I establish through 
global gene expression, chromatin enrichment, biochemical, and 
immunohistochemical analyses that TRIM24 represses hepatic lipid 
accumulation, inflammation, and fibrosis and damage in the murine liver. In the 
second part of my thesis, I show that loss of Trim24 leads to increased hepatic 
macrophage populations and implicates crosstalk with the hematopoietic niche in 
the bone marrow. Intersections of RNA-seq and TRIM24 ChIP-seq datasets 
 ix 
yielded novel gene targets of TRIM24 in mouse liver. Furthermore, I show that 
TRIM24 is enriched at promoters of genes involved in oxidative stress control, 
inflammation, and glucose metabolism, all processes that are misregulated in 
NAFLD and NASH progression. Further, biochemical analyses showed increased 
glucose metabolism and insulin sensitivity coupled with a decrease in visceral 
adipose tissue upon loss of Trim24. These findings recapitulate those found in 
human studies of lean (non-obese) individuals with NAFLD. Thus, this 
dissertation shows that complete loss of Trim24 offers a model of nonalcoholic 
fatty liver disease, steatosis, fibrosis and development of hepatocellular 
carcinoma in the absence of high-fat diet or obesity. In addition, this model 
offered an opportunity to identify specific immune cell populations, gene targets 
and metabolic pathways that are regulated by TRIM24.   
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BACKGROUND AND RATIONALE FOR THE STUDY 
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1.1. The liver: a fine tuned balance between metabolism and immunity   
 
      The liver, the largest solid organ in the body, houses an incredibly complex 
system that metabolizes carbohydrates, protein, lipids and glucose, and produces 
bile acids to aid in the breakdown of food for usable energy that is utilized by 
multiple organs in the body. In addition to these metabolic processes, the liver 
serves as an immune organ by filtering toxins from the blood and protects the body 
[1]. Patterns of signaling, import, and export are kept in perfect balance through 
these liver processes.  Blood, containing hydrophilic nutrients from the intestine, 
enters the liver via the hepatic portal vein, these nutrients are metabolized, and then 
distributed to the rest of the body through the central vein [2]. Oxygenated blood 
enters the liver through the hepatic artery, which resides within the portal triad (bile 
duct, portal vein, hepatic artery). Based upon the boundaries outlined by the hepatic 
vasculature, the liver is divided into functional units that are composed of lobules 
that surround a central vein and the borders are composed of portal tracts [3]. K. 
Jungermann proposed the use of “zones, ” after discovering that hepatocytes have 
specialized functions based upon their proximity to different vasculature [4] [5] .        
There are 3 zones in each lobule (Diagram 1): 1) periportal,  2) midportal, and  3) 
pericentral, with portal zones (1,2) being closest to the periphery and the central 
zone (3) being nearest to the central vein. Blood flows from the portal vein and 
hepatic artery to the central vein (zones 3 to 1), while bile flows in the opposite 
direction (zones 1 to 3). The various functions of the liver are carried out by either 
parenchymal (hepatocytes) or non-parenchymal cells. The bulk of the liver is 
composed of hepatocytes (parenchyma) that extend along the hepatic plate (from 
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the portal triad to the vein), and whose primary function is to maintain metabolic 
homeostasis and to proliferate upon damage [1] (Diagram 1). Lipogenesis occurs in 
zone 1, while fatty acid degradation occurs in zone 2 [2]. Additional zonation of 
metabolic functions applies to ammonia and glutamine metabolism/transport, 
glucose/energy metabolism, and drug metabolism (Diagram 1). Synthesis of serum 
proteins and albumin are common metabolic processes performed by all 
hepatocytes that occur across zones [2]. 
 
      While most of the liver is composed of parenchymal cells, non-parenchymal cells 
also play a critical role in homeostasis by moderating hepatic immune response. 
Non-parenchymal cells can be sub-divided into: stellate, endothelial, and Kupffer 
cells (Diagram 2). Stellate cells are found in the Space of Disse, between hepatic 
endothelial and epithelial cells and represent approximately 5-8% of the cells in the 
liver. While their main function is to store lipid droplets, stellate cells also store a 
large amount of vitamin A [6].  Upon liver damage, activated stellate cells respond to 
immune signals at the source of the injury and produce extracellular matrix (ECM) to 
form a scar, which can lead to fibrosis [7]. Fibrosis is defined as excessive 
deposition of the extracellular matrix (ECM), eventually leading to destruction and 
impairment of organ structure and organ function that can lead to various liver 
disease such as HCC [8]. Activated hepatic stellate cells and fibroblasts cause an 
increase in proliferation, fibrogenesis, contractility, matrix degradation, chemotaxis 
and cytokine release [9]. While still under debate, it is thought that activated 
fibroblasts arise from hepatic stellate cells [10].  Recent studies have shown that 
hepatic stellate cells are stimulated by platelet-derived growth factor (PDGF-)-BB 
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and transforming growth factor (TGF)-1, and/or epithelial growth factor (EGF) led to 
an increase in both migratory capacity and matrix metalloproteinase (MMP) 2-activity 
[9]. Further studies establish a connection between hepatic fibroblasts and 
hepatocytes in progression of fibrosis. In the past, direct contribution of hepatocytes 
to liver fibrosis was thought be relatively minor, studies by Kalluri et al. (2007) 
demonstrated that TGF-β1, a pro-fibrotic growth factor, induces adult mouse 
hepatocytes to undergo morphological and functional changes that are hallmarks of 
epithelial to mesenchymal transition (EMT) and is inhibited by bone morphogenic 
protein-7 (BMP7) [10]. Additionally hepatocytes that undergo EMT contribute to 
increase populations of activated fibroblasts in CCL4-induced liver fibrosis, thus 
linking hepatocytes, stellate cells, and fibroblasts to progression of hepatic fibrosis. 
In addition to functions in fibrotic progression, stellate cells secrete cytokines and 
growth factors to aid in regeneration of hepatic epithelial cells, such as 
cholangiocytes (bile cells) and hepatocytes [10].  Other non-parenchymal cells also 
serve important functions in the liver. Endothelial cells reside in the sinusoid of the 
liver and arise from hepatoblast cells during embryonic development [11]. Oval cells 
are intrahepatic endothelial “stem cells” that are thought to interact with hepatocytes 
to aid in liver regeneration following liver damage or surgical resection. Kupffer cells 
(KC,macrophages), which reside in the sinusoids, are the first macrophages that 
come into contact with foreign bacteria or material via the blood from the intestine 
circulated through the portal vein [12]. Hepatic KCs constitute 80-90% of the 
macrophages present in the body and, as suggested, are members of the immediate 
(innate) immune response to foreign, potentially dangerous material [13].  It is 
 5 
thought that KCs arise from circulating monocytes that migrate from the bone 
marrow to the blood and transform to macrophages that then migrate to different 
organs such as the liver [14]. Normally, KCs compose about 35% of the non-
parenchymal cells in the liver of adult mice. KCs in the liver increase in cell density 
and are activated following damage or interactions with foreign material (i.e. 
bacteria) and are associated with acute hepatitis (human) or chemical injury 
(rodents) [15, 16].   
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Diagram 1. Zonal anatomy and functions of the liver. A) The liver lobule with cut 
away view to show architecture and arrangement. B) View of the portal triad 
organization composed of bilary duct, portal vein and hepatic artery. Blood flows 
from the portal triad into the centrilobular vein, while bile, oxygen, glucagon and 
insulin flow/produced in the opposite direction. C) Zones of the liver and their related 
functions in metabolism. (Reprinted with permission from Monga, P.S. Ed. Springer 
Press. Molecular Pathogenesis of Liver Diseases. 2011) [2] 
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ammonia detoxification, and the metabolism of drugs and 
xenobiotics (Fig. 2.1). Other zonated processes include: lipid 
metabolism, with lipogenesis occurring perivenously and 
fatty-acid degradation periportally [2, 3]; Cyp7a1-mediated 
synthesis of bile acids derived from cholesterol, showing 
clear PV zonation [3, 4]; and the metabolism of several 
amino acids [3], the catabolism of histidine and serine being 
mostly periportal, and glutamine synthesis (associated with 
ammonia detoxification) being perivenous.
Glucose metabolism provides a historical example of com-
partmentalized metabolism. Jungermann showed that gluco-
neogenesis was mostly periportal, with gradual accumulation 
of phosphoenolpyruvate carboxykinase (Pepck1) in this 
region, whereas glycolysis was mostly perivenous (glucoki-
nase and pyruvate kinase L, but not their respective RNAs, 
being perivenous) [1]. However, the concentration gradients 
of these enzymes differ depending on nutritional status, sug-
gesting that nutrients and hormones play a role in the zona-
tion of these components of glucose metabolism. Please see 
Chap. 8 for a more detailed review of carbohydrate metabo-
lism in the liver.
Ammonia detoxification is subject to zonation and has been 
extensively studied by groups led by Gebhardt, Lamers, and 
Haussinger [5–7]. One of the major roles of the liver is the 
removal of harmful ammonia arriving from the intestine via 
the portal vein (Fig. 2.2). Ammonia is first metabolized by 
PP hepatocytes, through a high-capacity/low-affinity  system, 
to generate urea. This involves the enzymes carbamoyl-
phosphate synthetase (Cps1) and arginase 1 (Arg1). Residual 
ammonia is then converted to glutamine by perivenous hepa-
tocytes, through a low-capacity/high-affinity system involv-
ing the perivenous enzyme glutamine synthetase (Gs). 
Chapter 9 discusses protein metabolism.
Metabolism of drugs and xenobiotics also displays well 
defined zonation, occurring mostly in the PV area. The cyto-
chrome P450 system is responsible for the conversion of 
xenobiotics into excretable products. This involves monoox-
ygenation followed by conjugation with either glucuronic or 
sulfuric acid. Monooxygenation mainly occurs in the PV 
zone, with glucuronidation as the major conjugation reaction 
in these cells, whereas sulfation is the predominant conjuga-
tion reaction in PP cells [2]. Chapter 11 discusses detoxifica-
tion functi s of the liver.
Fig. 2.1 Structure and functions of the zonated liver lobule. (a) Three-
dimensional structure of the liver lobule. The liver lobule is centered 
around a branch of the centrilobular vein, limited at each end by the 
portal triad consisting of a branch of the portal vein, the hep tic artery, 
and a bile duct. The sinusoids and the vasculature are depicted in red 
(Hoehme et. al. [61]) (b) The liver cell plate, with blood circulation 
indicated in red. Bile is shown in green and circulates in the opposite 
direction to blood. The concentration of oxygen and hormones 
decreases along a continuous gradient from the PP area to the PV area. 
(c) Zonal functions. The proliferation of hepatocytes is achieved 
mostly by division of the mature hepatocytes themselves (circled 
arrow), which do not migrate along the portocentral axis, with prolif-
eration from oval cells observed only rarely (dotted circled arrow). 
The zonated metabolic systems include the ammonia detoxification 
system, glucose and energy metabolism, and xenobiotic metabolism. 
The proteins involved in each type of zonal metabolism are indicated. 
The proteins displaying zonation regulated at the posttranscriptional 
level are shown in italics. The PV positive Wnt targets are shown in 
orange, and the PP negative targets are shown in blue. These targets 
were identified by microarray analysis on PV and PP hepatocytes [3], 
and on ?(beta)-catenin-activated hepatocytes ([12] and unpublished 
data). Gk glucokinase; PkL  liver-specific pyruvate kinase; Sdh succi-
nate dehydrogenase; Idh3a isocitrate dehydrogenase 3a; Dlat dihydro-
lipoamide S-acetyltransferase; Gstm glutathione S-transferase mu; 
Sult5a1 sulfotransferase family 5A, member 1
	  
	  
 A. 
B. 
C. 
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Diagram 2. Cells of the liver. Each hepatic lobule contains a complex organization 
of hepatic cells composed mostly of hepatocytes (parenchyma) and stellate cells 
(non parenchyma) bordering the sinusoids that transfer bile and blood in and out of 
the liver, respectively. Non-parenchymal sinusoidal endothelial cells line the 
sinusoids and Kupffer cells reside within the sinusoids.  
(Modified from www.rutlandherald.typepad.com). 
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1.2. Transcription factors in the liver 
 
      The liver is responsible for a multitude of metabolic processes and efficiently 
converts food into usable energy for the body. Several key nuclear receptor 
transcription factors such as: PPAR (α, β, γ1, and γ2), HNF4 (α and γ), retinoid X-
receptor (RXR) α, and liver X receptor (LXR) (α and β) regulate fatty acid 
metabolism, which is one of the most utilized processes in the liver [17] (Diagram 3).       
Nonesterified fatty acids (NEFAs) bind to the ligand-binding domain of each of these 
nuclear receptors and function like hydrophobic hormones to control the function of 
the receptor. Dietary polyunsaturated fatty acids (PUFAs) function to suppress key 
transcription factors that control hepatic lipid metabolism and inflammation such as: 
SREBP-1, carbohydrate regulatory element-binding protein (ChREBP), max-like 
factor X (MLX), and nuclear factor κB (NFκB) [17]. The first transcription factors that 
are activated following liver resection or damage, along with NFκB, are Stat3 and 
AP-1 [18, 19] [20]. Additionally, gluconeogenesis in the liver is controlled by the 
forkhead box O1 (FoxO1) transcription factor and its coactivator, PGC1α [17]. Under 
normal conditions, these processes work in conjunction to effectively regulate both 
the metabolic and immune processes of the liver. However, upon misregulation of 
these processes, disease progression occurs. The presence of lipid peroxidation, 
which is the oxidative degradation of lipids, is indicative of oxidative stress [17]. 
These stress responses are linked to inflammatory responses that are controlled by 
transcription factors such as NFκB and are implicated in progression and 
pathogenesis of various diseases such as non-alcoholic fatty disease (NAFLD) [17].  
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Diagram 3. Hepatic Transcription factors and fatty acid metabolism.  Hepatic 
fatty acid metabolism overview. (Reprinted with permission from Annu. Rev. Nutr. 
2013. 33:249–69) [17]. 
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gene transcription. Our goal is to bring to-
gether up-to-date information on how fatty
acids control hepatic function through tran-
scriptional mechanisms. Our analysis exposes
gaps in our understanding of the molecular de-
tails of fatty acid control of several transcrip-
tion factors. Finally, we examine how fatty acid–
regulated transcription factors contribute to the
onset and progression of diet-induced nonal-
coholic fatty liver disease (NAFLD), a growing
health problem in Western societies.
FATTY ACID–REGULATED
HEPATIC TRANSCRIPTION
FACTORS
Fatty Acid–Regulated
Nuclear Receptors
Nonesterified fatty acids (NEFAs) bind to
the ligand-binding domain of several nuclear
receptors expressed in liver, including PPAR
(α, β, γ1, and γ2) (132), HNF4 (α and γ) (29,
129), retinoid X-receptor (RXR) α (69), and
liver X receptor (LXR) (α and β) (81). Fatty
acids are hydrophobic, and they function like
hydrophobic hormones (steroid and thyroid)
to control nuclear receptor function. Fatty acid
regulation of the PPAR family has been the
most extensively studied. PPARs heterodimer-
ize with RXRs and bind cis-regulatory elements
in promoters of responsive genes (38). All
PPAR subtypes bind saturated and unsaturated
fatty acids ranging in length from 16 to 20
carbons (C16−20), with in vitro binding affinities
ranging from Kd = 1 to 10 µM (132). Ligand
binding stimulates an exchange of coactivators
and corepressors on the chromatin-bound
receptors and the recruitment of additional
proteins involved in gene transcription, such as
ribonucleic acid (RNA) polymerase II (38, 96).
PPARα is the predominant PPAR subtype
in rodent liver, and it plays a major role in con-
trolling genes involved in fatty acid elongation,
desaturation, oxidation, and transport (52).
PPARα, however, is less active in human liver.
StudieswithPPARα-nullmice have established
that PPARα is required for PUFA induction of
• Phosphorylation
• Acetylation
• Ubiquitination
• Proteolysis
Fatty acid
Transcription
factor 
Gene 
Biological
response
Plasma
membrane
Protein mRNA 
Membrane
signaling
mechanisms
Fatty acid
metabolism
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Nucleus
Figure 1
Overview of fatty acid regulation of hepatic gene transcription.
genes encoding enzymes involved in fatty acid
oxidation, elongation, and desaturation, but it
is not required for PUFA suppression of en-
zymes involved in other fatty acid–regulated
metabolic pathways, such as glycolysis or DNL
(94, 126). Although PPARs are sensors of in-
tracellular fatty acids, studies with primary rat
hepatocytes suggest that PPARs respond dif-
ferently to various fatty acids. Challenging cells
with oleic acid (OA, 18:1, ω9) or eicosapen-
taenoic acid (EPA, 20:5, ω3) has different ef-
fects on PPARα activation or the induction of
PPARα target genes (85). Intracellular NEFAs
are considered to be amajor intracellular ligand
for PPARs, and NEFAs in cells are maintained
at very low levels, representing <0.1% of to-
tal cellular fatty acids. Challenging cells with a
fatty acid that is typically at very low abundance
in the liver, such as EPA, promotes a robust re-
sponse in PPARα target gene expression, e.g.,
cytochrome P450-4A (CYP4A) and cytosolic
fatty acyl thioesterase-1. In contrast, challeng-
ing cells with fatty acids that are highly abun-
dant in cells, e.g.,OA,has little effect onPPARα
activation or regulation of its target genes. In
addition, some fatty acids may not bind or
activate PPARs. Although EPA significantly
www.annualreviews.org • Fatty Acid–Regulated Transcription Factors in the Liver 251
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The progression of NAFLD has been connected with both misregulation of lipid 
metabolism, oxidative stress and damage in the liver and recruitment of Kupffer cells 
and leukocytes. The paracrine signaling from these cells releases cytokines such as 
interleukin 6 (IL-6) and tumor necrosis factor (TNF), which in turn cause progression 
of the disease in the surrounding parenchymal and stellate cells [17-19]. Chronic 
hepatic inflammation is known to be a causative factor in permanent hepatocyte 
damage, which in turn sets the stage for development of HCC. 
 
 
1.3. The two-hit theory in Non-alcoholic fatty liver disease (NAFLD) and Non-
alcoholic steatohepatitis (NASH).  
     In the disease progression spectrum from steatosis to steatohepatitis, a long- 
 
standing theory was proposed by Christopher Day and coined the  “two-hit theory”. 
This theory suggests that the “first hit” in the disease progression is the development 
of hepatic steatosis (lipid accumulation) [21]. If there are no other changes in the 
organ environment, genetic or otherwise, the disease usually does not progress. 
However, if a “second hit” is present, such as increased oxidative stress, DNA 
damage, or fibrosis, and the disease progresses to the more aggressive 
steatohepatitis [21]. Steatohepatitis is a condition that is defined by retention of lipids 
in the liver that causes a chronic inflammatory disorder, which left unchecked, 
progresses to cirrhosis. While the initial theory was proposed in cases of alcohol 
related disease progression, the same tenets have been cited in non-alcoholic fatty 
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).   
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1.4. NAFLD, NASH, HCC disease spectrum  
       NAFLD is now the most common liver disease in the Western world, however 
prevalence varies within different ethnic populations, genders, and spectrum of 
health [22]. NAFLD is defined by an excessive accumulation of triglycerides (TG) in 
the liver (steatosis) of individuals who do not consume excessive amounts of alcohol 
[23]. It is known to be the most common cause for liver damage (due to abnormal 
liver biochemistry and cirrhosis) and frequently causes the need for liver 
transplantation [24]. Histological standards dictate that over 5% of hepatocytes must 
possess steatosis to corroborate a diagnosis of NAFLD [25]. By definition, steatosis 
is the presence of vacuoles that contain lipid deposits in varying degrees of severity. 
These lipid-filled vacuoles are either distributed in small amounts throughout the 
cytoplasm (microvesicular steatosis) or completely engulf the cytoplasm and 
displace the nucleus (macrovesicular steatosis) [26]. There are two sub-types of 
NAFLD: (1) patients that present with solely steatosis and (2) the 10-20% with 
nonalcoholic steatohepatitis (NASH), a more aggressive disease, due to chronic 
inflammation and hepatocellular injury [27, 28].  
      NASH is further defined by liver-specific misregulation of cholesterol 
homeostasis, lipid accumulation, aberrant glucose metabolism, insulin resistance, 
and inflammation, which leads to a chronic state of metabolic imbalance [27, 28]. 
Histologically, NASH is defined by steatosis in hepatocytes and hepatocellular 
damage due to inflammation as evidenced by hepatic ballooning, Mallory bodies, 
infiltration of neutrophils, macrophages, and lymphocytes [26]. Additionally, 
megamitochondria and abnormal iron deposition are frequently present. Hepatic 
 12 
ballooning is most prevalent near areas of steatosis, while Mallory bodies are 
structures that arise due to eosinophilic infiltration.  While all of these conditions can 
occur in specific zones (1&3) of the liver, they are not restricted to these areas [3]. 
         NASH patients have a higher rate of cirrhosis, liver failure and hepatocellular 
carcinoma (HCC), compared to individuals with NAFLD [29]. While the processes 
causing progression from NAFLD to NASH are reversible, most patients have 
progressed to the irreversible state of cirrhosis or HCC by the time of diagnosis 
(Diagram 4).  
      Many patients present with hepatic steatosis but do not progress to chronic 
inflammation or fibrosis (NASH) [30]. However, there are 10-20% of patients who do 
progress from NAFLD to NASH [31]. Most studies have focused on either genetics 
or diet as the cause of NAFLD incidence and progression to NASH and more 
advanced disease. Activation of the oxidative stress response has been connected 
with inflammatory processes due to misregulated lipid metabolism [32]. Recent 
studies suggest that the reactive oxygen series (ROS), products of lipid peroxidation 
(lipotoxicity), and tumor necrosis factor-α (TNF-α) are responsible for the transition 
from steatosis to NASH [33]. Furthermore, progression of fibrosis has been shown to 
increase the risk of HCC 25-fold [34]. While poorly understood, it seems that these 
elements are instrumental in progression of NASH and setting the stage for HCC.  
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 Diagram 4: Morphological changes during NAFLD, NASH, and HCC 
progression.  A) Progressive disease begins with accumulation of simple steatosis 
due to TG accumulation in hepatocytes (NAFLD). NASH develops due to lipotoxicity 
associated with TG accumulation that causes inflammation, hepatocellular 
damage/apoptosis, and fibrosis (reversible processes). These processes are 
reversible, as the arrows illustrate. NASH commonly progresses to cirrhosis, and a 
higher risk of HCC development (non-reversible processes), which are irreversible 
processes. B) Microscopic sections representing the disease spectrum from normal 
liver, steatosis, NASH, and cirrhosis. Masson’s trichrome was used to stain collagen 
fibers (blue).  PT (portal triad=hepatic artery, bile duct, portal vein), CV (Central 
Vein).    Modified from Science, 2011: Vol. 332 no. 6037 pp. 1519-1523. Reprinted 
with permission from AAAS [29]. 
  
 
also cause hepatic steatosis (12). Themajor export
pathway for hepatic TGs is secretion into the
blood as VLDL (Fig. 2). Mutations in the struc-
tural protein of VLDL [apolipoprotein (apo)B] or
in the protein that adds TG to the nascent lipo-
protein particle in the endoplasmic reticulum (ER)
(microsomal TG transfer protein, MTTP) are ad-
ditional causes of hepatic steatosis. Individuals het-
erozygous for inactivating mutations in APOB
produce fewer VLDL particles and have a three-
fold increase in hepatic TG relative to healthy
individuals (15).
Whereas single-gene mutations cause rare
forms of severe steatosis, the increased preva-
lence of NAFLD in the general population over
the past 30 years is due to changes in the quantity
and composition of food (Fig. 2). The cardinal
role of obesity in the development of hepatic ste-
atosis is evident from cross-sectional correlations.
For example, in the Dallas Heart Study, a multi-
ethnic population-based sample that included
more than 2000 individuals from Dallas, Texas,
hepatic steatosis is uncommon among lean indi-
viduals [9% in individuals with body mass in-
dex (BMI) < 25 kg/m2] and highly prevalent
among the severely obese (51% in individuals
with BMI > 35 kg/m2) (16). Food composition
also influences hepatic fat deposition. Carbohy-
drates in general and fructose in particular play
important roles. Fructose consumption routes
dietary carbons directly to the liver in a form that
is primed to enter biosynthetic pathways, includ-
ing de novo lipogenesis. Unlike glucose, circu-
lating fructose is taken up almost entirely by liver
(17). Because fructose is phosphorylated at car-
bon 1 rather than carbon 6, it cannot be used to
A
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Hepatocellular
carcinoma
Normal
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NASH
Steatosis
Fig. 1. The disease spectrum of nonalcoholic fatty liver disease. (A) Schematic
of progression of NAFLD. The accumulation of TG within lipid droplets in hepa-
tocytes causes steatosis. Steatosis associated with inflammation, cell death, and
fibrosis is referred to as NASH, which can progress to cirrhosis. Individuals with
cirrhosis have an increased risk of hepatocellular carcinoma. (B) Histological sec-
tions illustrating normal liver, steatosis, NASH, and cirrhosis. Collagen fibers are
stained blue with Masson’s trichrome stain. The portal triad (PT), which consists of
the hepatic artery, portal vein, and bile duct, and the central vein (CV) are shown.
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      In order to better understand the pathways and possible mechanisms underlying 
disease progression, several mouse models have been created to study NAFLD and 
NASH (Table 1). Various methods have been used to recapitulate disease 
progression in the mouse model such as genetic, nutritional, chemically induced 
damage, and a combination of these factors. The goal of mouse models is to reflect 
the elements of human disease: histologically, biochemically, and metabolically. 
Thus, an effort has been made to create models that possess the hallmarks of 
NAFLD and NASH, such as metabolic syndrome, obesity, insulin resistance, chronic 
inflammation, hepatocellular damage, and eventual progression to HCC. Genetic 
models have focused mainly on altering expression of transcription factors 
connected to metabolism and inflammatory processes in the liver (Table 1). 
Nutritional models typically employ the high fat (Western), methionine and choline 
deficient, cholesterol and cholate or fructose diet to replicate the metabolic 
syndrome, obesity, histology, and progression of human disease. In damage- 
induced models, ethanol or CCL4 are typically administered, often along with altered 
diet. While many models have presented elements of the disease, none have 
completely replicated the entire spectrum of the human disease.  
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Table 1: Mouse models of NAFLD/NASH. Mouse models are divided into 
genetically modified (1-8) and diet induced (9-13). Resulting phenotype with relation 
to disease spectrum is shown in the table. Modified from: Riordan, JD, et al, Mamm 
Genome. 2014 [35]. 
 
 
 
 
 
degeneration. This phenomenon is often caused by cyto-
skeletal disruptions, which can be identified by the loss of
keratins 8 and 18, as detected by immunostaining (Lackner
et al. 2008). Dense, eosinophilic structures made up of
compacted cytoskeletal keratins called Mallory–Denk
bodies are also common in cells undergoing ballooning
degeneration.
In addition to histological evidence, liver injury may be
indicated by the presence of elevated levels of liver
enzymes alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) in the blood. However, liver
enzymes are not always increased in NASH, and they may
be increased in its absence. Therefore, histological analysis
must be performed to establish a definitive diagnosis of
NASH (Mofrad et al. 2003; Sorrentino et al. 2004).
Inflammatory infiltration, which can be observed on an
H&E stained section, is mostly lymphocytic. The presence
of hepatic fibrosis is not required for a NASH diagnosis,
but the two conditions frequently occur together. Charac-
terized by the accumulation of excess extracellular matrix
(ECM) and decreased cellularity, liver fibrosis results from
a decline in normal matrix turnover and an increase in
matrix deposition by activated hepatic stellate cells. It can
be detected by histological procedures that distinctly stain
Table 1 Genetic models of progressive NAFLD in mice
Gene/Model Modification NASH Fibrosis Liver
tumors
Observations in human liver disease
PI3K/AKT signaling
Pik3ca Liver-specific transgenic overexpression
of activated mutant
No No Yes Transgenic allele modeled after mutation
detected in HCC
Pten Liver-specific knockout Yes Yes Yes Decreased expression in NAFLD; Loss of
function common in HCC
Akt Liver overexpression via adenoviral or
hydrodynamic injection
Yes No Yes Increased expression in HCC associated with
upregulation of lipogenic genes
JAK/STAT signaling
IL-6 Constitutive knockout Yes No No aIncreased expression in obesity and type 2
diabetes
Il6st Constitutive knockout Yes Yes No aActivating mutations detected in liver cancer
Jak2 Liver-specific knockout Yes Yes No Sequence variants associated with metabolic
syndrome risk
Stat5 Liver-specific knockout No No Yes Pathway activation associated with cirrhosis
risk in NAFLD
PPAR signaling
Acox1 Constitutive knockout Yes Yes Yes Sequence variants in PPAR associated with
NAFLD
Lgals3 Constitutive knockout Yes Yes Yes Sequence variants in PPAR associated with
NAFLD
NF-jB signaling
NEMO Liver-specific knockout Yes Yes Yes Decreased expression in HCC
Atg5 Systemic mosaic deletion Yes No Yes Autophagy is decreased in NAFLD and HCC
Atg7 Liver-specific knockout Yes No Yes Autophagy is decreased in NAFLD and HCC
Becn1 Systemic heterozygosity Yes No Yes Autophagy is decreased in NAFLD and HCC
Polygenic
FLS strain Selective breeding Yes Yes Yes
TSOD strain Selective breeding Yes Yes Yes
SAM metabolism
Mat1a Constitutive knockout Yes No Yes Hypermethylation and decreased expression
in NAFLD, cirrhosis, and HCC
Bhmt Constitutive knockout Yes No Yes Decreased expression and loss-of-function
mutation in HCC
Gnmt Constitutive knockout No Yes Yes Hypermethylation and decreased expression
in NAFLD, cirrhosis, and HCC
NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis, HCC hepatocellular carcinoma
a Observation in humans is discordant with mouse model
J. D. Riordan, J. H. Nadeau: Non-alcoholic fatty liver disease
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       In human disease progression, there is a significant difference in occurrence 
between different ethnicities. Drawing from previous studies that linked two single 
nucleotide polymorphisms (SNPs) reference samples (rs) 738409 and 2281135, in 
the PNPLA3 locus [36] and elevated ALT [37] with induction of NAFLD, Li et al. 
presents a statistical model based upon these disease risk factors in the Hispanic 
American population [38]. This population was found to have a high prevalence of 
elevated ALT (39%), obesity (49%), and diabetes (30%), which are strongly 
associated with NAFLD [38]. Additionally, the study found that high rates of end-
stage liver disease were significantly higher in males than in females and Hispanics 
compared to other ethnicities [38]. While end-stage liver disease rates were higher in 
males, the SNP associated with NAFLD in PNPLA3 (rs738409) was only seen in 
females. African-American patients were found to have a lower prevalence of 
NAFLD than Caucasians [39]. Due to these differences in NAFLD and NASH 
incidence by race, the distribution of disease incidence may be explained by 
distribution of adipose tissue, triglycerides, and SNPs.  
       It is worth noting that lean individuals also develop NAFLD, although at a lower 
rate of incidence than obese individuals – 7% NAFLD incidence in lean individuals 
as compared to 28% NAFLD incidence in obese individuals [40]. Most of these lean 
patients with NAFLD were younger, Hispanic, and had lower prevalence of 
metabolic syndrome accompanied by better insulin sensitivity when compared to 
obese NAFLD patients [40]. Interestingly, most of the individuals who are diagnosed 
with non-obese NAFLD were female. Most mouse model studies have focused on 
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obesity-related NAFLD and NASH; however, further studies are needed to better 
understand the complexities associated with non-obese disease progression.  
      To date, there are several methods employed to diagnose NAFLD, but 
pathological assessment from biopsy is still the most widely accepted method for a 
definitive diagnosis of NAFLD and differentiation from NASH, due to the ability to 
study the tissue for presence and extent of fibrosis [24, 41]. Histological scoring 
methods such as the non-alcoholic liver disease activity score (NAS) [42] and 
histopathological algorithms for evaluation of liver lesions in morbidly obese patients 
[43] are being implemented to obtain a better evaluation of disease status in 
patients. However, there are many problems such as potential complications due to 
the complexity of the disease and invasiveness of the biopsy, cost, and 
inconvenience to the participant, making it a very unpopular means of diagnosis [38]. 
Thus, in most cases, other means must be used in diagnosis such as: magnetic 
resonance imagery (MRI), measurement of organic compounds in the breath [44], 
and the FIB-4 test (analyzes ALT, AST, platelet number, and age) [45]. The most 
common methods are ultrasound (US) measurement of alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) levels, both of which have numerous 
problems [24].  Previous studies have shown that US is unable is detect low grade 
or very small amounts of hepatic steatosis [24]. Additionally, relying solely on ALT 
and AST levels to determine diagnosis has been shown to be unreliable as these 
levels fluctuate within normal range in both NAFLD and NASH [46].  
      Treatment options for NAFLD and NASH are very limited and have varying 
levels of success. Since most patients are obese, weight management and 
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increased physical activity have been shown to improve liver histology by reducing 
hepatocellular damage due to lipid accumulation, while delaying progression [47]. 
Frequently, morbidly obese patients undergo bariatric surgery to reduce their weight 
and reduce excess lipid as a reservoir of disease [48]. When high-risk patients with 
metabolic syndrome are observed, preventative agents such as ursodeoxycholic 
acid (UDCA), omega-3 polyunsaturated fatty acids (N-3 PUFA), statins and pre- and 
probiotics are implemented with varying success [47]. In patients with accompanying 
metabolic disorders, such as insulin resistance, insulin-sensitizing agents such as 
metformin and thiazolidinediones (TZD) are prescribed. To combat oxidative stress 
and reduce hepatic fibrosis, vitamin E is the treatment modality of choice [48]. 
Surgical procedures such as liver transplantation are considered the last resort for 
irreversible end-stage cirrhosis and HCC. Thus, a combination of methods, not 
merely diagnostic but also genetic in nature must be employed to provide a better 
screening method in order to treat this disease prior to progression. Manipulation of 
key lipid metabolic and inflammatory related genes in the mouse model have 
provided information regarding NAFLD and HCC disease progression that has 
contributed to the field of knowledge regarding better diagnostic and treatment 
modalities. However, a mouse model that develops spontaneous disease 
progression through the entire spectrum of NAFLD, NASH, and HCC, following 
genetic manipulation, has not been achieved.  
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1.5.  TRIM24 as a transcriptional co-regulator   
 
 
      The Tripartite motif (TRIM) protein family is defined by conserved N-terminal 
domains of RING (Really Interesting New Gene), two B‑boxes, a coiled-coil domain 
and variable C-terminal domains, which contribute to TRIM protein functions in 
differentiation, development, oncogenesis and apoptosis. In mammals, TRIM24 is a 
member of the Transcription Intermediary Factor (TIF1) sub-family including TRIM24 
(TIF1α), TRIM28 (TIF1β/KAP1) and TRIM33 (TIF1γ), a subset within the larger TRIM 
family of 70 proteins [49]. This family of proteins is known to interact with each other 
and, in the case of TIF1γ, to have functions in epigenetic silencing, E3-SUMO-ligase 
activity, as well as interaction with MDM2 and E2F1 [50-52]. In our laboratory, 
TRIM24 was discovered to be a previously unknown negative regulator of p53 by 
Allton et al. (2009).  Utilizing mass spectrometry data from mouse and stem cell 
models that implemented C-terminal tandem affinity purified (TAP) tag fusion with 
the open reading frame (ORF) of Trp53, a mouse model was created that expressed 
endogenously regulated p53 (p53-TAPKI). Additional experiments showed TRIM24 
negatively regulates p53 through E3 ubiquitin ligase activity via the N-terminal RING 
domain.  Studies of the TRIM24 Drosophila homolog, Bonus, showed that mosaic 
clones, mutated in Bonus, were highly apoptotic. This phenotype was rescued by 
depletion of p53. Further studies in various human cancer cell lines cemented the 
conclusion upon depletion of TRIM24, led to p53-dependent apoptosis. TRIM24 has 
also been identified as a co-regulator of retinoid signaling, highly expressed in a 
profile of tumors, and associated with fusion partners such as Braf (T18) and Ret 
oncogenes in acute promyelocytic leukemia and papillary thyroid carcinoma [53-56].  
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      In addition to these functions, TRIM24 is a co-regulator of nuclear receptors via 
the LXXLL motif and a Plant Homeodomain (PHD)/Bromodomain histone “reader” of 
histone modifications: H3K4me0 and H3K23ac [57-60] (Diagram 5). The 
evolutionarily conserved LXXLL motif is essential for interaction with nuclear 
receptors (NRs) [61]. NRs are defined as ligand-inducible transcription factors that 
function to regulate transcription of target genes through binding of DNA sequences 
as homo/heterodimers [55]. NR homo- and heterodimers such as: RARα (Retinoic 
acid receptor alpha)/RXR (Retinoid X receptor), Androgen (AR), Estrogen (ERα), 
Progesterone (PR), and Vitamin D3 (VDR) [54, 55, 59, 62-64] have been shown to 
interact with the LXXLL motif of TRIM24.  
      In a mouse model targeting exon 4 of TRIM24 for germline deletion 
(Trim24dlE4/dlE4), it was discovered that RAR-mediated signaling was reactivated, 
through re-expression of RARα and repressed genes in the liver, leading to eventual 
HCC [65, 66]. Subsequent studies in Trim24dlE4/dlE4 mice showed that Trim24 
represses the vitamin D receptor (VDR) pathway in the kidney, suggesting up-
regulation of calcium sensor receptor (Casr) expression, which could account for the 
arterial calcifications (not seen in the liver) in this mouse [66]. Additionally, Trim24 
was shown to suppress HCC progression by inhibition of the IFN/STAT pathway via 
RAR dependent regulation of the Stat1 promoter [58]. Taken together, these findings 
suggested that Trim24 is a tumor suppressor and an “essential brake” for retinoic 
acid-induced transcription that protects against HCC and arterial calcification [65]. 
      Conversely, our laboratory discovered that TRIM24 is a co-activator of ERα-
mediated activation of transcription in human breast cancer cells. We further 
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established this transcriptional activation is facilitated by recognition of a unique 
histone signature H3K4me0/H3K23ac via the Plant Homeodomain (PHD) and 
Bromodomain. Depletion of TRIM24 by shRNA led to decreased breast cancer cell 
survival, which was exacerbated by addition of the ERα inhibitor, 4-OH-tamoxifen 
[59]. Breast cancer patient samples showed a positive correlation between TRIM24 
expression (immunohistochemistry) and poor prognosis [59]. Recent studies in 
immortalized human mammary epithelial cells (HMECs) show that TRIM24 
expression causes progression from a non-transformed to cancerous phenotype 
[67]. Furthermore, ectopic expression of TRIM24 led to malignant transformation in 
both cell line and xenograft models [67]. Over expression of TRIM24 led to 
increased glycolytic and tricarboxlyic acid (TCA) cycle gene expression in these 
transformed HMECs, suggesting a new role for TRIM24 in breast cancer 
progression and metabolism. Additional studies in MCF7 breast cancer cell lines, 
which harbor wild-type p53, showed that TRIM24 responds to stress and damage by 
negatively regulating p53 through an autoregulatory feedback loop [68]. This 
feedback loop was found to be independent of MDM2 and dependent upon direct 
binding of p53 to p53 response elements (p53 REs) in the distal promoter region of 
TRIM24 [68].  Thus, our laboratory has discovered numerous roles of TRIM24 as an 
oncogene in breast cancer, as well as mechanistic functions of TRIM24 and p53. 
However, we were interested in the dichotomy that existed between the role of 
TRIM24 as an oncogene in breast cancer and a tumor suppressor in a mouse model 
of HCC. Upon further examination of the Trim24dlE4/dlE4 mouse model, we observed 
that the RING domain, located in exon 1 of Trim24 could possibly remain active in 
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this model. As our laboratory had established that the RING domain is essential for 
E3-ubiquitin ligase mediated inhibition of p53, we reasoned that p53 could still be 
active in the Trim24dlE4/dlE4 model. To better understand how this could be 
contributing to disease progression, and to better understand the dichotomy 
between dual role of Trim24 as an oncogene (breast) and a tumor suppressor (liver) 
we developed a mouse model targeting the promoter region and exon 1 of Trim24 
for germline deletion (Trim24dE1/dE1, referred to here asTrim24-/-).     
 
1.6. Hypothesis and Aims of this work 
     Upon aging, the Trim24-/- mouse exhibited spontaneous development of hepatic 
lesions and HCC. Further studies showed that these hepatic lesions were filled with 
lipid and both hepatic lipid metabolic and inflammatory related gene expression were 
misregulated in these mice as well as NAFLD and NASH. These preliminary findings 
led me to hypothesize that the E3 ubiquitin ligase of p53, TRIM24, regulates genes 
that impact hepatic lipid inflammation and metabolism. Furthermore, I reasoned that 
TRIM24 could also be regulating specific systemic and hepatic immune cell 
populations, ultimately leading to development of NAFLD, NASH and HCC (Diagram 
6). The goal of this study was to characterize this novel mouse model and to 
determine the role of Trim24 in regulating mechanisms that protect the liver from 
aberrant lipid and glucose metabolism, chronic inflammatory damage and, 
ultimately, tumorigenesis.  
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Diagram 5. TRIM24 protein structure- Diagram of TRIM24 protein structure and 
domains. NR- Nuclear receptor.  
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Diagram 6. Model of the hepato-protective role of TRIM24 against the 
hallmarks of NAFLD, NASH, and HCC. Modified from www.uscs.surgery.edu.  
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2.1. Generation of germline Trim24dlE1 deficient mice. (Resource previously 
available in the laboratory, in collaboration with the Lozano laboratory, MD 
Anderson Cancer Center) 
 A conditional targeting vector (Fig. 1A) was constructed to delete the genomic 
fragment containing the core promoter and exon 1 of the Trim24 gene by insertion of 
two LoxP sites for homologous recombination. The 5’ arm (5182bp) was cloned by 
PCR with sense primer: AGGGTACCTGCGTCTGCTCT and antisense primer with 
an EcoR V site: ATGATATCATTCCAGGCCAGCCTGCTCTA.  LoxP sites were 
introduced into the promoter fragment (1.7kb up-stream of transcriptional start site 
(TSS) and into intron 1 for a total knockout arm length of 2651bp with the primer 
pair: sense primer with EcoRV site and LoxP sequence: 
ATGATATCATAACTTCGTATAATGTATGCTATACGAAGTTATTCAGAGATCTGCC
TGCCTCT and antisense primer with Xho I site:  
TTCTCGAGAAACAGACGGCAGCCAATCTG. The neomycin resistance gene (Neo) 
was fused to the phosphoglycerokinase (PGK) promoter (pGK-Neo) and inserted 
behind the LoxP site in intron 1 and flanked by two FRT sites for FLP-mediated 
excision.  The 2858bp fragment in intron 1 was cloned as 3’ arm using primer pair: 
sense primer with Sac II site: GATTCGCCGCGGCGAATCTTGTGCGTTCCGGG 
and antisense primer with Sal I site: AACGTCGACGTTCGGCTGCCTTCATACCA. 
Deletion of the knockout arm resulted in a frame shift, completely disrupting the 
remaining protein coding sequence.  
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      To generate Trim24-null mice, the linearized targeting vector (Fig. 1A) was 
electroporated into embryonic stem cells (ES, TC-1, MD Anderson Cancer Center) 
and positive ES cell clones were used to generate chimeric mice. Progeny were 
backcrossed to C57BL6/J mice (The Jackson Laboratory) for Trim24LoxPNeo/+ mice. 
Trim24LoxPNeo/+ mice were crossed to ROSA26-FLPeR mice (The Jackson 
Laboratory) to delete the Neomycin cassette: Trim24LoxP mice. Trim24LoxP mice were 
crossed to the zona pellucida 3 promoter-driven Cre-line (Zp3-Cre, The Jackson 
Laboratory): Trim24dlE1 mice. The Trim24dlE1/+ offspring were intercrossed to result in 
Trim24+/+, Trim24+/dlE1 and Trim24dlE1/dlE1. Mice were monitored for survival over a 
time-course of 585 days. For subsequent experiments, mice were backcrossed to 
129S1 (Jackson laboratory) mice and then intercrossed with C57BL6/J mice to 
create B6:129 mice. All animal experiments were approved by the IACUC of the 
University of Texas MD Anderson Cancer Center.  
2.2. PCR analysis of Trim24 genotypes. 
a. Genotyping of germline deletion.  
Genomic DNA was isolated by Proteinase K digestion and phenol-chloroform 
extraction, followed by PCR amplification. The primer targeting sites are shown in 
Fig 1 and sequences are: f1: ATGGAGATGAAGTGATGGGGGAT; f2:  
CAAGTCTTTGGGGAATTACAGA; r1: CCTGGTAACATAAGCAAAGGA; r2: 
AGGTTTACAGAAGGAGACAAT; r3: CTAGTGAGACGTGCTACTTCCATTTG and 
r4: AAATCTCCGAAAGCAGCAGA.  For detecting Trim24LoxPNeo germline transition, 
f1/r1 primer pair for Trim24+/+ (WT) allele and f1/r3 primer pair for Trim24LoxPNeo allele 
were used. The amplified fragment of 319bp (WT) and ~450bp (Trim2LoxPNeo) were 
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obtained. To confirm the deletion of Neomycin cassette, primer pair f1/r4 was used 
to yield products of 175bp for WT and ~320bp for Trim24LoxP (Floxed) mice. For 
detecting the deletion of proximal promoter and exon 1, PCR was performed with 
primer pairs f2/r2 and f2/r1 for WT and Trim24dlE1 alleles, respectively and the PCR 
products of 384bp (WT) and ~650bp (dlE1) were obtained.  PCR conditions for all 
primer sets were 32 cycles of 95ºC 4 min for preheating, then 95ºC 30 seconds, 
65ºC 45 seconds, and 72ºC 45 seconds followed by 72ºC for 5 minutes.  
 
b. Genotyping of liver specific deletion.   
        
      Albumin-Cre mice were obtained from Jackson Laboratory (B6.Cg-Tg (Alb/Afp-
cre)21Mgn/J003574, referred to throughout the paper as Albumin-Cre). These mice 
were bred to Trim24LoxP mice to obtain Albumin-Cre; Trim24LoxP/LoxP/+ (HKO/+- 
Hepatocyte specific Knockout/+, B6:129) mice. These mice genotypes were 
confirmed by ear punch and PCR for positive Cre and LoxP expression.  HKO/+ 
mice were intercrossed to obtain HKO/HKO mice (Albumin-Cre; Trim24LoxP/LoxP 
/Albumin-Cre;Trim24LoxP/LoxP). These mice are viable and can be bred through 
homozygous stock, litters were validated for positive Cre and LoxP/LoxP expression 
via ear punch. All mice were mixed B6:129 background. Integration of Cre 
expression was determined using primers: oMIR 1084 5’-
GCGGTCTGGCAGTAAAAACTATC (sequence from Jackson Labs), oMIR 1085 3’-
GTGAAACAGCATTGCTGTCACTT (sequence from Jackson Labs). PCR conditions 
were: 37 cycles of 94ºC 3 min for preheating, then 94ºC 30 seconds, 51.7ºC 1 
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minute, 72ºC 1 minute, (cycles 2-4 repeated 35 cycles), 72ºC 2 minutes.  Cre bands 
were located at 150 bp (Fig. 31).  
 
2.3. Southern blot analysis of Trim24 genotypes (Resource previously 
available in the laboratory) 
      For detecting the homologous recombination of Trim24LoxpNeo in ES cells, 
genomic DNA was digested with SpeI, analyzed by electrophoresis on a 1% agarose 
gel and blotted onto an Amersham HybondTM-N+ membrane (GE Healthcare, Cat. 
# RPN303B). The duplicated blots were then hybridized to 5’ and 3’ external probes 
respectively. The 5’external probe was obtained by PCR amplification using primer 
set 5’-GGTAACCAAGGAATGTGGGTCT and 5’-
GCCTGGTTTCTCATCATCTTTCCCT; and 3’ external probe was obtained by PCR 
amplification using primer set 5’- CCCATTGGTCCAGTCAGAACAT and 5’- 
GGGGAGGGGAATGAAGATAA. The detailed probe sequences are listed in Table 
2. Probes were labeled by EasyTides®, Deoxycytidine 5’triphosphate, [α32P] 
(PerkinElmer, Cat. #BLU513H250UC) using AmershamTM RediprimeTM II Random 
Prime Labeling System (GE Healthcare, Cat. # RPN1633), followed by purification 
with illustraTM ProbeQuantTM G-50 Micro Columns (GE Healthcare, Cat. #28-9034-
08). The correct patterns of hybridization were then visualized by exposing washed 
membranes to X-ray films (Kodak, Cat. #829 4985).  
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2.4 Western blot analysis of Trim24 genotypes (Resource previously available 
in the laboratory) 
      For protein analyses of TRIM24, TRIM28 and TRIM33 expression in mouse 
embryo fibroblasts (MEFs), two lines of early passages of Trim24+/+ and -/- MEFs 
(passage 2) were plated in 6-well plates and incubated for two days. The whole cell 
lysates (50 µg) were separated by SDS-PAGE on 7.5% gel, transferred to 
nitrocellulose membranes and immunoblotted with primary antibody overnight 
(1:5000 dilution). The primary antibodies are anti-TRIM24 (Proteintech Group, 
14208-1-AP), anti-TRIM28 (KAP1) (Abcam, ab22553), anti-TRIM33 (Abnova, 
H0005-1592-M01), and anti-β-actin (Sigma-Aldrich, A1978). After washing, the 
membrane was incubated with IRDye@800CW conjugated goat anti-rabbit IgG (LI-
COR, 926-32211) or IRDye@680LT conjugated anti-mouse IgG (LI-COR, 926-
68020) (1:20,000 dilution) as appropriate. The membranes were scanned and 
quantified with ODYSSEY CLx Infrared Imaging System.  
2.5. RNA extraction and quantitative Real-time (qRT-PCR analysis). 
      Briefly, total RNA from cyropulverized, homogenized mouse liver was extracted 
with 1 mL of TRIzol reagent (Life Technologies, Invitrogen) per (0.2 g amount of 
tissue. TRIzol and sample were pipetted up and down about 20X at room 
temperature. 200 µl of chloroform (Fisher) was added per sample and the sample 
was vigorously shaken for 1 minute. Following a 3 minute incubation at room 
temperature, the samples were centrifuged for 15 minutes at 10,000XG, 4°C. The 
aqueous phase was moved to a new tube and 500 µl of 100% isopropanol (Fisher) 
was added, the samples were shaken for 1 min, and then incubated at room 
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temperature for 10 minutes. Following centrifugation, (10 minutes at 10,000XG, 
4°C), the supernatant was discarded and the pellet was washed twice with 1 mL of 
75% ethanol (Pharmco-AAPER) (Vortex, 7500XG centrifugation, 5 min, 4°C). The 
ethanol was then removed and the RNA pellet was dried on ice and resuspended in 
20-50 µl DEPC (Sigma) water, depending on the size of the pellet. To determine 
RNA concentration and purity, the resuspended RNA pellet was diluted 1:1 in 2X TE 
buffer (10 mM Tris-HCL pH 7.5 -Fisher, 1 mM EDTA pH 8.0 - Fisher) and analyzed 
on the NanoDrop spectrometer. RNA with an absorbance curve of 1.85 or above 
was accepted as pure. 2.5 µg of RNA was added to 1 µl 10X DNAse Buffer 
(Promega), 1 µl DNase (Promega) and DEPC water to a total volume of 9 µl. The 
samples were spun down and incubated for 20-30 minutes at 37°C. The DNase 
reaction was stopped with 1 µl. 25mM EDTA and then the samples were moved to 
65°C for 10 minutes after a brief spin. After the samples were incubated on ice for 
>1 minute. The DNased RNA (dRNA) 8 µl was added to 1.5 µlRandom Hexamers 
(Invitrogen), 1.5 µl dNTP (Bioline), and DEPC water 1.5 µl and the sample was spun 
down and incubated for 65°C for 5 minutes, followed by >1 minute on ice. 4 µl of 5X 
First Strand Synthesis Buffer (Invitrogen), 2 µl 0.1 M DTT (Invitrogen), and 0.5 µl 
RNase inhibitor (Roche) was added to each sample, followed by a quick spin and 2 
minute incubation at 42°C. Finally, 1 µl of Single Strand Reverse Transcriptase 
(Invitrogen) and 0.5 µl of DEPC water was added to the sample and the PCR 
settings were: 42°C for 50 minutes, 70°C for 15 minutes.  
      Primers were designed bridging two exons using the mouse database in 
Ensembl (NCBI) to visualize the sequence for each gene. Exon sequences were 
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entered into the primer design software, OligoArhcitect (Sigma) and primer pairs 
were checked for specificity using BLAST (NCBI). Upon receipt, primers were 
resuspended in sterile water at a concentration of 100 µM and diluted 1:10 for 
working stock. To ensure that primers were specific, a standard curve experiment 
was performed using pooled cDNA from various mouse tissues and diluting primers 
1:1000, 1:100, and 1:10. For qPCR analysis, samples were prepared with 0.2 µl of 
each primer (Forward and Reverse), 5 µl   SYBR green PCR mastermix (Bio-Rad) 
and 1.6 µl of sterile water to 7 µl per well in addition to 3 µl of cDNA (1:10) (10 µl 
total/well) in a 96-well PCR plate (Life Technologies) Real-time qPCR was 
performed using primers for the indicated genes with the following cycles:  95°C 5 
minutes, 95°C 30 seconds, 55-60°C 30 seconds, 72°C 30 seconds for 40 cycles 
(Table 3).  Levels of RNA were normalized by comparison to Hprt.  
2.6. Histological and immunohistochemical studies  
a. Paraffin embedded sections.  
      Mouse tissues were fixed in 4% paraformaldehyde (PFA, Sigma) in PBS 
overnight, dehydrated in ethanol, embedded in paraffin using standard procedures. 
Sections (5 µm) were cut, deparaffinized, rehydrated, and stained with 
hematoxylin/eosin (H&E) using standard procedures in the MD Anderson Cancer 
Center Veterinary Medicine Pathology Core.  
 
b. Frozen tissue sections 
      Liver samples were fixed with 4% paraformaldehyde (PFA) in PBS over night at 
4°C, incubated in 30% sucrose in cold room with shaking overnight, embedded with 
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O.C.T compound (Tissue-Tek, #4583), frozen on dry ice and stored at -80°C before 
use. Frozen tissues were cut at a thickness of 10 µm at 12°C, air-dried on the slide 
for 30 to 60 minutes.  
 
 
c. Oil red O staining 
 Frozen sections were used for this procedure. The slides were incubated in 4% PFA 
for 10-15 minutes to dissolve the O.C.T. compound. Then, the slides were washed in 
PBS, followed by rinsing with water 3X for 5 minutes. Then, the slides were dipped 
quickly in 60% isopropanol and stained with freshly prepared ORO working solution 
(Electron Microscopy Science, #26503-02) for 7 minutes. After staining, the slides 
were quickly dipped in 60% isopropanol, washed immediately with water, 
counterstained for nuclear staining with Mayer’s Hematoxylin solution (Sigma-
Aldrich, #MHS16) for 5 minutes and sealed with mounting medium (Invitrogen, 
#P36930).  
 
d. Masson’s Trichrome Staining   
Paraffin sections were used for this procedure. The slides were deparaffinized using 
histoclear (National Diagnostics), 3X for 10 minutes. Then, the slides were 
rehydrated through alcohol: 100% ethanol (2X 5 minutes), 95% ethanol (2X 5 
minutes), 70% ethanol (2X 5 minutes), changing to fresh solution in between each 
time and finally to distilled water. The slides were incubated in Bouin’s Fixative 
(EMS) overnight at room temperature. Following the incubation, the slides were 
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washed in running water until the yellow color was no longer visible. After drying 
around the sample, but not allowing it to completely dry, a hydrophobic Pap Pen 
(Research Products International) was used to draw a circle surrounding the sample.  
Next, the slides were stained in Weigert’s Iron Hematoxylin Working solution (A + B 
solution, EMS) for 5 minutes, within the Pap Pen circle and then rinsed in running, 
distilled water for 10 minutes. The slides were then stained in Biebrich Scarlet-acid 
Fuchsin (EMS) for 15 minutes, Phosphomolybdic Acid-Phosphotungstic Acid (EMS) 
for 15 minutes, Aniline Blue Solution (EMS) for 10-20 minutes and finally rinsed with 
distilled water. 1% Acetic Acid (Sigma) was used to differentiate the slides for 3 to 5 
minutes, followed by dehydration (95% ethanol, 100% ethanol, 2X each quickly 
changing), clearing 2X quickly in histoclear, and mounting with Cytoseal Mounting 
Media (EMS) after drying around the sample. If the staining was faint, samples were 
rinsed in water for shorter periods of time and dried at 50°C from 1 hour to overnight 
before mounting (instead of dehydrating and clearing) to preserve the staining. The 
protocol was modified from Electron Microscopy Services (EMS) protocol. 
 
e. PAS Staining  
Periodic Acid Schiff (PAS) staining was used to determine glycogen and 
carbohydrate levels in cells. Paraffin sections were deparaffinized and rehydrated 
through xylenes and alcohol as stated previously. The slides were placed in 0.5% 
aqueous periodic acid (Sigma) for 5 minutes and then rinsed in tap water and 
deionized water for 5 minutes each. Then, the slides were placed in freshly made 
Schiff’s reagent for 15 minutes (5 g Sodium Metabisulfite-Sigma, 5 g pararosaniline- 
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Sigma, in 1 liter of 0.15M HCl, - Fisher, filtered with 3 g of activated charcoal 
(Sigma), cooled and stored away from light at ,4°C), followed by rinsing twice in 
deionized water (5 minutes each). The slides were then counterstained by dipping in 
filtered Harris hematoxylin (Protocol) for 2-3 seconds and rinsing in running tap 
water for 3 minutes. Then, the slides were decolorized by dipping in acid alcohol for 
2 seconds. The slides were developed in running tap water for 3 minutes to blue the 
hematoxylin. Finally, the slides were dehydrated through alcohols and xylene as 
stated previously and mounted. The protocol was modified from Current Protocols in 
Molecular Biology, 2007.  
 
f. Immunohistochemistry 
Paraffin sections were deparaffinized and rehydrated through xylenes and alcohol as 
stated previously. Antigen retrieval was performed using 100X Sodium Citrate Buffer 
(Vector) , diluted in water. 250 ml of this solution was heated for 3 minutes in the 
microwave in a slide container and then moved to a rice cooker that was heated to 
boiling. The slides were then placed in the boiling Sodium Citrate Buffer and 
steamed in the rice cooker for 30 minutes. The slides were cooled under running 
water. The area around the sample was dried, being careful not to allow the sample 
to dry and a Pap Pen was used to draw a circle around the sample. Next, the 
sample was blocked (against ubiquitous background signal) with 3% BSA (Jackson 
Labs ImmunoResearch) in PBS-Tween (0.1% Tween-20, Fisher in PBS) and 150 µl 
of goat serum from the Vectatstain ABC Kit (Rabbit, PK-610) for 30 minutes to 1 
hour at room temperature on a nutator.in a humidifying chamber (slide box with 
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moistened Whatman paper under slides). Next, the primary antibody, diluted in 
Blocking solution, was applied to the slides (immediately after removing the blocking 
solution) and the slides were incubated overnight at 4°C. Antibodies used for 
immunohistochemistry were anti-TRIM24 antibody (1:250, ProteinTech 14208-1-
AP), anti-cleaved CASPASE 3 antibody (1:500, Cell signaling, #9661), and anti-
F/480 antibody (Affymetrix 1:250 14-4801). Following the overnight incubation, the 
slides were washed 3X 5 minutes in PBS. The secondary antibody was then applied 
(For TRIM24 and CASPASE 3 - anti-Rabbit serum (Vectastain Kit ) 1:1000, diluted in 
blocking solution, F4/80 – anti-rat serum (Vector BA-9401) 1:1000) and incubated in 
1-1.5 hours at room temperature on a nutator in a humidifier chamber. The ABC 
blocking reagent (Vectastain) was prepared with 5ml of PBS and 1 drop A reagent + 
1 drop B reagent (Vectastain) and incubated for 30 minutes at room temperature. 
During this incubation, the secondary antibody was removed in PBS (3X 5 minutes, 
shaking on a nutator, room temperature). Then, the ABC reagent was added to each 
slide and the slides were incubated for 30 minutes at room temperature. Following 
this incubation, the slides were washed in PBS (3X5 minutes) and moved to sterile 
water. The slides were then developed with DAB staining solution using the DAB 
reagent kit (Vector SK-4100) using 2 drops buffer, 4 drops DAB, 2 drops hydrogen 
peroxide, 2 drops Nickel, and mixed with 2.5 ml of sterile water. The slides were 
then developed until the desired contrast was achieved -10-20 minutes). Following 
checking contrast levels under the microscope, the slides were washed with running 
water in a slow and steady stream from the frosted glass portion to the end of the 
slide until all reagent was removed. Next, the slides were counterstained with 
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Mayer’s Hematoxylin (EMS, cleaved CASPASE 3) or Nuclear Fast Red (Vector, 
TRIM24). The counterstaining with Hematoxylin was achieved using the same 
method implemented in DAB staining. Nuclear Fast Red staining utilized a very short 
incubation period (10 seconds to 1 minute). The slides were then washed in running 
tap water for 5 minutes and dehydrated through alcohols, cleared, mounted as 
described previously.  
 
2.7. Plasma collection.   
2 month old Trim24-/- and Trim24+/+ mice were fasted for 4 hours with water ad 
libitum (for metabolic, such as lipid panels, other tests used mice that were not 
fasting). Submandibular blood collection was performed, following administration of 
anesthesia (Isofluorane, Isothesia, Butler-Schein), using a 5 mm lancet (Goldenrod). 
Samples were collected with 4.5% EDTA to prevent clotting, incubated on ice, and 
centrifuged at 10,000 rpm, 10 minutes at 4°C to separate plasma and either snap 
frozen and stored at -80°C or submitted for analysis.   
 
2.8. Serum collection. 
The same protocol used in plasma collection was implemented in serum collection, 
except blood was collected without EDTA (Fisher). Samples were allowed to clot 
and were then centrifuged at 10,000 rpm, 10 minutes at 4°C to separate serum and 
either snap frozen and stored at -80°C or submitted for analysis.   
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2.9. ALT/AST and Lipid profile analysis.  
AST, ALT, total plasma cholesterol (TPC), plasma TG, non-HDL-C, and HDL-C were 
quantitated using an Olympus clinical analyzer (Olympus) [69] by either the MD 
Anderson Cancer Center Veterinary Core or by Dr. Richard G. Lee (Isis 
Pharmaceuticals). Hepatic lipid profiles were assessed using the Folch liver lipid 
extraction method [70] by collaborator Dr. Richard G. Lee (Isis Pharmaceuticals).  
 
2.10. Glucose tolerance/Insulin tolerance testing (GTT/ITT testing).  
2, 4, and 6 month old Trim24-/- and Trim24+/+ mice were fasted for 6 hours with water 
ad libitum beginning at 4 am in order to clear undigested food. At this time, both the 
top and bottom of the cage were changed to ensure that all food sources were 
removed.  A glucose solution of 2 g glucose (Sigma) in 10 ml sterile water was 
dissolved and filter sterilized using a .22 filter µn (Millipore). Just prior to the 
beginning of the test, each mouse was weighed to determine the amount of glucose 
per mouse to inject (Ex: 10X body weight = 25 g mouse -> 250 µl of glucose). For 
insulin injections, 5 µl of insulin (0.75 U/kg, Humulin-N, Eli Lilly) was diluted 1:1000 
in sterile PBS on ice. The amount needed for injection per mouse was calculated 
based upon body weight (Ex: Weight in grams/1000 X 7500 = dose in µl per mouse).  
A baseline blood glucose reading was taking via tail snip on a glucometer (One 
Touch Ultra Mini) prior to injection, after 6 hours of fasting. Insulin syringes (Becton 
Dickinson) were loaded with the correct amount of either glucose or insulin (kept on 
ice) for each mouse and the solution was injected into the abdomen via 
interperitoneal injection. Blood glucose readings were taken at 0, 15, 30, 60, 120 
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minutes following injection. Mice were allowed to recover for 1 week in-between 
testing sessions and were sacrificed after a week of recovery from the final test (Fig. 
38). 
 
2.11. Liver perfusion.    
2 month old Trim24-/- and Trim24+/+ mice were anesthetized using Isofluorane 
(Butler-Schein) and were checked for pedal reflexes. Under continued anesthesia, 
mice were restrained and the abdominal cavity was exposed. A 24G catheter 
(Terumo) was inserted into the inferior vena cava to the junction superior to the 
kidneys. Upon removal of the needle, the catheter was then attached to tubing fed 
through a peristaltic pump and cleared with freshly prepared Pre-clearing solution 
kept in a circulating water bath at 42°C (1X PBS, no calcium/magnesium, 0.2 M 
EGTA, pH 8.0, 1M HEPES pH 7.6) (Thermo Scientific, Sigma, MP Biomedicals). 
Sufficient blood clearance of the liver was closely monitored and the hepatic portal 
vein was clipped as an exit point for the clearing solution. Following sufficient hepatic 
blood clearance, freshly prepared Perfusion solution, also kept in a circulating water 
bath at 42°C  (1X PBS without calcium/magnesium, 1M CaCl2, 1M MgCl2, 70 mg 
Collagenase IV) (Thermo Scientific, Sigma, Worthington) was pumped through the 
vena cava to digest the liver in situ. The gall bladder was removed and discarded. 
The liver was removed and transferred to a 50 ml conical tube (Becton Dickinson) 
with William’s E media 500 mL (Sigma) supplemented with 5 mL of Insulin-
transferrin-selenium (ITS, Sigma), 5 mL Gentamicin-glutamate (G/G, Sigma), 10 % 
Fetal Bovine Serum (FBS, Gemini), and 5 mL Penicillin-Streptomycin (P/S, 
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Mediatech), on ice. After vigorously shaking to suspend the cells, the suspension 
was poured through a 100 um filter (BD Falcon) and a cotton tipped applicator 
(Fisher Scientific) was used to mix remaining tissue in order to ensure that the 
majority of cells were filtered.  The suspension was centrifuged at 4°C 50G for 2 min. 
The bottom layer of cells (hepatocytes) and the supernatant (non-parenchymal cells, 
immune cell portion) were separated with the supernatant and removed to a new 
tube.  
 
2.12. Hepatic Immune Cell Isolation.  
The supernatant fraction collected in the previous protocol (liver perfusion protocol) 
was washed with PBS and cells were pelleted at 2000G for 10 min (4°C). Prior to 
preparing the Percoll cushion, the solutions were pH adjusted with PBS in a 1:10 
dilution at room temperature. The 37% and 70% solutions were prepared with PBS.  
The cells were then resuspended in 37% Percoll (Sigma) and layered onto a 70% 
Percoll cushion. The bottom layer of Percoll was kept at half the volume of the top 
layer of Percoll containing the supernatant. Cells were centrifuged through this 
Percoll gradient at 2000G for 20 minutes, with no brake. Following centrifugation, a 
bulb pipet (Fisher) was used to gently remove the intermediate layer between the 
37% and 70% layers of Percoll, which contained the immune cell population. DMEM 
(Sigma) + 10% FBS (Gemini) + P/S (Mediatech) was added to the cell fraction and 
the mixture was centrifuged at 2000G for 5 minutes at 4°C. The cell pellet was 
resuspended in media on ice.  
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2.13. Bone marrow collection.  
Femora and tibiae of 2 month old Trim24-/- and Trim24+/+ mice were collected and 
the muscle was removed. The ends of the bones were removed and PBS + 2% FBS 
with 2mM EDTA (Fisher) was flushed through the bone shaft using a 22G needle 
(Becton Dickinson). Bone marrow was collected following the flushing of the bone 
and cells were disaggregated by gently pipetting up and down several times.  The 
bone marrow was then pelleted by centrifugation at 300G for 10 minutes and was 
either snap frozen for storage at -80°C or resuspended in buffer for analysis.  
 
2.14. Flow Cytometry Analysis.   
a. RBC Lysis.  
To remove red blood cell contamination, cells were pelleted by centrifugation (300-
400xg) at 4°C, the supernatant was removed, and the cells were resuspended in 
Lysis Buffer (eBioscience). Following incubation on ice for 4-5 minutes with 
occasional shaking, the reaction was stopped by diluting the Lysis Buffer (1:6) with 
1X PBS. The cells were centrifuged as previously and resuspended in Flow 
Cytometry Staining Buffer (eFluor® NC Flow Cytometry, eBioscience) so that the 
cell count was approximately 2x107 /mL.  
 
b. Cell Fixation and Staining.   
The antibodies in Table 14 were used for analysis and were combined with the Flow 
Cytometry Staining (FCS) buffer to the appropriate concentration. A 1:1 combination 
of cells and the antibody mixture was incubated for 30 minutes (dark, on ice). The 
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cells were then washed twice by adding the FCS buffer and subsequent 
centrifugation (300-400xg), 4°C for 5 minutes (supernatant was discarded). Cells 
were resuspended in the fixing buffer composed of 4% formalin/PBS (Fisher). The 
samples were then analyzed on the flow cytometer and gated using FlowJo 
software.    
 
c. FlowJo Analysis. (This analysis was done in collaboration with Huiyuan 
Zhang, MD/PhD).  
Briefly, samples were analyzed using forward and side scatter analysis to determine 
the cutoff for live versus dead cells. Then, the channels using the conjugated 
antibodies (Table 9) were compared to the CD45 status (Y-axis) of the cells to 
determine which cells were hematopoietic versus non-hematopoietic. Cells were 
then sorted and gated based upon cell surface markers for lineage and identification 
(Table 14).  
 
2.15. CyTOF (sample preparation and analysis)   
 
a. Antibody labeling.   
For each antibody (Table 15, DVS Sciences), labeling was achieved using the 
MaxPar Metal Labelling Kit (DVS Sciences).  
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b. Sample staining and fixation. 
Cells harvested from either the liver or bone marrow were resuspended in Wiliam’s 
E media or DMEM, respectively (Invitrogen), and washed with PBS. Following 
washing, the cells were resuspended in serum-free media and an equal amount of 
50 µM cisplatin (Sigma Aldrich) was added dropwise to a final concentration of 25 
µM to stain for cell viability. After a 1 minute incubation and quenching with PBS + 
1% BSA (Equitech-Bio Inc), cells were centrifuged and resuspended in serum free 
medium.100 µM Iododeoxyuridine (IdU)  (Sigma Aldrich) was added in serum free 
medium to label cells in S-phase. Following subsequent incubation and 
centrifugation and washing with PBS+1%BSA, cells were fixed with PBS + 1.5% 
paraformaldehyde (Sigma Aldrich) for 10 minutes at room temperature. Cells were 
incubated and then washed and resuspended in PBS.  
 
c. Sample permeabilization and labeling.  
Cells were centrifuged, washed with PBS, vortexed, permeabilized with methanol 
(MeOH) (Fisher) and incubated at 4°C for 1 hour to overnight (depending on the 
tissue). On the day of analysis, approximately 1.5 million cells stored in MeOH  were 
centrifuged, MeOH was decanted, and cells were washed with wash buffer 
(PBS+0.5% BSA+0.02% sodium azide) and PBS. Then previously labeled 
antibodies were pooled per analysis and added to the washed cells, which were then 
incubated with gentle rocking for 45 min-1 hour at room temperature, followed by 
additional washes in wash buffer and PBS.  
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d. IR-intercalator staining. 
Note: The following steps were performed immediately before the samples were 
analyzed.  
IR-interacalator (DVS Sciences) was diluted 1:1000 in PBS+1.6% formaldehyde 
(Sigma Aldrich), added to the labeled cells, and incubated for 20 minutes at room 
temperature with gentle rocking. Following incubation, samples were washed with 
wash buffer. Immediately prior to analyzing each sample, the cells were 
resuspended in bead solution (DVS Sciences) and filtered using Falcon round 
bottom tubes with cell-strainer cap (BD Biosciences) submitted for CyTOF analysis.  
 
e. viSNE analysis.  (This data analysis was performed by Ryan McCarthy, PhD) 
The Visual Stochastic Neighbor Embedding (viSNE) figures were generated using 
the t-Distributed Stochastic Neighbor Embedding (t-SNE) algorithm to visualize the 
high dimensional data on a two dimensional map as previously described [71]. The 
viSNE plots were generated based on data from the cell surface markers listed in 
Table 15 to group cells that shared phenotypically similar characteristics. Cell type 
identity in the viSNE plot was manually annotated based upon markers expression 
of markers listed in Table 15.  
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2.16. Chromatin Immunoprecipitation (ChIP). Modified from protocol in Kurinna, 
et al., Hepatology, 2010 [72].    
 
a. Making the liver lysate.  
      Wild-type (Trim24+/+) quiescent liver samples from 2 month old mice (pooled 
genders) were cyropulverized and weighed to approximately 0.5g per mouse (total 
volume was 2 g) on ice. The samples were then rinsed with cold PBS (sterile) and 
centrifuged at 50XG, 2 minutes at 4°C twice to remove residual blood. The samples 
were cross-linked with 556 µl of 37% Formaldehyde (Sigma) in 20 ml of sterile water 
and rotated at room temperature for 15 minutes. The cross-linking process was 
stopped with 6.8 ml of 0.5 M Glycine (Fisher) while rotating for 10 minutes at room 
temperature. Next, the samples were centrifuged at 2000 rpm, 7 minutes at 4°C and 
the supernatant was discarded. The liver pellet was resuspended using a wide bore 
pipet, in 4 ml of 1X PBS with 40 µl protease inhibitors (PI’s, Sigma) and 4 µl of 
PMSF (MG/ICN), 0.1M in 100% ethanol). The samples were then dounced in a 
tissue homogenizer (Wheaton, Tight) 7 times on ice. The homogenate was then 
transferred to a 15 ml conical tube (Becton Dickson) and centrifuged at 2000 rpm, 7 
minutes at 4°C. The pellet was then resuspended in 4 ml of Cell Lysis Buffer 
(Appendix 1) with PI and PMSF. The sample was again dounced 4 times on ice 
(Wheaton, tight) and divided into tubes so that the final volume was maximum of 800 
µl per tube. The lysates were incubated on ice for 15 minutes and centrifuged at 
5000 rpm, for 5 minutes at 4°C. The supernatant was discarded and the pellet was 
resuspended in 250 µl of Nuclear Lysis Buffer (Appendix 1) with PI and PMSF and 
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incubated for 10 minutes on ice (vortexing every 2 minutes). 0.1 g of acid washed 
glass beads (Sigma) were added per tube and samples were transferred to a 
programmable Bioruptor machine (Diagenode) to sonicate and shear the chromatin 
fragments in the samples. The machine was sufficiently cooled and set as follows: 
30 cycles, 30 seconds on, 30 seconds off, rest for 30 minutes to cool down and 
repeat. Samples were then centrifuged at 14000 rpm for 30 minutes at 4°C and the 
supernatant was pooled and then divided into 200-300 µl aliquots per tube. The 
samples were snap frozen and stored at -80°C.  
 
b. Testing the lysate.  
      To test the size of the chromatin fragments, 20 µl of lysate was added to 20 µl 
2X SM2 buffer (Appendix 1) and 1 µl of 150U MNase (micrococcal nuclease-
Worthington) at room temperature in tubes labeled for the following timepoints in 
minutes: 0 (Stop solution of 1/10th volume of 10X EDTA/EGTA – Appendix 1 already 
in tube), 15, 30, 45. At the end of each timepoint, the stop solution (see previous) 
was added and 300 µl of TE Buffer with 1.5 µl of RNase A (10mg/ml, Worthington) 
was added to digest RNA and the sample was incubated for 30 minutes at 37°C. 
Then, 15 µl of 10% SDS (Bio-Rad) and 7.5 µl Proteinase K (MP Biomedicals, 10 
mg/ml) was added to the sample to digest proteins and the sample was incubated 
for 4 hours (minimum) at 37°C. The crosslinks were reversed overnight at 65°C. The 
samples were then extracted with 400 µl of Phenol:Chloroform (1:1 Buffered Phenol 
- Fisher, Choloform – Fisher), vortexed vigorously, and centrifuged at 13,000 rpm for 
5 minutes. The supernatant was removed to a new tube, where the 
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Phenol:Chloroform extraction was repeated as above. Next 400 µl of chloroform was 
added to the sample and extracted as above. The upper phase was removed to a 
new tube with a final volume of approximately 200-250 µl and DNA was precipitated 
with 1/10 volume of 3M Sodium Acetate (Fisher), 2 volumes of 100% ethanol, and 
20 µg glycogen (Sigma). The tubes were inverted to mix and incubated at -20°C for 
>1 hour (or -80°C for 1 hour), followed by centrifugation 13,000 rpm for 15 minutes 
at room temperature. After the supernatant was removed, the DNA pellet was 
washed twice with 70% ethanol, inverting the tube and centrifuging at 13,000 rpm for 
2 minutes. The pellet was then air dried and resuspended in sterile water to a final 
volume of approximately 50 µl.  The DNA samples (0, 15, 30, 45 minutes of MNase 
digestion) were ran on a 2.0% agarose gel (composed of Agarose – Gene Mate and 
1X TβE (10X to 1 L – Tris, Boric Acid –Sigma, 0.5M EDTA)) and visualized using 
ethidium bromide staining to determine which sample had the correct amount of 
digestion to achieve chromatin fragments on average 500bp (ranges from 150bp-
1kb). The optimal timepoint for MNase digestion was 15 minutes.     
c. MNase digestion, lysis, pre-clearing, and addition of antibody to the 
samples.  
      Protein A sepharose beads (GE Healthcare) were swollen in water over night at 
4°C. The beads were then washed and resuspended in Lysis Buffer (Appendix 1) 
with PI’s and PMSF to make a 50% slurry and kept on ice. MNase digestion was 
performed as described in the previous section using the digestion timepoint of 15 
minutes. The input sample tube was placed at -80°C. The remaining samples were 
brought to a final volume of 500 µl with Lysis Buffer (Appendix 1) and PI’s with 
 48 
PMSF.  The lysates were then pre-cleared with 3 µl of normal sheep IgG (Fisher) for 
1 hour at 4°C on the nutator. 50 µl of the bead slurry was added to each of the pre-
clearing tubes were rotated for another hour at 4°C on the nutator. The samples 
were then centrifuged at 5000 rpm for 3 minutes at 4°C. The supernatant was 
transferred to a new tube and 4-5 µg of TRIM24 (Proteintech) antibody to the allotted 
tubes. For binding controls, 3 µl was IgG alone was added to a tube and 5 µg 
histone H3 antibody (anti-Rabbit pAb Abcam ab1791) alone was added to another 
tube. Samples were rotated overnight at 4°C.   
 
 
d. Washing and removal of RNA/Protein from samples.   
      The samples were centrifuged at 13,000 rpm for 2 minutes at 4°C. The 
supernatant was transferred to a new tube and 50 µl of Protein A bead slurry was 
added using a wide bore pipet. The samples were then rotated for 1 hour at 4°C. 
Then, the samples were washed at 4°C, rotating with the following solutions 
(Appendix 1) : RIPA Buffer – 10 minutes, High Salt Solution – 10 minutes, LiCl Wash 
– 5 minutes, and TE Buffer – 2X 10 minutes. In between each wash, the samples 
were centrifuged at 5000 rpm for 3 minutes and the supernatant was carefully 
removed and discarded without disturbing the beads. Following these washes, 300 
µl of TE and 1.5 µl of RNase A (10 mg/mL) was added to digest RNA to both the 
sample and Input tubes, which were then incubated for 30 minutes at 37°C. Then, 
15 µl of 10% SDS and 7.5 µl of Proteinase K (10mg/mL) was added to the samples 
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to digest any residual protein and incubated at 37°C for a minimum of 4 hours. 
Finally, the cross-links were reversed by incubation at 65°C for 6 hours to overnight.  
 
e. DNA extraction and qPCR.  
      For extraction methods, see previous section. Following extraction, 2 µl DNA 
was added to 8 µl Real time qPCR mastermix (see qPCR methods section) per well 
in a 96 well plate.  
 
f. Designing primers for ChIP.  
      ChIP primers for potential Trim24 binding in promoter regions (half-sites for 
RARE or NR binding) of genes associated with lipid regulation are listed in Table 4. 
Primers for top gene candidates (Nrf2, Saa1, Lpin1, Gck, *Gbe1, and Jun*) are listed 
in Table 4.   
*Data not shown. 
2.17. RNA-seq data analysis. (This data analysis was preformed by Zeynep C. 
Akdemir, PhD) 
The sequencing of 6 RNA-Seq samples (3 biological replicates of RNA samples 
from livers of Trim24-/- and Trim24+/+ mice) produced Illumina 75 bp paired-end 
sequenced reads. These reads were aligned to the mouse genome (mm9), through 
the use of TopHAT 1.4.1 with –r 150 –G UCSC_genes.gtf (downloaded from UCSC 
mm9 July 2007) parameters[73]. EdgeR was applied to determine differentially 
expressed genes between Trim24-/- and Trim24+/+ samples at a false discovery rate 
(FDR) adjusted p-value (q-value) of 1%[74]. DAVID functional annotation tool was 
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employed to establish biological functional annotation of differentially expressed 
genes in Trim24-/- samples compared to Trim24 samples.  UCSC genome browser 
was used to visualize RNA-Seq reads along Trim24, using Mouse July 2007 
(NCBI37/mm9) assembly[75, 76].   
 
2.18. ChIP-seq data analysis. (This data analysis was preformed by Zeynep C. 
Akdemir, PhD) 
      ChIPseq was performed with pooled liver tissue from five mice at 10 wks of age 
(male and female). After sequencing, mapped reads are aligned to the genome and 
TRIM24 chromatin-enrichment profiles are generated using peak-calling programs 
(MACS or MACS2) in comparison to Input. TRIM24 binding was determined relative 
to transcription start sites (TSS’s) of RefSeq genes, defined on the UCSC genome 
browser site.  Programs such as MEME-Chip or TRAP are used to analyze DNA 
regions at binding peaks for transcription factor consensus binding motifs [77, 78].  
This approach nominates candidate regulatory proteins that are likely recruited by 
TRIM24 to chromatin and that play key roles in each biological function and 
pathways. As a first approach to identifying the genes regulated by TRIM24, we 
used nearest neighbor within 10kb of TRIM24 binding. This data was further 
overlapped with 2 month old male and female RNA-seq analysis using the list 
comparison program from the Whitehead Institute for Biomedical Research.  
Following integration, the gene lists were analyzed using Igenuity Pathway Analysis 
(IPA) and DAVID to determine associated biological pathways with most significantly 
misregulated genes. 
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2.19. Variant analysis. 
Ensembl Nucleotide (http://www.ensembl.org/Multi/blastview) and Blast databases 
(http://www.ncbi.nlm.nih.gov/) were used to predict Trim24 spliced variants and their 
expressed protein isoforms. 
 
2.20. Statistical analysis. 
Student’s t test was used in all statistical analysis and data were represented as 
mean ± STDEV. Differences at P< 0.05 with two-sample unequal variance were 
considered to be statistically significant for RNA analysis, with P<0.1 considered 
statistically significant for RNA-Seq analysis.  
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CHAPTER III 
 
TRIM24 suppresses development of spontaneous hepatic lipid accumulation 
and hepatocellular carcinoma in mice 
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3.1. Introduction  
 
      TRIM24 is highly expressed in multiple types of human cancers, including breast 
[59, 79], head and neck [80], non-small cell lung [81], glioblastoma [82], and HCC 
[83]. In contrast to apparent oncogenic functions of TRIM24 in humans, analysis of a 
mouse model with cre-mediated excision of exon 4 of Trim24 (Trim24dlE4/dlE4) 
suggested that TRIM24 is a liver-specific, retinoid-dependent tumor suppressor [84]. 
However, recent evidence shows that the Trim24dlE4/dlE4 mouse is not null for Trim24 
in the liver, as it retains normal levels of Trim24 RNA lacking exon 4 [85]. 
Additionally, I used utilized Ensembl and BLAST databases to predict that alternative 
start sites of Trim24 transcription could yield native isoforms of Trim24 lacking E4, 
as expressed in the Trim24dlE4/dlE4 mouse [85]. These isoforms are in frame and are 
predicted to produce proteins known as TRIM24 variants 1 and 3, which have high 
similarity to BRAF (Variant 1: 84% protein identity, Variant 3: 64% protein identity) 
(Table 9). HCC occurs in the Trim24dlE4/dlE4 mouse without apparent progression 
from NAFLD, due to activation of retinoid-dependent enhancers present in 
endogenous, murine VL30-retroviral transposons inserted across the mouse 
genome [85]. These long terminal repeat (LTR) enhancers are repressed by 
TRIM24/TRIM33 heteromeric complexes, similar to silencing of proviral DNA 
expression by TRIM28 [86]. In this mouse model, loss of TRIM24/TRIM33-mediated 
repression causes aberrantly high expression of inflammatory pathway genes linked 
to neoplastic inflammation in the liver. 
 The expression of Trim24 RNA lacking exon 4 (E4), as observed in Trim24dlE4/dlE4 
mice [85], leaves unresolved whether this aberrant RNA or encoded protein isoforms 
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exhibit dominant negative or gain-of-function, contributing to the observed HCC 
phenotype. These unknowns and, importantly, the documented over expression of 
TRIM24 in human cancers, including HCC [83], led us to create a conditional 
knockout mouse that is null for Trim24 expression by genetic targeting of the 
promoter and first exon (Trim24dlE1/dlE1).  
3.2. A Trim24-/- mouse generated by deletion of promoter and exon 1. 
      We engineered a conditional knockout mouse of Trim24 by genetic targeting of 
the transcription start site and first exon (Fig. 1). To generate germline Trim24 
deletion, Trim24LoxP mice were bred with Zp3-Cre–expressing mice to obtain 
Trim24+/dlE1 progeny. Trim24+/+, Trim24+/dlE1 and Trim24dlE1/dlE1 progeny were 
confirmed by PCR analysis (Fig. 2) and were viable and fertile in both males and 
females. Deletion of Trim24 occurs without allelic compensation, shown by protein 
and RNA analyses of mouse embryonic fibroblasts (MEFs) (3B), from Trim24+/+, 
Trim24+/dlE1 and Trim24dlE1/dlE1 E12.5 embryos (Fig. 3A), adult whole liver and 
hepatocytes as evidenced by immunohistochemistry (Fig. 3C-E).  
      Deep sequencing of RNA (RNA-seq), from Trim24+/+ and Trim24dlE1/dlE1 liver (2 
mos), showed no detectable expression across the Trim24 locus in Trim24-/- (Fig. 4). 
Quantitative RT-PCR analysis of all three, potential protein-coding isoforms of 
Trim24 (http://useast.ensembl.org/) with primers covering Trim24 exon 2/3, exon 7/8, 
exon 11/13, and the 3’UTR (Table 3) confirmed complete loss of Trim24 RNA 
expression in MEFs (Fig. 3B). Since our analyses of Trim24 expression show that 
the Trim24dlE1/dlE1 mouse is truly null for Trim24 expression, it is further discussed as 
Trim24-/-  
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Figure 1. Scheme for generation of the Trim24-/- mouse. Murine Trim24 gene 
exons (E1-E19), Southern blot -5’/ 3’ probes, and primers (f1, f2, r1, r2, r3, r4) for 
genotyping are shown with diagrams of crosses to delete E1 and promoter.  
Dta – Diptheria toxin subtype A, Neo –Neomycin cassette, FRT – Flippase 
recognition target, LoxP – Locus of X over P1.  Diamond = LoxP sites, Circle =FRT 
sites. 
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Figure 2.  PCR Genotyping analysis confirming deletion of Trim24 exon 1. 
Samples were obtained from tail snips. +/+ = Wild-type, +/- = Heterozygous, -/- = 
Null. PCR products of 384bp (WT) and ~650bp (dlE1) were obtained using primer 
pairs targeting f2/r2 and f2/r.  
 
 
 
 
 
 
 
 
 
 
+/+      +/-      -/-  
   -/-
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Figure 3. Confirmation of Trim24 deficiency.  A) Southern blot. DNA extracted 
from ES cell clones was digested with Spe I and analyzed with the 5’ and 3’ probes. 
Clone A6 and F7 showed the appropriate bands. B) (a) Western blot analysis of 
TRIM24 protein expression in MEFs of the indicated genotype. β-actin, as a loading 
control. (b) Relative TRIM24 protein levels in Trim24+/+, Trim24+/-, and Trim24-/- 
MEFS.  C) Real-time PCR analysis revealed all isoforms were deleted in Trim24-/-
 
liver (n=3) using primers targeting Exon2/3, Exon7/8, Exon 11/13, and 3’UTR. D) 
Western blot analysis for TRIM24 protein expression in Trim24+/+ and Trim24-/- liver 
(n=3), compared to β-tubulin control. E) TRIM24 immunohistochemistry analysis 
using TRIM24 (Protein tech) antibody in Trim24+/+ and Trim24-/- liver (n=3) at 2 
months of age. Bar: 4X: 500 µm; 40X: 50 µm.  
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.   
 
 
 
 
 
 
 
 
 
Figure 4.  Loss of Trim24 RNA expression in Trim24-/- liver: RNA-seq of  
Trim24-/- and WT. The figure represents a UCSC genome browser snapshot of the 
sequencing and positive peaks for Trim24 expression in Trim24+/+ and Trim24-/- 
mouse liver at10 weeks of age. Vertical lines are peaks that denote positive 
expression of the gene coinciding with specific regions of the gene (exons and 
introns), as shown in the Trim24+/+ mouse liver, whereas in the Trim24-/- mouse liver, 
lack of positive expression/peaks confirm complete deletion of the gene.  
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      TRIM24 belongs to the TRIM protein TIF1 subfamily (C-VI) of which there are 
three members: TRIM24, TRIM28 and TRIM33 [87]. These proteins have a high 
degree of homology and form heteromeric complexes that vary according to cell type 
[87]. TIF1α (TRIM24) and TIF1β (TRIM28) amino acid sequences share 32% identity 
and 54% similarity over their entire length [55]. Most of the homology is stronger in 
the N- and C- terminal regions than in the central region. In the N-terminal region, 
homology exists between several evolutionarily conserved domains: the RBCC 
subfamily of RING finger proteins, one to two B box-type fingers, and a putative 
coiled-coil domain [54, 88]. The C-terminal region contains homology in the zinc or 
PHD finger and bromodomain regions, respectively [55]. Further studies showed that 
in addition to these conserved domains, TIF1γ (TRIM33) and TIF1α share a 25 
amino acid-long, tryptophan- and phenylalanine-rich sequence downstream from the 
coiled coil motif. This sequence is highly conserved between all three TIF1 proteins 
and identical between TIF1α and TIF1γ (TRIM33) [61].  
      We determined if other TIF1 subfamily members potentially compensate for loss 
of Trim24 [3][89], and analyzed Trim28 and Trim33 RNA and protein from wild type 
(WT) and Trim24-/- MEFs (Fig. 5). These analyses showed no significant differences; 
therefore, it is unlikely that any phenotype of the Trim24-/- mouse is due to 
compensatory functions of TRIM28 or TRIM33. 
3.3. Trim24-/- mice develop hepatocellular lesions, steatosis and HCC.  
      A major phenotype of Trim24-/- mice is development of macroscopic white 
lesions in the liver by 4-6 months of age (Fig. 6A; a), compared to the normal 
morphology of Trim24+/- liver and Trim24+/+ liver (Fig. 6A; b, 7). H&E staining showed 
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that Trim24-/- liver lesions are composed of both micro- and macro-vesicular 
steatosis (Fig. 6A; c, d). Oil Red O (ORO) staining revealed that all hepatocytes 
within the lesions of Trim24-/- liver are filled with lipid (Fig. 6A; e, f) in contrast to 
Trim24+/+ liver (Fig. 7). Further, hepatic lipid accumulation can be seen as early as 2 
weeks of age (Fig. 8A) with significant accumulation of lipid in foci at 2 and 4 months 
of age (Fig. 8B, C). Trichrome staining to assess fibrotic progression was negative 
for collagen and mucin in Trim24-/- liver at 3 and 10 weeks of age (Fig. 9A,B), when 
lipid accumulation is already obvious, but was positive for fibrosis by 6 months (Fig. 
6A; g, h). Trim24+/+ liver remains negative at all ages (Fig. 9).
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Figure 5. Deletion of TRIM24 has no effect on TRIM28/33 expression. A) 
Western blot analysis of TRIM24, 28, and 33 protein expression in MEFs. β-actin - 
loading control and * - non-specific. B) Trim28 and Trim33 expression in MEFs (RT-
qPCR).  
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Figure 6. Lipids and fibrosis increase in aging Trim24-/-. 6 month liver, lesions 
(arrows) (a) Trim24-/-, (b) Trim24+/-; (c,d) Vacuolated lesions with steatosis (H&E, 
black arrows indicate borders of lipid filled lesions). (e,f) Lipid accumulation using Oil 
Red O staining (black arrows indicate borders of lipid filled lesions). (g,h) Fibrosis 
(arrows indicate positive staining, Trichrome). Bar: 500 µm (4X) and 50 µm (40X).  
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Figure 7. Normal morphology, lipid accumulation and fibrosis in age-matched 
Trim24+/+ liver (6 months). (a) Macroscopic analysis, (b, c) Histologic analysis by 
H&E staining, (d, e) Lipid accumulation analysis by Oil Red O staining, and (f, g) 
Fibrosis analysis by Trichrome staining. Bar: 4X: 500 µm; 40X: 50 µm.  
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Figure 8. Lipid accumulation in Trim24-/- livers. (A-C) Oil Red O staining of liver 
sections from Trim24-/- A) 2 weeks, B) 10 weeks, and C) 4 months. Arrows indicate 
positive staining for accumulation of lipids. Bar: 200 µm for 10X and 50 µm for 40X.  
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Figure 9. Fibrosis is not evident in young Trim24-/- livers. Trichrome staining of 
liver sections from Trim24-/- compared to Trim24+/+(a-b) 3 weeks and (c-d) 10 weeks. 
Bar: 500 µm for 4X and 50 µm for 40X (n>5). Postiive staining is dark blue and is not 
evident in these sections. For reference section, please consult Fig. 6h.  
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Significantly increased RNA levels of several collagen and matrix metallopeptidase 
(Mmp) genes and transforming growth factor-β receptor 2 (Tgfbr2) indicate 
upregulation of fibrotic and damage-related pathways at 10 weeks of age, but 
fibrosis is not apparent until 6 months of age  (Fig. 6,9,10). We saw progression of 
liver disease: between 9 and 23 months, the liver to body weight ratio (liver index) of 
Trim24-/- mice increased 2.7 fold, compared to Trim24+/+ and Trim24+/- mice (Fig. 11). 
Numerous macroscopic hepatic tumors (>2mm) were present in all Trim24-/- mice 
(29/29), regardless of gender (Fig. 12). In contrast, there was no evidence of hepatic 
tumors or anomalies in age- and background-matched Trim24+/+ (0/17, 12-15 
months) and Trim24+/- (0/11, 12-18 months) mice (Table 5, Fig. 13). At 18 months, 
Trim24-/- liver showed a spectrum of hyperplastic lesions, preneoplastic foci of 
cellular alteration (FCA) and neoplastic lesions of hepatocellular adenoma (HCA) 
with and without fatty changes (Fig. 12, a-i). The non-nodular or nodular HCA 
lesions had a vacuolated cell mass compressing the non-tumoral parenchyma (Fig. 
12D; b,c). ORO staining revealed lipid accumulation in vacuolated cells of the tumor 
(Fig. 12D; d, e). Locally invasive hepatocellular carcinoma (HCC) with nodules (Fig. 
12D; f, g) or without nodules (Fig. 12D; h, i) was seen in terminal mice. The relative 
presence or absence of nodules is evidence of both nodular and non-nodular HCC, 
therefore suggesting a heterogeneous tumor population. The distribution of tumor 
pathologies in Trim24-/- mice, ages 9-21 months (n=27), were 26% HCA, 33% HCC 
with HCA, 22% HCC without HCA, and 19% indeterminate (other) (Fig. 14). Trim24-/- 
mice have a median survival time of 409 days as compared to Trim24+/+ (no deaths 
at 585 days) (Fig. 15).  
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Figure 10. Fibrosis gene expression is upregulated upon loss of Trim24. 
Fibrosis genes up-regulated in 10 week Trim24-/- liver: n=6, *p<0.05; **p<0.01; 
***p<0.005.  
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Figure 11. Liver index is increased in Trim24-/- mice. Trim24-/- (n=29), Trim24+/+ 
(n=17) and Trim24+/- (n=11). ***p<6.7E-08. Mean ± SD.  
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Figure 12. Aging Trim24-/- mice develop hepatocellular carcinoma (HCC). 18 
month Trim24-/-: Multiple, large lesions (Hepatocellular adenoma – HCA) (b, c) 
Vacuolated (d, e) Lipid positive. (f,g) Invasive HCC without nodules. (h, i) Nodules. 
(Black Arrows = Boundary. T, tumor; NT, non-tumor). Bar: 500 µm (4X) and 50 µm 
(40X).  
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Figure 13. Normal morphology in livers of Trim24+/+ (a, 12 months) and 
Trim24+/- (d, 18 months) mice. (A) Histological analysis of liver sections from (b,c) 
aging Trim24+/+, (e,f) Trim24+/, in lower (4X: b,e) and higher (40X: c,f) magnification 
of H&E stain, respectively. Bar: 500 µm for 4X and 50 µm for 40X.  
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Figure 14. Distribution of HCC progression in aging Trim24-/-  livers. (A-B) 
Trim24-/- mice ages 9-21 months (n=27) Findings are reported as % of total. 
Hepatocellular Adenomas (HCA) have distinct borders (black arrows) with minimal 
cellular atypia of hepatocytes, and minimal or no disruption of the basement 
membrane (black reticulin stain). Hepatocellular Carcinomas (HCC) have poorly 
defined borders, high degree of cellular atypia, marked disruption of the basement 
membrane and loss of normal tissue architecture, with formation of thick trabeculae 
(green arrows) of multiple layers of neoplastic hepatocytes. Bar: 4x: 500 µm; 10x: 
200 µm; 40x: 50 µm.  
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Figure 15.   Trim24-/- mouse survival curve. Trim24-/- mice (n=45) have a median 
survival time of 409 days compared to Trim24+/+(n=7) with no deaths at 585 days. 
****p<0.0001.  
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3.4. Inflammation, injury and degeneration are increased in adult Trim24-/- 
mice. 
Key components of NASH in humans are aberrant plasma and intrahepatic lipid 
levels with accumulation of lipids, mainly triglycerides (TG), and increased 
hepatocelluar inflammation and steatosis, with subsequent injury and degeneration 
[90]. I quantified indicators of liver damage and NASH in plasma from Trim24+/+ and 
Trim24-/- mice (7 each).  Both alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels were significantly increased in Trim24-/-, suggesting 
liver damage (Fig. 16). In human NASH, there is dysfunction in the normal lipase-
mediated hydrolysis of TG in the liver to yield fatty acid and glycerol. Human patients 
have elevated plasma and hepatic TG levels, often associated with obesity [90]. In 
contrast, Trim24-/- mice are not obese: visceral fat and hepatic TG levels decreased 
(Fig. 16,17). Although plasma cholesterol and lipoprotein levels decreased, plasma 
TG and hepatic lipids increased (Fig. 16).        
       In further assessment of potential NASH, we performed histological analyses 
and quantified expression of genes associated with hepatocellular steatosis, injury 
and degeneration. Histological analysis of young adult Trim24-/- liver (10 weeks) 
revealed degenerated or damaged hepatocytes throughout (Fig. 18). Swollen, 
vacuolated cells (Fig. 18C; b, arrows), Mallory bodies (Fig. 18C; c, arrow), and 
nuclear inclusion bodies (Fig. 18C; d, arrow and insert) are characteristic of Trim24-/-
, unlike Trim24+/+ liver at 10 weeks (Fig. 18). An increase in cleaved-Caspase-3-
positive hepatocytes suggested hepatocellular damage induced cell death in the 
Trim24-/- liver by 10 weeks (Fig. 18C; e, f, arrow; quantified in Fig. 18D). Consistent 
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with these observations, expression of pro-apoptotic genes Bax and Caspase12 and 
ER stress gene Ddit3 (DNA-damage inducible transcript 3) are significantly 
increased in 10-week Trim24-/- liver (Fig. 19A). These signs of serious liver damage 
accompanied significant changes in specific pro-inflammatory gene expression (Fig. 
19B).  Taken together, lack of Trim24 in mice recapitulates many of the parameters 
of human NAFLD and a majority of NASH symptoms with age, although obesity did 
not occur (Fig. 16,17).  
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Figure 16. Hepatocellular damage and dysfunction in 2 month Trim24-/-. (A) 
ALT/AST: Trim24-/- (n=7), Trim24+/+ (n=6). (B) Lipoprotein, TG: Trim24-/- (n=7), 
Trim24+/+ (n=7; except TG n=6). Mean ± SD. * p<0.05, **p<0.01.  
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Figure 17. Abdominal peripheral fat is decreased in Trim24-/- mice. (A-C) 
Abdominal peripheral fat weights from 2, 4, and 6 month old Trim24+/+, Trim24+/-, and 
Trim24-/- male and female mice (n>5).    
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Figure 18. Trim24-/- livers show evidence of increased hepatocellular damage. 
A) a-d) Abnormal cells: Trim24-/- liver (H&E). (b, arrows) Damaged/vacuolated 
hepatocytes.  (c, arrow) Mallory, (d, arrow and inset) Nuclear inclusion bodies. (e, 
f, arrow) Apoptotic hepatocytes (IHC: cleaved Caspase 3). Bar: 500 µm (4X); 200 
µm (10X); 50 µm (40X). B) Cleaved Caspase 3 positive hepatocytes, Trim24-/- (20X 
field). C) Histological analysis (H&E staining) shows (a) normal morphology of 
Trim24+/+ liver at 4X and (b) 40X and (c) cleaved CASPASE 3 IHC negative staining 
at 4X and (d) 40X. Bar: 4x: 500 µm; 40x: 50 µm.  
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Figure 19. Apoptosis and fibrosis related genes are upregulated in Trim24-/-  
liver.  A) Apoptosis-related genes, B) Fibrosis-related genes, n=6 liver samples 
(mean ± SD),10 weeks. p value: *p<0.05; **p<0.01; ***p<0.005.   
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3.5. Genome-wide analysis of RNA expression in Trim24-/- liver  
To assess the global impact of TRIM24 on gene expression, we performed deep 
sequencing of RNA (RNA-seq).  Three biological RNA replicates were isolated from 
male Trim24+/+ and Trim24-/- liver at 10 weeks of age and sequenced (Fig. 4). A total 
of 763 genes showed statistically significant changes and differential expression at a 
false discovery rate (FDR) adjusted p-value (q-value) of 1%, calculated by EdgeR 
RNA-Seq analysis [91].  An approximately equal number of genes were activated or 
repressed in Trim24-/- (Table 6), consistent with TRIM24 functions as a co-repressor 
or -activator of transcription [92-95].   
 The top five biological functions identified by DAVID analysis [96] of up-regulated 
genes in Trim24-/-, reflecting loss of TRIM24 function as a co-repressor, are protein 
folding, defense response, RNA metabolism, cell cycle regulation and ER-nuclear 
signaling (Fig. 20) (Table 6).  Genes with decreased expression in Trim24-/-, 
reflecting loss of TRIM24 function as a co-activator, were grouped into biological 
functions of oxidation/reduction, steroid metabolism, lipid biosynthesis, fatty acid 
metabolism and steroid biosynthesis (Fig. 20). From this analysis, I hypothesized 
that the dual role of TRIM24 as a co-repressor and co-activator of transcription 
provided a link between the misregulated metabolic and inflammatory pathways 
observed in the phenotype of the Trim24-/- mouse. These links led me to pursue a 
more in-depth analysis involving overlap of this RNA-seq dataset and ChIP-seq to 
determine TRIM24 specific regulatory roles in metabolism, inflammation, and 
disease progression (see Chapter IV for more details).  
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Figure 20. Loss of TRIM24 causes hepatic misregulation of lipid metabolic, 
stress, and inflammatory related gene expression.    A) RNA-seq, DAVID 
Analysis - Top 5 enriched biological functions for up-regulated and down-regulated 
genes in Trim24-/-  versus Trim24+/+ liver at 10 weeks. B) Confirmation of 
misregulated gene from DAVID categories. qRT-PCR fold change with Trim24+/+=1 
(dashed line), n=3 each (mean ± SD). *p<0.05; **p<0.01; ***p<0.005.  
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3.6. Lipid metabolism and inflammation are aberrantly regulated in Trim24-/- 
liver. 
We assessed key genes associated with biological functions significantly impacted 
by loss of Trim24, as well as aberrantly regulated in human NAFLD and NASH [29, 
35].  Hepatic lipases, lipid transport/receptors and pro-inflammatory factor genes 
were significantly up-regulated, consistent with both the Trim24-/- phenotype and 
human NAFLD to NASH progression (Fig. 21 A,B, Table 7). Inconsistent with human 
NASH, genes associated with endogenous fatty acid synthesis (i.e. FASN, Scd1 and 
Acaca), were generally and significantly down-regulated (Fig. 21 A,B, Table 7). 
These inconsistencies between human NAFLD and NASH and the Trim24-/- mouse 
need to be further studied to determine if each model is directly comparable to each 
other. 
 Overall, loss of Trim24 decreased expression of genes involved in a) de novo 
lipid synthesis, b) apolipoproteins and lipid droplet/lipid storage, and c) VLDL 
transporter and receptors; as well as, increased expression of genes d) encoding 
lipases and apolipoprotein receptors and e) involved in proinflammation/fibrosis (Fig. 
21 A,B). Expression changes and levels of individual genes differ in levels and time 
of induction, likely reflecting developmental and epigenetic regulation during aging.   
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3.7. TRIM24 directly regulates genes in lipid metabolic, inflammation and  
damage pathways  
 
As a histone reader, TRIM24 does not bind DNA in a sequence-specific manner but 
rather interacts with specific histone post-translational modifications via a C-terminal 
PHD/bromodomain [59]. TRIM24 enrichment at chromatin may recruit specific 
TRIM24-interacting transcription factors, e.g. nuclear receptors RARα or estrogen 
receptor, to DNA binding sites [59, 84]. Ingenuity Pathway Analysis [97] of the most 
significant, differentially expressed, down-regulated gene pathways (by p-value): 
LPS/IL-1 inhibition of RXR function, FXR/RXR activation, super-pathway of 
cholesterol biosynthesis, PXR/RXR activation, and maturity onset diabetes of young 
(MODY) signaling, further supported TRIM24/nuclear receptor regulatory 
interactions. Thus, we used nuclear receptor DNA binding motifs (GGTCA half-sites) 
[98, 99] to focus ChIP-PCR analysis (Fig. 22) of TRIM24-chromatin interactions and 
assess direct regulation of genes altered in Trim24-/- liver.  
 Among the apolipoprotein genes (Fig. 21), we found significant TRIM24 binding 
at Apoa1, Apoc3 and Apod1 (Fig. 22). Several de novo lipid synthesis genes down-
regulated in the Trim24-/- liver, such as Acacb, were bound by TRIM24 at verified 
RARα binding sites [100]. Additionally, TRIM24 bound and directly regulated lipase 
Pnpla3, as well as VLDL transporter Mttp and the Vldlr gene (Fig. 21). Increased 
expression of several lipases in Trim24-/- liver (Fig. 21) suggests an imbalance in 
energy use or feedback response to accumulation of lipid [101].   TRIM24 was also 
enriched at genes, associated with inflammation and liver damage, with significantly 
altered expression (Figs. 10, 21). Pro-inflammatory factors Ccr2, Icam and Il-1a, as 
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well as liver damage and apoptosis genes, Ddit3, Bax and Casp12, had TRIM24 
enrichment, consistent with changes in gene expression and liver damage in Trim24-
/-. TRIM24 binding at the RARE/ERE consensus sites of Apoc3, at -150, and Ccr2, at 
-100, proved insignificant, reinforcing that not all predicted RARE/ERE sites show 
TRIM24 recruitment in liver tissue. These studies of TRIM24-chromatin interactions 
and direct regulation of target gene expression support a significant role for TRIM24 
in homeostasis by regulating genes of the lipid metabolic, inflammatory, and 
apoptotic pathways of the liver.  
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A 
 
B 
 
  
Figure 21. Loss of TRIM24 causes misregulation of inflammatory, stress, and 
lipid metabolic related gene expression indicative of NAFLD/NASH.  A) TG 
hydrolysis (lipases), pro-inflammation, and lipid transport gene expression at 3 and 
10 weeks. B) De novo lipid synthesis, storage, secretion, and transport gene 
expression at 3 and10 weeks. (A and B) qRT-PCR fold change with Trim24+/+=1 
(dashed line), n=3 each (mean ± SD). *p<0.05; **p<0.01; ***p<0.005.  
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Figure 22. TRIM24 regulates hepatic lipid metabolism, stress and inflammation 
genes.   Trim24+/+ 2-months liver tissue ChIP: Significant binding by TRIM24: 
*p<0.05; **p<0.01; ***p<0.001, ****p<0.0001. NS – nonspecific binding. Y-axis: 
TRIM24 enrichment as % input DNA.  
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3.8. Discussion.  
      Altered regulation of hepatic lipid metabolism, accompanied by chronic 
inflammation, is clearly linked to higher incidence of HCC in humans [85, 102]. 
Aberrant expression of several key genes in these pathways is associated with 
progression from NAFLD, where lipid metabolic and regulatory genes are indicated, 
to NASH, where inflammation is thought to play a major role in driving progression to 
HCC [103]. Here, we show that histone reader TRIM24 plays a direct role in the 
regulation of liver fat metabolism and inflammatory processes, prior to tissue 
damage and fibrosis. Additionally, global expression analyses of the Trim24-/- liver 
unveiled pathways, such as the Unfolded Protein Response and EndR-Nuclear 
Signaling, closely associated with human NAFLD, inflammatory stress and 
progression to apoptosis and tissue damage [104]. When Trim24 expression is 
completely absent, there is spontaneous development of disease across the 
spectrum of NAFLD-NASH-HCC, even when Trim24-/- mice are fed a normal diet. 
Mouse models genetically engineered for altered expression of Sfrp, Nemo, Pnpla3-
Il48M, Adiponectin, Mttp, ApoB and ApoC3 genes exhibit this disease progression, 
but only when stimulated by a high fat diet [101, 103]. Our finding that TRIM24 
directly regulates certain of these genes, such as Pnpla3, ApoC3, and Mttp, 
suggests an epigenetic hierarchy. TRIM24 may be a linchpin in transcription 
networks that intersect to prevent NAFLD and progression to HCC, due to its ability 
to serve as either an epigenetic co-repressor or co-activator of nuclear receptors and 
other transcription regulators [105] [59, 60].  
 The phenotype of a previous Trim24 mouse model with an exon 4 (E4) deletion, 
Trim24dlE4/dlE4, suggested that the only significant function of TRIM24 was prevention 
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of hepatic inflammation, as a co-repressor of retinoid-dependent genes and LTR-
driven enhancers [60, 85]. In contrast, although specific inflammatory-associated 
genes were altered in liver devoid of Trim24, we did not see an early or major 
response of RAR-regulated or retrovirus LTR-regulated genes associated with 
inflammation (Fig. 23, 24). Rapid development of HCC in the E4-deletion 
Trim24dlE4/dlE4 model lacks apparent progression through NAFLD or NASH, and a 
role for TRIM24 in pathways of lipid/fatty acid/steroid metabolism, 
oxidation/reduction and ER stress was not apparent, as summarized in Table 8. 
 Interestingly, alternative start sites of Trim24 transcription yield native isoforms of 
Trim24 lacking E4, as expressed in the Trim24dlE4/dlE4 mouse [85], and predicted to 
produce proteins known as TRIM24 variants 1 and 3, which have high similarity to 
BRAF (Variant 1: 84% protein identity, Variant 3: 64% protein identity) (Table 9). 
Intriguingly, chromosomal translocation and fusion of proto-oncogene BRAF and 
TRIM24 are reported in specific leukemias [106, 107]. Comparison of the two mouse 
models of TRIM24 function (Table 8) suggests that inflammation is the major driver 
that causes liver dysfunction to progress rapidly to HCC but when lipid metabolic 
pathways are significantly misregulated, prior to inflammation and damage, a more 
progressive development of HCC occurs.  These findings suggest that aggressive 
limitation of inflammation in human NAFLD patients may subvert or greatly delay 
development of HCC.   
 It remains unclear why aberrantly high expression of TRIM24 is associated with 
multiple human cancers, including HCC [83]; although, in a much smaller cohort of 
patients, significantly lower than normal levels of TRIM24 is reported [108]. This 
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discontinuity may be due to TRIM24 functions in hepatic homeostasis with over- or 
under-expression leading to a regulatory imbalance. Additionally, not all hallmarks of 
NAFLD and NASH [109] are observed with loss of Trim24, although hepatic 
steatosis, inflammation and fibrosis, with hepatocyte injury and apoptosis, are 
present. Complete loss of Trim24 caused a striking decrease in peripheral fat 
accumulation, along with elevated serum triglycerides and hepatocyte lipid 
accumulation, characteristics recently associated with NAFLD among nonobese 
patients [110]. Further study of the Trim24-/- mouse and manipulation of diet may 
offer mechanistic insights as a model of human NAFLD, which may progress to 
NASH and HCC, among nonobese patients.    
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Figure 23. Retro-viral associated gene expression is increased in Trim24-/- 
mice. Genes associated with VL30-retrotransposon viral control show upregulated 
mRNA expression levels in Trim24-/- livers (10 weeks, performed with the same RNA 
as used in RNA-Seq, all additional samples were age matched) and the data shown 
represent n=3-5 male liver samples (mean ± SD). Dashed line is Trim24+/+ gene 
expression, normalized to 1.  mRNA expression levels were normalized to Hprt, 
*p<0.05. 
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Figure 24. Some retinoid responsive genes are misregulated in Trim24-/- livers 
at 3 and 10 weeks of age. mRNA levels of genes shown to be retinoid responsive 
show varying levels of differential expression compared to wildtype control. All 
mRNA expression levels of 3 & 10 week livers were performed represent n=11, n=12 
male liver samples, respectively (mean ± SD). All mRNA expression levels were 
normalized to Hprt, *p<0.05; ***p<0.005.  
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CHAPTER IV 
 
TRIM24 suppresses progressive chronic inflammation and protects from 
secondary metabolic disorders associated with NASH progression. 
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4.1. Introduction.  
      Macrophages throughout the body arise from committed hematopoietic cells in 
the bone marrow. Macrophage precursors are released from the bone marrow as 
monocytes and seed into various organs, such as the spleen [111]. As monocytes 
travel from circulation to specific organs, they differentiate into either macrophages 
or dendritic cells (DCs), which have a primary function to aid the innate immune 
response by phagocytosis [112].  Several cell surface markers are available that are 
positive in macrophages but not DCs, such as F4/80, CD1b, CD18, CD68, and FC 
receptors. However, it should be kept in mind that since both of these cell types 
arise from common myeloid progenitor populations, these markers are not 
completely definitive, but provide the best mode of identification available at present 
[112].    Based upon location and phenotype, macrophages are divided into sub-
populations: osteoclasts (bone), alveolar (lung), histiocytes (connective tissue), and 
Kupffer cells (liver) [113]. All of these tissue specific macrophages work with DCs to 
maintain homeostasis.  Seminal studies in the 1980’s by Mosmann et al. found T 
helper (Th) cells could be divided into two distinct categories based on their 
activation and production of either IFNγ (Th1) or IL-4 (Th2) [114]. Mills et al. found 
that macrophages showed differential activation based upon stimulus with either 
LPS or IFNγ in mouse models with Th1 or Th2 backgrounds [115]. They found that 
M1 macrophages produced toxic nitric oxide (NO), while M2 macrophages produced 
trophic amines. Further studies showed that development of classically activated 
(M1) and alternatively activated (M2) macrophages was independent of T and B 
cells and reliant on transforming growth factor–beta (TGF-β) inhibition of induced 
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nitric oxide synthase (iNOS) [112] [116]. M1 macrophages are activated by the 
presence of bacteria, protozoa, and viruses and have roles in antitumor immunity. 
M2 macrophages have anti-inflammatory functions and typically regulate wound 
healing and fibrosis [117, 118]. Interestingly, M2 macrophages regulate metabolic 
functions [119] and are induced by peroxisome proliferator activated receptor-γ 
(PPAR-γ) signaling to maintain adipocyte function, along with glucose and insulin 
metabolism, in prevention of diabetes and obesity. [119, 120]. In tumorigenesis, M1 
macrophages are considered tumor protective, with tumor suppressive roles that 
antagonize immune-suppressive activities of M2 macrophages. M2 macrophages 
and other regulatory macrophages (also tumor-associated macrophages) reportedly 
suppress immune responses to tumor progression and promote tumor growth, 
invasion, metastasis, and angiogenesis [121-126].  
      Multiple studies suggest that progression from NAFLD to NASH is accomplished 
via increased circulating NEFAs, adipokines, hepatocellular damage, oxidative 
damage, and endoplasmic reticulum stress, all of which are associated with aberrant 
inflammatory processes [127-129]. The progression of HCC is also known to be 
associated with these processes, which are dependent upon KCs that are primed to 
promote tumorigeneis [130]. However, little is known about the causative 
mechanisms and specific cell populations in the liver underlying progression from 
NAFLD to NASH and ultimately HCC.  
     Regulation of glucose metabolism and insulin sensitivity is a key component of 
healthy metabolic function. The endpoint of glucose and insulin homeostasis is to 
provide usable energy in the form of sugar and ATP to the brain through a complex, 
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highly regulated network that manages the influx and efflux of glucose between the 
pancreas, liver, muscle, and brain [131]. Glucose can be produced from 3 sources 
(apart from the ingested form): fat, proteins, and glycogen [131].  Adipose tissue 
serves as the main reserve for glucose and, ultimately, energy in the body. Proteins 
are the substrates for gluconeogenesis, which is the process by which proteins are 
broken down into glucose mainly by the liver and the kidneys (only during prolonged 
fasting and acidosis) [131-133]. More specifically, the liver, along with muscle, is 
instrumental in converting glucose taken from the bloodstream to glycogen, through 
glycogen synthesis. Briefly, during intake and digestion of a meal, glucose levels in 
the blood rise, causing secretion of insulin by beta cells of the pancreas. As glucose 
enters the liver via the portal vein and into hepatocytes, the secreted insulin 
activates glycogen synthase. A protein known as glycogenin, the substrate for 
glycogen synthase, has the ability to bind and produce short chains of glucose. 
Once there are 10 or more glucose residues in the chain, proglycogen and glycogen 
synthase elongate the chain and transfer a free glucose to the ends of the chain. 
Uridine diphosphate (UDP) is needed as the energy source for the reaction and 
drive the reaction leading to the final product of glycogen [131].  
      During fasting, the liver converts stores of glycogen to glucose in a process 
known as glycogenolysis. First, glycogen is converted to glucose-6-phosphate (G6P) 
by glyocogen phosphorylase. Glucose-6-phosphatase then converts G6P to free 
glucose (Fig. 25). Following extended periods of fasting (>8 hours), the liver 
gradually reverts to gluconeogenesis to replace glycogenolysis [131]. This turnover 
is accomplished by a signaling cascade set in motion by a decrease in hepatic 
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glycogen, which in turn leads to a decrease in blood glucose and insulin levels. The 
pancreas then increases glucagon secretion, mobilization of gluconeogenesis 
precursors, free fatty acids (alternative forms of energy), increases intracellular 
production of cyclic adenosine monophosphate (cAMP) and signals to increase 
hepatic gluconeogenesis. Conversely, when hepatic glucose levels have reached 
appropriate levels, insulin is secreted from the pancreas, causing a marked decline 
in cAMP levels, hepatic glucose output, and inhibition of glucagon secretion [134]. 
For these processes to occur, glucose, due to its hydrophilic nature, relies on 
glucose transporters for entry into the cell  (Table 10). There are two types of 
glucose transporters: the sodium-dependent glucose transporter (SGLT) family and 
the glucose transporter (GLUT) family. SGLT family members transport against the 
concentration gradient via a sodium electrochemical gradient, while GLUT family 
members utilize facultative transport [135]  The glucose transporter or solute carrier 
2A (SLC2A) proteins are divided as follows: Class I (SCL2A1-4, 14), II  (SCL2A 5, 7, 
9, 11), III (SCL2A 6,8,10,12,13) based upon their action in various organs and 
dependence on insulin [136].  Once glucose has entered the cytosol via the glucose 
transporter, glycolysis must be utilized in order to convert 1 mole of glucose into 2 
moles of ATP, 2 moles of NADH, and 2 moles of pyruvate  (Fig. 25) (glycolysis and 
TCA cycle).  Under aerobic conditions, pyruvate is then converted to acetyl CoA 
(substrate of mitochondria to generate ATP) via the tricarboxylic acid (TCA) cycle 
and nets 36 moles of ATP for every mole of glucose. Anaerobic conditions force the 
cell to solely rely on glycolysis, where pyruvate is converted to lactate, which in turn 
produces the factors needed for glycolysis.  
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It is well established that dramatic shifts in metabolism are associated with cancer 
incidence [137]. Due to massive increases in energy expenditure by cancer cells, 
shifts in glucose-dependent metabolic activity toward increased aerobic glycolysis 
are common in invasive cancers [138]. The ability of cancer cells to alter metabolic 
activity provides a critical source of increased energy for processes that are 
hallmarks of cancer progression: uninhibited proliferation through evasion of growth 
inhibitory signals, migration, angiogenesis and vascularization, and metastasis of 
cells to distant target organs [139]. While oncogenes, tumor suppressors and 
metabolic transformation in cancer cells are recognized as key components in 
potential therapeutic strategies, little is known regarding how these linked processes 
relate to one another. 
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Figure 25. Glycolysis, TCA cycle, and Fatty Acid Regulation.  
Modified from Nature Genetics 2014, 46, 24-32 [140] 
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metabolic diseases (P = 4 × 10−6, 265 genes); genetic association to 
cancer was also highly evident (P = 6 × 10−10, 431 genes). Overall, 
genes associated with protein, carbohydrate, lipid and nucleic acid 
metabolism were highly mutated by SB. Several other processes were 
also targeted, including oxidoreduction and metabolism of ATP, orga-
nophosphate, hormones, isoprenoid and vitamins (Supplementary 
Table 6).
To determine whether similar genetic changes occur in human 
HCC, we measured metabolic gene expression levels in 18 HBV-
positive human HCC tumors and 9 liver-SB/HBsAg tumors using 
quantitative RT-PCR (qRT-PCR). The deregulation of key metabolic 
genes was positively correlated in these two species, and similar gene 
expression signatures were found for most genes (Supplementary 
Fig. 15). The classification of HCC CIS genes has thus highlighted 
the importance and specificity of targeting metabolic genes in HCC. 
The fact that normal hepatocytes display important general meta-
bolic functions that most likely need to be reorganized during malig-
nant transformation may explain the reprogramming by SB of many 
aspects of hepatocyte metabolism.
Metabolic profiling and mapping of mouse HCC tumors
To better understand how genetic changes in metabolic genes affect 
hepatic tumor metabolism, we performed nontargeted metabolic 
profiling on eight food-restricted liver-SB/HBsAg animals. We used 
chemical derivatization and gas chromatography coupled to time-of-
flight mass spectrometry (GC/TOFMS) to identify the differences in 
metabotypes between malignant (tumor mass >3 mm) and adjacent 
normal liver tissue. We verified the quality of the acquired metabo-
lomics data by principal component analysis (PCA) and partial least-
squares discriminant analysis (PLS-DA) (Supplementary Fig. 16). 
Even with eight matched samples, statistical analyses using t test and 
Welch test were able to identify 56 annotated metabolites that were 
significantly changed in tumors compared to normal adjacent tis-
sues (Supplementary Fig. 17). Consistent with the transposon data, 
we noticed significant alterations corresponding to specific meta-
bolic pathways. For instance, carbohydrate metabolism was affected 
through increased levels of glucose and fructose and reduced levels of 
ribitol, ribonic acid and allonic acid. The levels of several amino acids, 
including isoleucine, valine, asparagine, tyrosine, methionine, serine, 
leucine, phenylalanine, threonine and alanine, were also significantly 
(P < 0.01) downregulated in tumors, which is consistent with data 
from human tumors56. Moreover, we found components of nucleic 
acids, including ribose, pyridine, uracil and uridine, at higher levels 
in tumors. We then integrated the genetic (Supplementary Table 1c), 
expression4 and metabolic results (Supplementary Table 7) in order 
to identify potential correlations. We noticed a marked consistency 
Figure 5 Mapping of genomic and metabonomic 
data to metabolic pathways disrupted in HCC. 
To understand the metabolic pathways that are 
disrupted in HCC at the genetic, mRNA and 
metabolite levels, we used data from the liver-
SB/HBV screen (Supplementary Table 1c),  
human expression data4 and metabolomic 
results (Supplementary Table 7). Metabolites 
are written with larger font size, and genes 
are written with smaller font size. Red or blue 
fonts indicate that the gene expression or 
metabolite amount is increased or decreased, 
respectively, in HCC tissue as compared to 
adjacent nontumor tissue. The CIS genes that 
are listed in Supplementary Table 1c are labeled 
with asterisks. This map focuses on glycolysis, 
the TCA cycle, glutaminolysis and the pentose 
phosphate (PP) pathway. Despite the increased 
glucose uptake (Glut1 and Glut2 (Glut1/2)) and 
consumption, the tumor cells predominantly 
expressed the pyruvate kinase M2 isoform 
(Pkm2), which converts phosphoenolpyruvate 
(PEP) to pyruvate less efficiently than Pkm1 
does70. This promotes the accumulation and 
shuttling of glycolytic intermediates such 
as glucose-6-phosphate (G6P), fructose-6-
phosphate (F6P) and fructose-1,6-biphosphate 
2 (FBP) to the PP pathway and macromolecular 
synthesis69. Thus, this termination of the 
glycolysis metabolic pathway, together with 
dysregulation of Pcx and Pdk1 and Pdk2 
(Pdk1/2), would prevent pyruvate from entering 
the TCA cycle. This would also lead to a 
truncated TCA cycle and insufficient glucose-
dependent citrate production. However, most 
of the TCA-cycle gene products (Idh1, Idh2 (Idh1/2), Sdha, Fh and Ogdh) and corresponding intermediates are upregulated in tumor cells, except for 
the downregulation of the aconitase gene family (Aco1 and Aco2 (Aco1/2)), suggesting the TCA cycle is at least partially activated. Our results imply an 
activation of glutaminolysis (Cat2, Gls and Glud1 and Glud2 (Glud1/2)) that converts glutamine to ?-ketoglutarate to replenish TCA-cycle intermediates. 
Effective maintenance of citrate synthesis is possible through reductive carboxylation of glutamine-derived ?-ketoglutarate by Idh1/2 (ref. 73). These 
adaptations around glycolysis and the TCA cycle could allow rapid generation of both ATP for bioenergetics and important metabolites for biosynthesis. 
In addition, the breakdown of citrate by Acly could constitute a primary source of acetyl-CoA (ac-CoA) for fatty acid and lipid synthesis. Moreover, 
upregulation of Ldha could convert glutamine-derived pyruvate to lactate that is excreted by the Mct4 transporter outside the cells68.
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Table 10. Glucose transporter genes expressed in the liver.  Modified from 
World J Gastroenterol. 2012;18(46):6771-81 [136].  
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Metabolic syndrome (MS) is a growing problem in the Western world, and is 
commonly defined by: dyslipidemia manifested as hypertriglycemia, glucose 
intolerance (fasting hyperglycemia), insulin resistance, and central obesity [141].  
The equivalent of MS in the liver is manifested in NAFLD, NASH, and HCC. As 
discussed in the first chapters of this work, our mouse model of Trim24 deletion, 
which completely lacks Trim24 expression, showed different results from the original 
deletion of exon 4 of Trim24 [85, 105]. We discovered a previously unknown role for 
TRIM24 in hepatic homeostasis, as an epigenetic regulator of oxidation/reduction, 
lipid, steroid and fatty acid metabolism, as well as unfolded protein response and 
ER-stress and inflammatory pathways; all without manipulation of dietary fat or 
chemical induction.  This mouse also shows hallmarks and progression of NAFLD, 
NASH, and HCC by misregulation of key metabolic and inflammatory related genes 
in the liver. However, key components of secondary metabolic syndrome such as 
aberrant glucose metabolism and insulin sensitivity, accompanied by central obesity 
were not defined in this model.   
       I reasoned that it would be important to not only test the specific immune cell 
populations that were regulated by TRIM24 in NAFLD and NASH progression, but to 
also determine if a metabolic link, possibly related to this progression, was “setting 
the stage” for transformation of normal hepatic cells to cancer. Therefore, in this 
chapter, I focus on establishing the status of aberrant inflammation and metabolism 
in the Trim24-/- mouse model.   
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4.2. Germline deletion of TRIM24 causes on increase in hepatic macrophage 
populations.  
      Since previous studies detailed in the first portion of this work, showed that 
germline deletion of Trim24 causes dysregulation of genes related to NAFLD and 
NASH progression, I utilized this same model in an effort to understand the effects of 
TRIM24 loss on specific, hepatic immune populations and their contributions to the 
disease progression of this mouse model. Utilizing immunohistochemistry for F4/80, 
I found that hepatic macrophage populations (dark blue staining marked by arrow) 
were increased in comparison to control at 2 months (10 weeks of age) (Fig. 26). To 
further determine if this increase in hepatic macrophage populations was significant, 
I perfused and isolated hepatic immune cells and analyzed by Flow Cytometry using 
the cell surface markers listed in Table 14. I found that hepatic macrophage (CD45+, 
F4/80+) populations were significantly increased in Trim24-/- liver, suggesting 
possible macrophage infiltration (Fig. 27). Additionally, though not significant, 
myeloid lineage (CD45+, CD11b+) populations were increased in Trim24-/- liver (Fig. 
28). These findings suggest that Trim24 may have an immuno-protective role in the 
liver to regulate macrophage and myeloid populations.    
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Figure 26. Hepatic macrophages are increased in Trim24-/- liver. IHC for F4/80, 
cell surface marker for macrophages is shown by positive blue staining in liver 
sections. Trim24+/+ and Trim24-/- liver are shown at 10x: 200 µm; 40x: 50 µm. Arrow 
indicates positive F4/80 staining for macrophages. N=3 for both genotypes, 10 
weeks of age.  
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Figure 27. Hepatic macrophages are increased in Trim24-/- liver. A) Flow 
cytometry using cell surface markers for CD45 (Pacific Blue) and F4/80 (PerCP-Cy5-
5-A) showed an increase in hepatic macrophages in Trim24-/- liver compared to 
control. B) Quantification of the cell populations in A). 10 weeks of age, isolated from 
whole liver. N=3 per genotype. **p<0.01.  
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Figure 28. Hepatic myeloid cells are increased in Trim24-/- liver. A) Flow 
cytometry using cell surface markers for CD45 (Pacific Blue) and Cd11b (PE). 
showed an increase in hepatic hepatic myeloid populations in Trim24-/- liver 
compared to control. B) Quantificaton of the cell populations in A). 10 weeks of age, 
isolated from whole liver. N=3 per genotype.  
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4.3. Intersection of RNA-seq and ChIP-seq analysis reveals differentially 
expressed TRIM24 bound metabolic and inflammatory target genes  
     While the results of the phenotypic analysis of both the germline and liver-specific 
deletion pointed to TRIM24 as a potential regulator of both metabolic and 
inflammatory processes, I needed further evidence of a direct regulatory function of 
TRIM24. Thus, I mined unpublished liver RNA-seq (male and female, 10 weeks, 
Trim24+/+ and Trim24-/-) and TRIM24-ChIP-seq (liver; pooled genders, 10 weeks, 
Trim24+/+) to determine the transcriptional activity of TRIM24 in early disease 
development (2 months of age). I chose this timepoint due to the fact that early 
changes in the liver are likely critical catalysts for disease progression. Intersection 
of the RNA-seq and TRIM24-ChIP-seq datasets revealed direct TRIM24 gene 
targets that could be divided into categories of repressed or activated by TRIM24. 
Functional annotation analyses revealed that TRIM24-repressed genes are primarily 
involved in inflammatory and oxidative stress response, whereas genes activated by 
TRIM24 are involved in lipid and glucose metabolism (these categories will be 
discussed later in the chapter) (Figs. 29-30, Table 11). The first category of TRIM24 
repressed genes, NRF2-mediated Oxidative Stress Response, includes genes such 
as Jun, JunD, JunB, and Nrf2 (Nfe2l2).  The oxidative stress response causes not 
only activation of genes associated with acute phase inflammatory response (such 
as Nrf2) as well as proto-oncogeneic families such as the Jun family. Upon loss of 
Trim24, loss of repression of these genes has been shown to be integral to the 
progression of HCC [142] [143]. 
 
 105 
The Aryl Hydrocarbon Receptor (AHR) Signaling/ATM Signaling categories include 
genes such as Jun, Cdkn1a, and Nrf2. AHRs have been shown to be integral in 
protection against toxins, immune system defects and homeostasis of 
hematopoiesis in AHR knockout mouse models [144]. Additionally, ATM signaling, 
especially in the case of Cdkn1a (p21) is implicated in misregulation of cell cycle 
homeostasis, leading to genomic instability, cell damage, and in the case of the liver, 
chronic damage if not tightly regulated [145]. The Acute Phase Response Signaling 
category includes genes such as Jun, Saa1, and Saa2. The first mounted response 
of the immune system is the acute phase response, which includes phagocytosis of 
foreign material by macrophages [146]. Saa1/2 (serum amyloid A) are associated 
with inflammatory acute phase response and secreted primarily by hepatocytes 
[147]. Additional studies have linked SAA proteins to stimulation of monocytes and 
macrophage misregulated lipid metabolism [147, 148]. Finally, the UVA-Induced 
MAPK Signaling category includes genes such as Jun and Parp12. Parp12 has 
been shown to be associated with increase cellular damage and DNA injury [149]. 
Taken together, these changes are consistent with increased inflammation and 
damage observed in NAFLD, NASH, and HCC progression. 
The genes that are most significantly misregulated and bound by TRIM24 are 
involved in inflammatory/oxidative stress response pathways, I found that Nrf2 and 
Saa1 were significantly bound by TRIM24 and up-regulated upon loss of TRIM24. 
TRIM24 enrichment at these gene promoters was validated by ChIP-qPCR, thus 
providing evidence of direct regulation of these genes by TRIM24 (Fig. 31). While 
both binding levels were significant, Nrf2 is the most significantly regulated gene by 
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TRIM24, suggesting that misregulation of Nrf2 expression is the most likely 
contributing to a combination effect that leads to the phenotype evident in the 
Trim24-/- mouse liver. Thus, while Nrf2 misregulation is a key factor in disease 
progression, loss of Trim24 is the overall driver of the changes that are occurring in 
the mouse model, as evident by both RNA- and ChIP-seq analyses.   
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Figure 29. Integrated RNA- and ChIP-seq and identification of TRIM24 bound, 
differentially expressed gene targets that are repressed by TRIM24. A) Venn 
diagram of overlapping 10 week male and female Trim24-/- liver RNA-seqs with 
Trim24+/+ liver pooled gender ChIP-seq. B) IPA analysis of top differentially 
expressed TRIM24 bound gene pathways. 
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Figure 30. Integrated RNA- and ChIP-seq and identification of TRIM24 bound, 
differentially expressed gene targets that are activated by TRIM24. A) Venn 
diagram of overlapping 10 week male and female Trim24-/- liver RNA-seqs with 
Trim24+/+ liver pooled gender ChIP-seq. B) IPA analysis of top differentially 
expressed TRIM24 bound gene pathways. 
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IPA Pathway – TRIM24 
activated genes 
Genes 
Triacylglycerol Biosynthesis Lpin1, Lpin2 
Trehaolose Degradation II 
(Trehalase) 
Gck 
L-cysteine Degradation III Got1 
Methylglyoxal Degradation I Glo1 
Glutamate Degradation II Got1 
 
 
                    
 
Table 11. Top 5 IPA categories and gene targets from integration of RNA- and 
ChIP-seq in mouse liver. A) TRIM24 activated pathways are mainly concentrated 
in oxidative stress and inflammatory related (acute phase response) pathways. B) 
TRIM24 repressed pathways are mainly concentrated in lipid and glucose metabolic 
pathways. 10 week male and female Trim24-/- liver RNA-seqs with Trim24+/+ liver 
pooled gender ChIP-seq. 
 
 
 
 
 
 
 
 
 
IPA Pathway – TRIM24 
repressed genes 
Genes 
NRF2-mediated Oxidative 
Stress Response 
Jun, JunD, JunB, Nfe2l2 
Aryl Hydrocarbon Receptor 
Signaling 
Jun, Cdkn1a, Nfe2l2 
Acute Phase Response 
Signaling 
Jun, Saa1, Saa2 
ATM Signaling Jun, Cdkn1a 
UVA-Induced MAPK 
Signaling 
Jun, Parp12 
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Figure 31. TRIM24 binds oxidative stress response and inflammatory related 
genes in the liver. Trim24+/+ 2-month liver tissue ChIP: Significant binding by 
TRIM24: N>4 *p<0.05;  ***p<0.001. Significance is based upon comparison to non-
specific binding control. Male and female liver samples were pooled for this analysis. 
Y-axis: TRIM24 enrichment as % input DNA.  
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4.4. Trim24-/- mice exhibit increased glucose metabolism and insulin sensitivity  
     As mentioned previously, secondary metabolic disorders, such as insulin 
resistance and diabetes, frequently accompany human NAFLD and NASH 
progression. In order to determine if loss of Trim24 recapitulates this phenotype, I 
performed glucose tolerance (GTT) and insulin tolerance (ITT) tests on 2, 4, and 6 
month old mice (Fig 32).  Interestingly, while mice exhibit misregulation of hepatic 
lipid metabolic genes as early as 10 weeks (2 months) of age, they do not exhibit 
signs of diabetes. In fact, GTT and ITT test results show that both male and female 
Trim24-/- mice metabolize glucose at a faster rate and are more sensitive to insulin 
than their wild-type counterparts over a time-course of age, which becomes more 
significant as the disease progresses (Figs. 33-34). Gene expression of glucose 
transporters and insulin receptor substrates that are typically misregulated in 
metabolic disease (Irs 1/2 levels are decreased, glucose transporter levels are 
increased) showed an increase in expression of Irs1 (not significant), but no 
changes in Irs2 or Glut2 expression (data not shown). Gene expression levels of 
specific, key components of hepatic glycolysis were decreased in Trim24-/- liver 
compared to control (Fig. 35). I further tested the livers collected from fasting 
Trim24+/+ and Trim24-/- mice that were tested in GTT and ITT experiments for 
metabolism of glycogen by Periodic Acid Schiff (PAS) staining. PAS staining detects 
polysaccharides such as glycogen by breaking down the components of the sugars 
to produce aldehydes that react with Schiff’s reagent to produce a purple-magenta  
color. Upon staining, I found that as the disease progressed, Trim24-/- liver showed 
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less hepatic glycogen compared to control (arrows, Fig. 36). These results suggest 
that Trim24 expression may be instrumental in keeping hepatic glycogen storage 
levels stable as a source of easily convertible energy for the body. Taken together, 
these metabolic and gene expression studies confirm that while glucose metabolism, 
insulin sensitivity, and glycogen storage are aberrant upon loss of Trim24, diabetes 
does not occur.  
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Figure 32. Workflow of glucose and insulin tolerance tests (GTT/ITT). 1) Mice 
were fasted for 6 hours from 4 a.m. – 10 a.m. to clear undigested food. Weight was 
recorded and glucose/insulin was calculated based upon body weight just prior to 
beginning the testing period. 2) An initial tail snip and blood glucose reading were 
taken to establish a baseline reading. 3) Mice were injected interperitoneally (I.P.) 
with either glucose or insulin and sampled at 15, 30, 60, and 120 minutes following 
injection. 4) After the final reading, mice were allowed to recover for a week before 
the reciprocal test was performed. Another week of recovery was allowed prior to 
serum/plasma collection, euthanasia and harvesting.  
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Figure 33. Glucose metabolism and insulin sensitivity increases in male 2, 4, 
and 6 month Trim24-/- mice. A) Glucose tolerance tests were performed over a two 
hour time period, following six hours of fasting. The Y-axis represents blood glucose 
levels following glucose injection (mg/dL) and the X-axis represents time following 
glucose injection (min). B) Insulin tolerance tests were performed over a two hour 
time period, following six hours of fasting. The Y-axis represents blood glucose 
levels following insulin injection (mg/dL) and the X-axis represents time following 
insulin injection (min). N>10. Mean ± SD. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 34. Glucose metabolism is relatively unchanged and insulin sensitivity 
increases in female 2, 4, and 6 month Trim24-/- mice. A) Glucose tolerance tests 
were performed over a two hour time period, following six hours of fasting. The Y-
axis represents blood glucose levels following glucose injection (mg/dL) and the X-
axis represents time following glucose injection (min). N>10. Mean ± SD. *p<0.05. 
B) Insulin tolerance tests were performed over a two hour time period, following six 
hours of fasting. The Y-axis represents blood glucose levels following insulin 
injection (mg/dL) and the X-axis represents time following insulin injection (min). 
N>10. Mean ± SD. * p<0.05, **p<0.01. 
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Figure 35. Hepatic gene expression levels of glycolysis related factors are 
decreased upon loss of Trim24 (2 months of age). mRNA levels of glucose 
metabolism genes show varying levels of differential expression compared to 
wildtype control (dotted line). All mRNA expression levels of 10 week livers were 
performed represent n=3 liver samples, respectively (mean ± SD). All mRNA 
expression levels were normalized to Hprt, *p<0.05; **p<0.01, ***0.001.   
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Figure 36. Loss of TRIM24 leads to decreased glycogen metabolism during 
aging. PAS staining of aging Trim24-/- compared to Trim24+/+ liver at A) 10 weeks, B) 
4 months, and C) Aging (>7 months). Bar: 4x: 500 µm; 40x: 50 µm. Arrows indicate 
dark pink staining = positive glycogen staining.   
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4.5. Loss of TRIM24 causes a decrease in visceral body fat  
        The storage of lipid is necessary to serve as an alternative energy source, but 
excess stores of lipid can cause a myriad of disorders such as metabolic syndrome 
and NAFLD. The majority of patients that present with NAFLD or NASH are obese 
and diabetic, however a subset of patients is lean and otherwise healthy [38]. Given 
the results obtained by testing glucose, insulin, and glycogen metabolism, I 
reasoned that Trim24-/- mice are likely to be lean. To measure the amount of visceral 
white fat in our mice (as a comparison to human disease), I weighed the mice and 
recorded total body and visceral abdominal white fat weights. From these analyses, I 
found that Trim24-/-  mice have lower overall body weight and visceral fat weights in 
both genders at 2, 4, and 6 months of age (Fig. 37-38). There were no appreciable 
differences in liver index at these timepoints, which are prior to HCC progression 
(Fig. 39). Thus, Trim24-/- mice are non-obese and non-diabetic.  
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Figure 37. Loss of TRIM24 causes a decrease in total body weight during 
aging. Body weights are expressed in grams. A) 2, B) 4, C) 6 month male and 
female mice n>5. Mean ± SD. * p<0.05, **p<0.01, ****p<0.0001. 
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Figure 38. Loss of TRIM24 causes a decrease in visceral white fat weight 
during aging. Visceral white fat weights are expressed in grams. . A) 2, B) 4, C) 6 
month male and female mice n>5. Mean ± SD. * p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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Figure 39. Loss of TRIM24 has no effect on liver index prior to HCC 
progression. Liver indeces are expressed in grams and calculated by divided body 
weight by liver weight. A) 2, B) 4, C) 6 month male and female mice n>5. Mean ± 
SD. * p<0.05. 
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4.6. Overlap of RNA-seq and ChIP-seq analysis reveals differentially expressed 
TRIM24 bound lipid and glucose metabolic target genes      
     Based on the analysis of genome-wide expression (see Section 4.3), TRIM24 
activated gene targets are primarily involved in lipid and glucose metabolic 
pathways. The Triacylglycerol Biosynthesis category includes the genes: Lpin1/2. 
Lpin1/2, which are key genes associated with lipid storage. The Trehalose 
Degradation II (Trehalase) category includes the Gck gene, which is a key enzyme 
involved in the first step of glycolysis. The next categories, L-cysteine Degradataion 
III and Glutamate Degradation II include the Got1 gene. Got1 (glutamic-oxaloacetic 
transaminase 1) is a gene that is induced by p53 and is responsible for amino acid 
metabolism as well as urea and TCA cycles [150]. The final category, Methylglyoxal 
Degradation I, includes the gene, Glo1 (glyoxalase I). Glo1 functions to detoxify 
reactive metabolites that are a byproduct of hyperglycemic metabolism [151]. Upon 
ChIP-qPCR validation, I found that Lpin1 and Gck were significantly bound by 
TRIM24. (Fig. 40)  While these mice are not obese and do not develop diabetes, 
hepatic metabolism of lipid and glucose are severely misregulated. 
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Figure 40.  TRIM24 binds lipid and glucose genes in the liver.  Trim24+/+ 2-month 
liver tissue ChIP: Significant binding by TRIM24: *p<0.05; **p<0.01,  ***p<0.001. 
Significance is based upon comparison to non-specific binding control. Male and 
female liver samples were pooled for this analysis. Y-axis: TRIM24 enrichment as % 
input DNA.  
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4.7. Discussion.  
      Taken together, these results suggest that our Trim24-/- mouse model 
recapitulates disease progression that is similar to non-obese NAFLD patients. The 
TRIM24-repressed genes, Nrf2 and Saa1, are indicative of aberrant hepatic and 
systemic inflammatory changes. More specifically, Nuclear factor erythroid-derived 
2, like 2 (Nrf2 or Nfe2l2) encodes a transcription factor that regulates the expression 
of genes that encode anti-oxidant and ROS-detoxifying proteins [152]. RXRs can 
form homo- and hetero-dimers with other nuclear receptors such as those for 
retinoid receptor α (RARα) or peroxisome proliferator-activated receptors (PPARs) 
[142]. In a study of rat macrophages, PPARγ was shown to directly interact with 
NRF2 and repress its transactivation [153]. Additionally, overexpression of PPARγ 
was shown to inhibit Nrf2 transcription [153].  
       As previously discussed, TRIM24 is a co-regulator of RARα, RXR, and ERα, 
and possibly PPARγ. Thus, though further studies must be done, it is possible that 
TRIM24’s co-regulation of these nuclear receptors that bind to Nrf2 are keeping the 
progression of NAFLD and NASH in check in normal mice. Activated Nrf2 has been 
shown to both delay proliferation and cause apoptosis in the regenerating liver [152]. 
Additionally, activated Nrf2 is implicated during tumor initiation and progression 
[154]. Nrf2 redirects of glucose and glutamine into anabolic pathways, allowing 
enhancement of metabolic activity, growth, tumor cell proliferation in both human 
cancer cell lines and mice [155]. Additionally, NRF2 also upregulates expression of 
anti-apoptotic proteins, such as Bcl-2 and BcL-xL, increasing drug resistance and 
survival in cancer cells [156, 157].   With loss of Trim24 expression, Nrf2 expression 
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is upregulated, leading to increased oxidative stress and misregulated metabolism, 
aberrant processes in the disease progression of NAFLD and NASH.  
      The TRIM24 activated genes, Lpin1 and Gck, indicate a pivotal regulatory role of 
TRIM24 hepatic lipid and glucose metabolic changes observed in the mouse model. 
Lpin1 is a transcriptional co-regulator of fatty acid oxidation and inflammatory genes 
[158]. In the liver, Gck is a key gene that controls glucose uptake and glycogen 
synthesis [159, 160]. As TRIM24 directly binds these genes, their downegulation in 
Trim24-/- liver is indicative of the metabolic phenotype observed in these mice.                                                                                             
      When compared to the predictive factors for non-obese NAFLD patients, some 
interesting observations can be made. A comparison of lean to overweight-obese 
NAFLD patients shows that lean NAFLD patients are younger (65% less than 45 
years of age), male, and less likely to present with hypercholesterolemia and insulin 
resistance (diabetes) [40] (Table 12). While the causes of this dichotomy have not 
been determined, it is postulated that underlying causes could include genetic 
predisposition, intestinal dysmotility, and other metabolic abnormalities not 
associated with obesity [40]. Thus, the findings in our Trim24-/- mice offer a 
promising model to further dissect the mechanism underlying disease in non-obese 
NAFLD patients and offers an opportunity to expand the knowledge about both 
TRIM24 and an understudied area of the disease spectrum.   
 
 
 
 
 
 
 126 
 
 
 
 
 
 
 
 
 
 
Table 12.  Predictive factors of NAFLD in lean compared to obese patients. 
Modified from Medicine. 2012;91(6):319-327 [40]. 
 
 
 
 
 
 
 
 
in comparison to the overweight-obese NAFLD group, the lean
NAFLD cohort was younger (p G 0.0001), more commonly fe-
male (p = 0.189), with significantly lower prevalence of IR (p G
0.0001), DM (p G 0.0001), hypercholesteremia (p G 0.0001), and
hypertension (p G 0.0001). Furthermore, in comparison to over-
weight-obese NAFLD patients, lean NAFLD patients had lower
AST (p = 0.0002) and lower ALT (p G 0.0001) levels, lower
HOMA score (p G 0.0001), and lower platelet count (p = 0.0075)
(see Table 1).
Multivariate analysis comparing lean NAFLD to overweight-
obese NAFLD showed that lean NAFLD was independently as-
sociated with younger age, female sex, and a decreased likelihood
of having IR and hypercholesterolemia (see Table 3).
Assessment of Predictors of NASH in the US
Population
As noted previously, 307 individuals (2.21% T 0.20% of the
entire study cohort) fulfilled our definition for NASH. This
NASH cohort represents 11.78% T 1.03% of the NAFLD cohort.
In fact, the prevalence of NASH was 0.10% T 0.05% in the lean
cohort (1.38% T 0.62% of lean individuals with NAFLD) and
3.86% T 0.35% in the overweight-obese cohort (13.92% T 1.25%
of overweight-obese individuals with NAFLD) (p G 0.0001).
Individuals with NASH were less commonly African-
American than NAFLD patients without NASH (5.51% T
1.19% vs. 8.87% T 1.39%, respectively; p = 0.0054) and more
commonly Hispanic (13.07% T 2.33% vs. 6.88% T 1.28%; p G
0.0001). They were more likely to be aged less than 45 years
(56.24% T 5.02% vs. 43.90% T 2.25%; p = 0.0340) and less
likely to be aged more than 65 years (9.38% T 2.74% vs.
16.35% T 1.32%; p = 0.0296) compared to their non-NASH
NAFLD counterparts (Table 4).
Additionally, NAFLD patients with NASH were more
likely than NAFLD patients without NASH to have visceral
obesity (88.67% T 3.41% vs. 63.81% T 1.75%, respectively;
p G 0.0001), hypercholesterolemia (90.16% T 3.31% vs.
81.96% T 1.51%; p = 0.0293), and hypertension (45.58% T
5.29% vs. 34.05% T 1.76%; p = 0.0360) (see Table 4).
Multivariate analysis comparing the NASH cohort to the
non-NASH NAFLD cohort showed that NASH was indepen-
dently associated with being Hispanic (odds ratio EOR^, 1.72;
95% confidence interval ECI^, 1.28Y2.33) and less associated with
being African-American (OR, 0.52; 95% CI, 0.34Y0.78). Patients
in the NASH cohort were more likely to be younger (age OR,
0.96; 95% CI, 0.94Y0.98) and more likely to have components
of metabolic syndrome (other than DM and IR, which were
part of the definition), such as hypertension (OR, 2.44; 95%
CI, 1.44Y4.13) and BMI 925 (OR, 13.41; 95% CI, 4.80Y37.51)
(Table 5).
DISCUSSION
In the current study, using a nationwide representative sam-
ple of the United States population, we found the prevalence
of radiologically demonstrated NAFLD to be 18% and that of
NASH to be 2.6%. These rates are similar to those previously
reported for NAFLD and NASH (as reviewed in Introduction).
Furthermore, as expected, we found that the prevalence of
NAFLD and NASH are much higher in overweight or obese
individuals than in the lean population. In fact, the prevalence of
NAFLD in the lean population was only 7% (compared to 28%
in the overweight-obese population). A similar prevalence of
lean NAFLD, as low as 9%, was previously reported from the
Dallas Heart Study,7,14 although to our knowledge the current
study is the first to evaluate the prevalence of lean NAFLD
using a nationwide sample.
Although the prevalence of NAFLD in lean individuals is
lower than that in overweight-obese individuals, a substantial
number of lean individuals in the United States have NAFLD. A
comparison of lean and overweight-obese patients with NAFLD
to their respective controls without liver disease shows that lean
NAFLD patients are more likely to have components of meta-
bolic syndrome. Additionally, they are most likely to be Hispanic.
In fact, comparing both types of NAFLD patients (lean and
overweight-obese) to their own controls without liver disease
shows that predictors of NAFLD in both lean and non-lean
TABLE 3. Independent Predictors of NAFLD in Lean Cohort and Overweight-Obese Cohort
Predictor OR (95% CI) P
Factors associated with NAFLD in lean cohort compared to lean controls
Hispanic ethnicity 1.74 (1.20Y2.51) 0.0037
Diabetes mellitus 4.50 (2.51Y8.08) G0.0001
Hypertension 1.68 (1.19Y2.35) 0.0033
Factors associated with NAFLD in overweight-obese cohort compared to overweight-obese controls
African-American ethnicity 0.50 (0.39Y0.63) G0.0001
Hispanic ethnicity 1.25 (1.01Y1.56) 0.0394
Male sex 1.33 (1.12Y1.58) 0.0015
Age 1.01 (1.01Y1.02) 0.0002
Insulin resistance 4.23 (3.58Y4.99) G0.0001
Hypercholesterolemia 1.48 (1.10Y1.98) 0.0091
Hypertension 1.26 (1.02Y1.56) 0.0337
Excellent or very good self-reported health 0.79 (0.65Y0.96) 0.0195
Factors associated with lean NAFLD compared to overweight-obese NAFLD
Age 0.98 (0.97Y0.99) 0.0008
Male sex 0.60 (0.41Y0.87) 0.008
Insulin resistance 0.10 (0.07Y0.16) G0.0001
Hypercholesterolemia 0.34 (0.22Y0.51) G0.0001
Abbreviations: NAFLD = nonalcoholic fatty liver disease, OR = odds ratio, 95% CI = 95% confidence interval.
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in comparison to the overweight-obese NAFLD group, the lean
NAFLD cohort was younger (p G 0.0001), more commonly fe-
male (p = 0.189), with significantly lower prevalence of IR (p G
0.0001), DM (p G 0.0001), hypercholesteremia (p G 0.0001), and
hypertension (p G 0.0001). Furthermore, in comparison to over-
weight-obese NAFLD patients, lean NAFLD patients had lower
AST (p = 0.0002) and lower ALT (p G 0.0001) levels, lower
HOMA core (p G 0.0001), and lower platelet count (p = 0.0075)
(see Table 1).
Multivariate analysis comparing lean NAFLD to overweight-
obese NAFLD showed that lean NAFLD was independently as-
sociated with younger age, female sex, and a decreased likelihood
of having IR and hypercholesterolemia (see Table 3).
Assessment of Predictors of NASH in the US
Population
As noted previously, 307 individuals (2.21% T 0.20% of the
entire study cohort) fulfilled our d finition for NASH. This
NASH cohort represents 11.78% T 1.03% of the NAFLD cohort.
In fac , th prevalence of NASH was 0.10% T 0.05% in the lean
cohort (1.38% T 0.62% f lean individuals with NAFLD) and
3.86% T 0.35% in the overweight-obese cohort (13.92% T 1.25%
of overw ight-obese individuals with NAFLD) (p G 0.0001).
Individuals with NASH were less commonly African
American than NAFLD patients without NASH (5.51% T
1.19% vs. 8.87% T 1.39%, resp ctively; p = 0.0054) and more
commonly Hispanic (13.07% T 2.33% vs. 6.88% T 1.28%; p G
0.0001). They were more likely to be aged less than 45 years
(56.24% T 5.02% vs. 43.90% T 2.25%; p = 0.0340) and less
likely to be aged more than 65 years (9.38% T 2.74% vs.
16.35% T 1.32%; p = 0.0296) compared to their non-NASH
NAFLD counterparts (Table 4).
Additionally, NAFLD patients with NASH were more
likely than NAFLD patients without NASH to have visceral
obesity (88.67% T 3.41% vs. 63.81% T 1.75%, respectively;
p G 0.0001), hypercholesterolemia (90.16% T 3.31% vs.
81.96% T 1.51%; p = 0.0293), and hypertension (45.58% T
5.29% vs. 34.05% T 1.76%; p = 0.0360) (see Table 4).
Multivariate analysis comparing the NASH cohort to the
non-NASH NAFLD cohort showed that NASH was indepen-
dently associated with being Hispanic (odds ratio EOR^, 1.72;
95% confidence interval ECI^, 1.28Y2.33) and less associated with
being African-American (OR, 0.52; 95% CI, 0.34Y0.78). Patients
in the NASH cohort were more likely to be younger (age OR,
0.96; 95% CI, 0.94Y0.98) and more likely to have components
of metabolic syndrome (other than DM and IR, which were
part of the definition), such as hypertension (OR, 2.44; 95%
CI, 1.44Y4.13) and BMI 925 (OR, 13.41; 95% CI, 4.80Y37.51)
(Table 5).
DISCUSSION
In the current study, using a nationwide representative sam-
ple of the United States population, we found the prevalence
of radiologic lly demonstrated NAFLD to be 18% and that of
NASH to b 2.6%. These rates are similar to those previously
reported for N FLD d NASH (as reviewed in Introduc o ).
Furthermore, as expected, we found that the pr valence of
NAFLD and NASH are much higher in overweight or obese
individuals than in the lean population. In f ct, the prevalence of
NAFLD in th lean population was only 7% (compared to 28
in the overweight-obese population). A similar prevalence of
lean NAFLD, as low as 9%, was previously reported from the
Dallas Heart Study,7,14 although to our knowledge the current
study is the first to evaluate the prevalence of lean NAFLD
using a nationwide sample.
Although the prevalence of NAFLD in lean individuals is
lower than that in overweight-obese individuals, a substantial
number of lean individuals in the United States have NAFLD. A
comparison of lean and overweight-obese patients with NAFLD
to their respective controls without liver disease shows that lean
NAFLD patients are more likely to have components of meta-
bolic syndrome. Additionally, they are most likely to be Hispanic.
In fact, comparing both types of NAFLD patients (lean and
overweight-obese) to their own controls without liver disease
shows that predictors of NAFLD in both lean and non-lean
TABLE 3. Independent Predictors of NAFLD in Lean Cohort and Overweight-Obese Cohort
Predictor OR (95% CI) P
Factors associated with NAFLD in lean cohort compared to lean controls
Hispanic ethnicity 1.74 (1.20Y2.51) 0.0037
Diabetes mellitus 4.50 (2.51Y8.08) G0.0001
Hypertension 1.68 (1.19Y2.35) 0.0033
Factors associated with NAFLD in overweight-obese cohort compared to overweight-obese controls
African-American ethnicity 0.50 (0.39Y0.63) G0.0001
Hispanic ethnicity 1.25 (1.01Y1.56) 0.0394
Male sex 1.33 (1.12Y1.58) 0.0015
Age 1.01 (1.01Y1.02) 0.0002
Insulin resistance 4.23 (3.58Y4.99) G0.0001
Hypercholesterolemia 1.48 (1.10Y1.98) 0.0091
Hypertension 1.26 (1.02Y1.56) 0.0337
Excellent or very good self-reported health 0.79 (0.65Y0.96) 0.0195
Factors associated with lean NAFLD compared to overweight-obese NAFLD
Age 0.98 (0.97Y0.99) 0.0008
Male sex 0.60 (0.41Y0.87) 0.008
Insulin resistance 0.10 (0.07Y0.16) G0.0001
Hypercholesterolemia 0.34 (0.22Y0.51) G0.0001
Abbreviations: NAFLD = nonalcoholic fatty liver disease, OR = odds ratio, 95% CI = 95% confidence interval.
Younossi et al Medicine & Volume 91, Number 6, November 2012
324 www.md-journal.com * 2012 Lippincott Williams & Wilkins
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Diagram 7.  Future direction studies.  
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TRIM24 and metabolism…a balancing act?  (Refer to Diagram 7.) 
      This work has established the regulatory functions of TRIM24 in metabolic and 
inflammatory processes. The germline deletion of Trim24 recapitulates the hallmarks 
of NAFLD, non-obese NASH and progression to HCC without a change in diet. 
Further studies are needed to see if Trim24-/- mice will develop secondary metabolic 
effects when they are fed a high fat or “Western diet” (42 kcal from fat) that generally 
leads to development of obesity. Further dissection of this question with mouse 
models of both germline and liver-specific deletion of Trim24 is needed to better 
understand the complexities of TRIM24’s regulation of metabolism and inflammation 
under dietary challenge. Comparison of changes in disease progression, spectrum, 
metabolic parameters, and dysfunction between systemic and intrinsic (hepatic) 
models will lead to further understanding of the regulatory mechanisms governing 
metabolism and inflammatory processes that are utilized by TRIM24. By 
implementation of this diet and our genetically altered model system, we will be able 
to better establish the altered pathways kept in check by TRIM24 that protect against 
HCC progression. 
       Our Trim24-/- mice exhibit misregulated lipid and glucose metabolic gene 
expression leading to changes in glucose/insulin tolerance and visceral fat 
accumulation at 2, 4, and 6 months of age. Due to the fact that HCC does not 
develop until later timepoints in these mice, further studies should be performed in 
order to study glucose metabolic gene expression that could be misregulated due to 
cancer progression. It is well established that changes in cellular metabolism are 
occur due to aberrant expression of various key components of glucose metabolism, 
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such as glucose transporters, upon progression of cancer. In fact, in mouse models 
of NAFLD progression, it has been reported that there is a switch to the Warburg 
effect, which involves aberrant glucose metabolism via misregulation of glucose 
transporters and enzymes that are key to glycolysis, which is associated with cancer 
progression [161]. Overexpression of GLUT1 (both protein and RNA) is linked to 
multiple cancers such as: hepatic, pancreatic, breast, esophageal, brain, renal, lung, 
cutaneous, colorectal, endometrial, ovarian, and cervical cancers [162].  GLUT2 
(protein and RNA) is normally expressed in the liver, pancreatic islet cells, and 
retina, with over expression observed in breast, colon, and liver carcinoma [163]. 
GLUT5 (both protein and RNA) is over expressed in liver metastasis compared to 
primary lung cancer [57] [164].  
      Further analysis of the role of Trim24 in protection from aberrant glucose 
metabolism, associated with cancer progression (Warburg effect) should be 
addressed. Experiments utilizing liver and primary hepatocytes from aging Trim24-/- 
mice should be performed to analyze glucose enzyme gene and protein in vitro and 
in vivo to determine if the Warburg effect is indeed a factor in disease progression. 
Further measurement of changes in hepatic metabolism could also be analyzed by 
mass spectrometry of metabolic output. RNA- and ChIP-sequencing of aging mice 
from Trim24-/- liver would aid in further dissection of the regulatory role of TRIM24 in 
transformed cancer cell metabolism due to HCC progression.  
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      This point leads us to the dichotomy of TRIM24, where in some instances it is an 
oncogene and others a tumor suppressor. While our germline deletion mouse 
models support the role of TRIM24 as a tumor suppressor, recent human HCC 
studies show over expression of TRIM24 [83]. Furthermore, TRIM24 is implicated in 
a regulatory capacity in oxidation/reduction and metabolism by studies in our 
laboratory, using an induced human mammary epithelial cell (iHMEC) culture model 
[67]. Over expression of TRIM24 in HMECs led to an increased glycolytic and 
tricarboxylic acid (TCA) cycle gene signature, increased activation of glucose 
metabolic pathways and transformation of these HMECs. Xenografts of TRIM24 
over expressing HMECs led to development of mid-to high-grade TRIM24-
dependent tumors [67]. Mouse models of both over expression and deletion of 
TRIM24 are available to address this dichotomy (Table 13). To better understand 
this balance in expression, we have mice that overexpress full length Trim24 that 
have been crossed to mice expressing the liver specific promoter (Tg Alb/Afp-Cre; 
Trim24 FL). Further characterization of these mice in comparison to the liver specific 
deletion mouse (Alb-Cre;Trim24flox/flox) and germline deletion (Trim24-/-) will clarify 
the balance of Trim24 expression in disease progression in the liver. More 
specifically, RNA- and ChIP-sequencing in the liver of each of these models in 
comparison to the sequencing data from the Trim24 germline deletion will reveal 
gene targets that are both unique and shared between the models to determine the 
impact of varying levels of Trim24 expression on disease progression in the liver. 
Furthermore, to address the tissue specific dichotomy of Trim24 as an oncogene in 
breast cancer and a tumor suppressor in the liver, our laboratory has crossed mice  
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Table 13. Current mouse models available in the Barton laboratory for further 
studies. 
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expressing a breast specific (MMTV-Cre) promoter to Trim24 overexpression (Tg 
MMTV-Cre; Trim24 FL) and deletion (MMTV-Cre; Trim24flox/flox). Characterization of 
these models along with comparison of sequencing (RNA- and ChIP-) to liver 
specific models will provide insight to the dual nature of Trim24.   
      This study could be further expanded to dissect the alterations of TRIM24 levels 
that are responsible for hepatic metabolic disease that sets the stage for progression 
to HCC. TRIM24 is a histone reader and helps recruit transcription factors to work 
with chromatin and regulate gene expression.  Since it interacts with and can co-
regulate several different transcription factors, in addition to its ability to also regulate 
p53 by ubiquitination, loss or delay of timely and ordered TRIM24 interactions (too 
low) or gain (too high) impacts gene networks or cellular machines that interconnect 
and must be precisely regulated. In the liver, metabolic imbalance leads to lipid 
accumulation and inflammatory signaling, which progresses to tissue damage, 
fibrosis and HCC. Molecular and metabolic analyses methods that have been 
implemented in this work could also be employed to determine regulatory 
mechanisms that are dependent on TRIM24 and how they respond to altered levels.  
 
Do specific domains of TRIM24 regulate inflammatory and lipid metabolic 
processes in the liver?  
      TRIM24 is a multi-functional protein that negatively regulates p53, co-regulates 
nuclear receptors and binds to a specific histone modification signature.  While this 
dissertation did not focus on the roles of specific domains of TRIM24 in the mouse 
models discussed, the Barton laboratory has several key mouse models that can be 
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implemented to determine which of these functions is critical in development of 
NAFLD and progression to HCC.  These models utilize genetic rescue with 
transgenic expression of specific forms of TRIM24 (full-length, RING mutant, LXXLL 
mutant and PHD/Bromo mutant) and could be implemented in a background of 
Trim24 loss in the liver, in hematopoietic organs or globally (Table 13). 
     I propose that TRIM24 levels must be kept in balance to maintain homeostasis, 
and it is loss of homeostasis that leads to metabolic disruption.  First, to establish 
cause-and-effect at a molecular level, we could determine the specific domain or 
domains of TRIM24 that can complement loss-of-function and protect the liver from 
metabolic imbalance and progression of disease through mouse models that are 
available in the lab. A liver specific deletion model of the bromo-domain of Trim24 is 
being characterized in the laboratory (Tg Alb/Afp-Cre; Trim24N980A). The results 
from this model are particularly important in light of a bromo-specific Trim24 inhibitor 
that is under development in collaboration with the Institute of Applied Cancer 
Sciences (IACS) at MD Anderson Cancer Center, based upon studies of inhibition in 
breast cancer cells. If mutation of the bromo-domain inhibits disease progression 
(rescues the phenotype) in the liver, this inhibitor will prove a potentially excellent 
therapeutic option for multiple cancers.  Additionally, we have transgenic models 
with mutations of each domain of Trim24 (Table 13) readily available for further 
studies in both the liver and breast in the lab as well. Studies in these mice will 
reveal the extent to which p53-signaling (RING), nuclear receptor interactions 
(LXXLL) or histone reader functions (PHD and Bromo) partially or wholly rescue 
hepatic loss of TRIM24 functions in preventing chronic liver disease and metabolic 
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syndromes.  We will use blood collection and analyses of ALT/AST, total plasma 
cholesterol (TPC), plasma TG, non-HDL-C, and HDL-C, as early indicators of 
potential metabolic imbalance without sacrifice of the mice.  These indicators will 
prioritize molecular analyses in an ordered manner. Thus, the tools are ready to 
further analyze important remaining questions regarding the balance, function of 
domains, and links to p53 expression and Trim24 in liver and breast cancer. 
 
Does TRIM24 impact crosstalk between hepatocytes and immune cells in liver 
disease?  
      To determine if loss of Trim24 causes systemic and/or hepatic-specific 
inflammation, we conditionally deleted Trim24 in the liver, by crossing Alb-Cre and 
Trim24LoxP/LoxP mice. I initiated such experiments in our laboratory by testing whether 
changes in immune cell populations upon loss of Trim24 were exclusive to the liver. 
Previous data on germline deleted mice showed that there was a significant increase 
in M2 macrophage gene expression (Arg1, Mgl2, IL4RA, Fiz) in bone marrow-
derived macrophages (Fig. 41). These changes led me to hypothesize that TRIM24 
regulates immune populations in both the liver and bone marrow and when 
removed, causes aberrant M2 macrophage activation, leading to progression of 
NAFLD and NASH to HCC.  
      In order to understand if hepatic-specific deletion of Trim24 is sufficient to cause 
changes in bone marrow macrophage precursor populations, I utilized Cytometry 
Time of Flight Mass Spectrometry (CyTOF). CyTOF is a variation of flow cytometry 
that using antibodies labeled with heavy metal ion tags in the placed of 
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fluorochromes. Readout by time-of-flight mass spectrometry allows for combination 
up to 40 antibodies, for both extra- and intra-cellular signaling in a single sample. I 
applied this method to analysis of bone marrow collected from Floxed Trim24Loxp/Loxp 
and hepatic-specific Trim24 knockout mice (Alb-Cre; Trim24Loxp/Loxp). I reasoned that 
by using a mouse model that possessed liver specific deletion of Trim24 and normal 
bone marrow, I could determine if Trim24’s regulation of immune populations was 
cell autonomous (hepatic specific) or extended to systemic immune regulation (non-
autonomous). The Alb-Cre; Trim24Loxp/Loxp mice were generated in our lab 
(unpublished results) and were verified for Cre expression and Floxed Trim24Loxp/Loxp 
status by genotyping for Cre expression and analysis of hepatic Cre gene 
expression (Fig. 42 A-B). Analysis of TRIM24 expression in the liver specific deletion 
mice as compared to germline deletion liver samples showed that while TRIM24 
expression was negative in parenchymal cells (hepatocytes), non-parenchymal cells 
exhibited positive staining (Fig. 42C, Arrow). This raises the possibility that 
expression of TRIM24 in non-parenchymal cells in the Alb-Cre; Trim24Loxp/Loxp liver 
may be involved in changes in disease progression when compared to the germline 
deletion mouse. To this end, although not fully characterized, preliminary data from 
these mice show that they develop the hallmarks of disease progression, but at a 
different rate (Fig. 43) when compared to germline deletion of Trim24. Thus, in order 
to determine if liver damage had occurred at the same age as the germline deletion 
model, I measured ALT/AST in the circulating serum of 2 months (10 week) old mice 
(Fig. 44). The liver damage enzyme levels were significantly increased compared to 
control, and closely recapitulated the results from the germline deletion model, thus 
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indicating early hepatic damage events associated with NAFLD and NASH 
progression.  
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Figure 41. Bone marrow derived macrophages have increased M2 macrophage 
associated gene expression in Trim24-/-. Genes associated with M2 macrophages 
show upregulated mRNA expression levels in Trim24-/- bone marrow derived 
macrophages (cultured from bone marrow using GM-CSF treatment to isolate) by 
qPCR analysis. N>3, *p<0.05., **p<0.01, ****p<0.0001. 
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Figure 42. Analysis (PCR, qPCR, and IHC) confirming Cre expression and 
localization in Albumin-Cre; Trim24LoxP/LoxP. liver. A) Genotyping showing positive 
expression of Cre.  Samples were obtained from ear punch. + = Cre,.B) Gene 
expression analysis of Cre expression by qPCR shows significant increase in 
Albumin-Cre; Trim24LoxP/LoxP. liver compared to control. 3 weeks of age, N>3, 
****p<0.0001. C) Immunohistochemistry (IHC) for TRIM24 in Trim24+/+, Trim24-/-, and 
Alb-Cre;Trim24LoxP/LoxP liver sections shows hepatocyte specific loss of TRIM24 
expression in germline and liver specific deletion mice. However, positive TRIM24 
staining is still apparent in non-parenchymal cells in the liver specific deletion sample 
(Arrow = positive, dark brown staining).  
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Figure 43.  Timeline of disease progression and incidence of HCA and HCC in 
Trim24-/- versus Albumin-Cre; Trim24LoxP/LoxP. A) Trim24-/- liver morphology 
showing lipid filled lesions present at 6 months compared to no visible lesions in 
Albumin-Cre; Trim24LoxP/LoxP at 5 months. At 12-18 months of age, Trim24-/- liver 
retain lipid filled lesions and develop HCC. HCC also develops in Albumin-Cre; 
Trim24LoxP/LoxP at 10-15 months. B) Quantification of HCA and HCC incidence in 10-
15 month old Trim24-/- and Albumin-Cre; Trim24LoxP/LoxP mice. M=Months. 
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Figure 44. Hepatocellular damage and dysfunction in 2 month Albumin-Cre; 
Trim24LoxP/LoxP mice. ALT/AST: Albumin-Cre; Trim24LoxP/LoxP (n>5), Floxed 
Trim24LoxP/LoxP (N>5). Mean ± SD. * p<0.05, **p<0.01  
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      Upon collection of bone marrow from these mice, to quantify CyTOF analysis, I 
utilized markers (including CD34, CD19, CD45, CD45RA, CD117 and CD11b, Table 
15) and distinguished hematopoietic cell types and lineages including hematopoietic 
stem cells (HSCs), common myeloid progenitors (CMPs), as well as cell types 
comprising the lymphoid, erythroid and myeloid lineages. The Visual Stochastic 
Neighbor Embedding (viSNE) algorithm was used to condense 13 parameters or 
dimensions of data into 2 dimensions of data to allow for visualization of single cell 
changes based upon the markers from our analysis (Table 15).  Comparison of bone 
marrow cellularity between samples revealed a significant decrease (p<0.02) in the 
percent populations of non-activated neutrophils (Ly-6g+, CD11b-) and a significant 
increase (p<0.002) in activated neutrophils (Ly-6g+, CD11b+, IFNg+) in the Alb-Cre; 
Trim24Loxp/Loxp bone marrow indicating an increase in the inflammatory response 
(Figs. 45-46). Additionally the promyelocyte population (Ly-6g-, CD11b+) was 
significantly increased (p<0.02) in the Alb-Cre; Trim24Loxp/Loxp mice. (Figs. 45-46) 
The promyelocyte lineage gives rise to macrophage populations in the bone marrow. 
While preliminary data suggest that the inflammatory response is diminished in the 
liver-specific knockout, it is clear that the Trim24-/- liver signals to bone marrow, as 
indicated by increased activated neutrophil and induced pro-myelocytes levels (Figs. 
45-46).   
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Figure 45. Liver-specific deletion of Trim24 increases the abundance of 
myeloid lineage precursor cells in the bone marrow. viSNE analysis was 
performed to quantify cellularity and construct a map of hematopoiesis based upon 
the measured parameters; representative viSNE analysis for A) Ly-6g signalling B) 
CD11b and C) CD34 signaling are shown. Comparison of bone marrow cellularity 
between samples revealed significant decrease in the percent populations of non-
activated neutrophils (Ly-6g+, CD11b-) (Region 1 – all maps) and a significant 
increase in activated neutrophils (Ly-6g+, CD11b+, IFNg+) (Region 3 – all maps) in 
the Alb-Cre;Trim24LoxP/LoxP bone marrow indicating an increase in the inflammatory 
response. Additionally the promyelocyte population (Ly-6g-, CD11b+) (Region 2 – all 
maps) was significantly increased in the Alb-Cre;Trim24LoxP/LoxP mice compared to 
Floxed Trim24LoxP/LoxP bone marrow. (N=4, 10 weeks, *p<0.02, **p<0.002) Intensity 
of signaling is quantified using log2 scale as represented by the color scale bar, 
Red=High intensity, blue=low intensity.  
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Figure 46. Liver-specific TRIM24 knockout induces an inflammatory response 
in the bone marrow and increases the abundance of myeloid lineage precursor 
cells. Comparison of bone marrow cellularity between samples revealed significant 
decrease in the percent populations of non-activated neutrophils (Ly-6g+, CD11b-) 
and a significant increase in activated neutrophils (Ly-6g+, CD11b+, IFNg+) in the 
Alb-Cre;Trim24LoxP/LoxP bone marrow. The promyelocyte population (Ly-6g-, 
CD11b+) was significantly increased in the Alb-Cre;Trim24LoxP/LoxP mice compared to 
Flox Trim24LoxP/LoxP bone marrow. (N=4,*p<0.02, **p<0.002).  
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         As discussed in this work, progression of NAFLD to more serious liver disease 
is complex and poorly understood, marked by changes in lipid metabolism, as well 
as systemic and hepatic inflammation. Experiments with isolated liver and bone 
marrow immune cells clearly show that loss of TRIM24 causes an increase in 
macrophage, neutrophils, and myeloid progenitor populations in both locations. 
Further analysis indicates that metabolism, inflammatory processes, and oxidative 
stress genes are directly regulated by TRIM24. These findings suggest that not only 
are metabolic and inflammatory processes regulated by TRIM24, but specific 
immune cell populations are as well.  
      Remaining questions center upon the difference between the inflammation that 
we observe in germline deletion of Trim24 as compared to the liver specific deletion 
model. Experiments testing serum levels of circulating cytokines such as IL-6 and 
TNF-α by, which are both misregulated in NAFLD and NASH progression and key 
markers of macrophage activity, should be implemented [112]. Changes in 
circulating levels in serum (measured by ELISA) would be an indication of NASH 
development. Continued studies should also be performed to determine if cytokines 
levels are misregulated in the liver. To determine when changes in inflammatory 
processes occur, an extensive study beginning with embryonic development through 
aging should be performed to determine the nature of inflammation (acute, chronic, 
etc) and age of onset, if it occurs. This study should not only be performed in the 
germline deletion, but also the liver specific deletion of Trim24. By performing the 
study in both mouse models, the timing, by study of when lipid metabolic versus 
inflammatory genes were misregulated, could be ascertained. Additionally, since the 
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liver specific deletion of Trim24 possesses normal Trim24 expression in the bone 
marrow, this model could be used to determine the role of Trim24 in metabolism and 
inflammation in the liver versus bone marrow (compared to Trim24-/-).  Once this is 
established, a pivotal study utilizing commercially available cytokine inhibitors, such 
as Tocilizumab (IL-6 inhibitor), should be preformed at the onset of inflammation to 
determine if the phenotype can be rescued by inhibition of misregulated 
inflammatory processes. As a cautionary note, inhibitors should be chosen based 
upon action on affected cytokines that found to be misregulated (i.e. IL-6) and 
special care should be taken to avoid inhibitors that have high rates of liver damage 
as a side effect.  
       This same strategy could be further extended to hematopoietic organs (such as 
bone marrow, spleen, lymph nodes), by crossing Tie2-Cre and Trim24LoxP/LoxP mice. 
By segregating liver-specific and hematopoietic-specific functions of Trim24, several 
important questions would be addressed: broadly, how immune cells influence liver 
disease progression to HCC and, specifically, the regulatory impact of TRIM24 in 
each tissue compartment.  Previous studies have shown that recruited hepatic 
macrophages, arising from the hematopoietic stem cell niche, home to the liver due 
to Ccr2 signalling [165]. This signaling is significantly increased in Trim24-/- liver at an 
early age (Fig. 19). The majority of individuals with NASH are also obese and suffer 
from obesity related diabetes.  While our Trim24-/- mice model a phenotype similar to 
non-obese NASH patients (without diabetes), we realize that they have not been 
exposed to environmental factors, such as high fat diet, which is typically implicated 
in patients. Thus, this condition can be modeled in the Trim24-/- mice by introducing 
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a Western high fat diet (42% kcal from fat) at weaning. By changing this 
environmental factor, the role of TRIM24 and increased lipid consumption could be 
potentially linked to the NASH phenotype. We have identified both metabolic and 
inflammatory gene targets of TRIM24. Additionally, in-depth analysis of histone 
modifications that are associated with the regulatory elements of key inflammatory 
and metabolic genes should be analyzed in Trim24+/+ or Trim24-/- liver to understand 
the epigenetic mechanisms involved in NAFLD, NASH, HCC disease progression.  
 
Links between TRIM24, p53 and HCC?  
      Recent studies have reported that p53-expressing, senescent stellate cells 
release factors increase production of tumor-inhibiting, M1-state macrophages 
capable of attacking senescent cells in culture [166].  Conversely, they report that 
proliferating, p53-deficient stellate cells secrete factors that stimulate production of 
tumor-promoting, M2-state macrophages and enhance the proliferation of 
premalignant cells leading to HCC [166]. Macrophages cultured from the bone 
marrow of Trim24-/- mice and stimulated with Il-6 show activation of phosphorylated 
STAT, a gene associated with M2 macrophage induction and activation of p53 (data 
not shown).  A determination of whether this phenotype is evident in our model, as 
an important and previously unknown regulatory capacity of Trim24 or the regulatory 
relationship between p53 and TRIM24, is critical.  
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Implications for inflammasome-directed crosstalk between bone marrow  
and liver leading to progression of the NAFLD, NASH, HCC spectrum. 
       While our studies have highlighted the importance of cell- and lineage-specific 
contributions to the NAFLD, NASH, and HCC disease spectrum, additional studies 
should be undertaken to address the contribution of the inflammasome within these 
cell populations. In short, the inflammasome represents a complex of intracellular 
proteins in both parenchymal and nonparenchymal liver cells that respond to 
damage or danger signals, usually the result of pro-inflammatory cytokine signaling 
(IL-1α,  IL-1β, TNF- α) [167]. The inflammasome then signals to activate caspase-1, 
IL-1β, and IL-18 [167]. Recent studies have shown that knock-down of IL-1α or IL-1β 
in liver parenchyma, but not bone marrow, protected mice from diet-induced liver 
damage due to steatohepatitis and fibrosis [168, 169].  It is important to fully 
characterize the molecular pathways involved, and more importantly to establish 
early, potentially sentinel events for better diagnoses and potential therapeutic 
avenues. Our previous RNA- and ChIP-seq were done with whole liver, but this 
current work has established a method to isolate specific cell types from the liver: 
hepatocytes and HSC-derived cells, using the modified protocols from [170]. 
Therefore, more in-depth studies of crosstalk between the liver and bone marrow 
should be undertaken, using the methods established in this study, to determine the 
role of TRIM24 in activation of the inflammasome in a systemic or hepatic-specific 
manner.  
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TRIM24 and human NAFLD, NASH, and HCC.   
      Current biomarkers for NASH and HCC are virtually non-existent with little 
concrete evidence regarding biomarkers, mutations, or SNPs that are common in 
patients [171]. Early detection methods for disease have the potential to drastically 
reduce the incidence of late-stage disease through preventative therapy. Since we 
have such a striking, spontaneously progressive disease phenotype in our Trim24-/- 
mice, TRIM24 has the potential as a biomarker of disease. Thus, patient samples 
(blood/tissue) from both non-obese and obese individuals with liver damage and 
HCC from collaborating clinics at the UT Medical Center could be used to establish 
baseline TRIM24 expression levels as compared to healthy patients. To better 
understand inflammatory parameters affected in patients with disease, additional 
screening for immune populations and cytokine expression could also be performed. 
IHC staining for TRIM24 and immune factors to determine possible correlations 
between expression levels and disease progression could be performed on available 
human liver samples. Sequencing of these samples could also be utilized to 
determine the presence of mutant Trim24, possible related SNPS, or common gene 
targets that are observed in the Trim24-/- mouse model. Due to the dimorphisms 
reported in previous studies [22, 38, 40], it will be important to analyze data keeping 
gender and ethnic backgrounds separate.  These studies would be designed with 
the aim of understanding the mechanisms and triggers behind disease progression 
and the role of TRIM24 in the process.   
 
 
 150 
 
 
 
 
 
 
 
 
 
 
CHAPTER VI 
 
CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 151 
Conclusions 
 
      The “two-hit’ hypothesis of NAFLD and NASH progression states that an initial, 
aberrant accumulation of hepatic lipid (steatosis) is the first step toward disease 
progression [21]. Next, the second hit is accumulation of dysregulated oxidative 
stress, inflammation, and cellular damage. Upon germline deletion of TRIM24, we 
discovered that both “hits” were present in our mouse model, which led to further 
characterization and dissection of regulatory mechanisms of TRIM24 in this study. In 
the first part of this work, I characterized the Trim24-/- mouse model, showing that, 
upon loss of TRIM24, mice spontaneously develop hepatic steatosis, inflammation, 
hepatocellular damage and eventually HCC. These results, upon further biochemical 
and gene expression analysis (by RNA-seq and qPCR), identified key gene targets 
that are commonly misregulated in NAFLD and NASH progression. ChIP analysis 
showed direct enrichment of TRIM24 at both metabolic and inflammatory gene 
targets. 
      In the second part of this work, I described a cell population-specific, regulatory 
role for TRIM24 through isolation of both hepatic- and hematopoietic (bone marrow)- 
derived immune cells. These studies utilized both germline and liver-specific 
(Albumin-Cre; Trim24LoxP/LoxP) Trim24 deletion mice and showed that specific 
immune cell populations such as macrophages and myeloid lineage cells are 
misregulated in both sites. These results were further dissected by identification of 
increased markers of macrophage (M2) activation (tumor promoting/oncogenic) and 
identification of key inflammatory gene targets directly bound by TRIM24  (Nrf2 and 
Saa1) by integration of RNA- and ChIP-seq datasets.   
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      I also established in this section that loss of TRIM24 causes misregulation of 
systemic glucose/insulin levels and decreased visceral white fiat. These findings 
along with identification of TRIM24-bound gene targets involved in lipid and glucose 
metabolism (Lpin1, Gck, and Gbe1) from integration of RNA- and ChIP-seq 
datasets, suggest a direct role for TRIM24 in hepatic metabolism. Thus, my 
dissertation research demonstrated that TRIM24 is a key regulator of hepatic lipid 
and glucose metabolism and inflammation. Upon deletion of Trim24, the mouse 
model closely models the hallmarks of human NAFLD, non-obese NASH, and HCC. 
Taken together, this work supports the “two-hit” hypothesis and provides a novel 
model of spontaneous non-obese NAFLD/NASH/HCC progression. This project has 
provided the tools to further dissect the role of TRIM24 in metabolism and 
inflammation in multiple mouse models and organ systems (Diagram 8). 
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Diagram 8.  Working model summarizing the effects of TRIM24 loss in the mouse 
model.  
 
 
 
 
 
 
 
 
 
 
 
 
?" ?"?"
Aberrant"Lipid"Metabolism"
✓"
Insulin"resistance""
Diabetes"
✗"
Metabolic"Syndrome"
Obesity"
Fibrosis"
Hepatocellular""
damage"
"Inﬂamma>on"
NAFLD" NASH" HCC"
✓"
✓"
✗"
✓"
Aberrant"Glucose"
metabolism/insulin"
sensi>vity"
NonDobese"
Aberrant"metabolism"
✓"
✓"
✓"✓"
Trim24'/')
✓"
TRIM24"directly"regulates"oxida>ve"
stress/inﬂammatory"related"genes"
Hepa>c"macrophage"
popula>on"increased"
Bone"marrow"derived"
macrophages"express"M2"
macrophage"markers"
✓" ✓"
TRIM24"directly"regulates"
lipid/glucose"metabolic"genes"
Hepa>c"and"serum"lipid"levels"are"misregulated"upon"loss"of"Trim24"
"
 154 
CONTRIBUTIONS:  
 
 
I would like to thank the following people for their contributions to this dissertation:  
 
- Dr. Shiming Jiang- for his guidance, expertise, and help with the characterization of  
 
the germline and liver specific Trim24 deletion mouse models.  
 
- Sabrina Stratton and Dr. Zeynep C. Akdemir- for their support, expertise, and help  
 
with ChIP and bioinformatics analysis.  
 
- Kendra Allton and Hui Wei- for their help with genotyping and generation of MEFs.  
 
- Dr. Ryan McCarthy- for his expertise with CyTOF and viSNE analysis and many  
 
helpful suggestions. 
 
- Dr. Huiyuan Zhang- for her expertise and help with immune experiments in bone  
 
marrow derived macrophages, liver, and Flow Cytometry.  
 
- Peirong Yang, Dr. Hussein Abbas, Dr. Vinod Pant, Dr. Sean Post, and Dr.  
 
Guillermina Lozano -for their invaluable assistance and generosity while making the  
 
Trim24-/- mouse.  
 
-Dr. Richard Lee – for his expertise, generosity and help with the ALT/AST and  
 
hepatic lipid panels.   
 
-Dr. Mihai Gagea – for his expertise in pathology and help in determining disease  
 
progression in our mouse models.  
 
Without their generosity and support, this work would not have been possible. 
 155 
Table 2: Sequences of 5’ probe and 3’ probe used for Southern blot 
 
5’ probe for Southern blot:  
ggtaaccaaggaatgtgggtctatctgacaaactgtcactgtatcttatgaattcattgttattcagtaaattctgacattgc
agaaagacaggcttcacttcagtctattactttgtgttccaaaaaaggactagagatgtcccccacactcatgtctgtca
ctttagccatccagtgagggttttttttcaatctacaaataatgttctgaaaacataaaatatctgggaagaaaacaggtg
ataagggaatggaaagatcattttaatcttgaatcatgaactctccacctgagcatatgactctgaagaagaagctaat
caaaccaaatgcttatggtggaccagaggacaagaagactaaaccaagttggggggggggaggggaattctcatt
atcttcagtggaatttgagaaatgttgaaaggaatacagaggataagaggtagttctaggatccagtaaatgatagtct
atctagagagtttacttgcccttgggttggggggtccagaagatcaccttcagttcaaatgagcttcttatgagatctcaa
aatacagaagaaactgttagtcattcacttaggtacaatgtattacatcaaaaggatggaaatccatatcagcagaag
aagctatatagggaaagatgatgagaaaccaggc 
 
3’ probe for Southern blot:  
cccattggtccagtcagaacataaagaggtggaatgtccttctcttctggtgagcagggatcaattagctggggtatcgt
gacctcgggttcctagaatagagtttagtgattttcctctgggctttttacatcaaggagatcttgtcaaacataaagtggc
ctgggcaagaatatagatggaggaacctctgcactgagttgctttgtcacaaatacttgagtttatgctgttgctatttata
ataaaccacctttttttgtctctaatccttgagttacttgccattgtcataagaaacttactatctgtgaaacttgggattctttat
taggttgcaggaaaggtggaatctcatagtagtttgtctcaaaggggcttgcttgctggaaaggtaatgcaggtataac
attaatcttattctatgtaaccttgggtgacctctgactcttgagtgctaggttcaaaggcatgctttatcaggctcaaatctt
aatcttaattgcaataatgttatgttgatgctgaggagtaagccttgtaaatataaagcactcactaccatgaagctccc
agtttttaattcttagatgtatttttgtatttatcttcattcccctcccc 
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Table 3: Primers for real-time PCR analysis of mRNA expression 
Genes Sense Antisense 
18S RNA TCAAGAACGAAAGTCGGAGGTT GGACATCTAAGGGCATCACAG 
Acaa1b/a* GGGCTGACTGTGAATGAC TGAGTAGCGTGACAACCT 
Acaca* AGCAGATCCGCAGCTTG ACCTCTGCTCGCTGAGTGC 
Acacb* ATAGAGAAGGTGCTCATC TTCATTACGGAACATCTC 
Aco2 GAAGAACATTAACATTGTCCGTAA CGCAGGTATGTCTTTCCC 
Acox* CCAAGACCCAAGAGTTCA CAGGACTATCGCATGATTG 
Acss3* AGCCTAAGGTGGTTGTTACG GCCTGTGCTGTCCTATCC 
Adar GGAAGAAGACTCGGAGAA ACTCAAGCAGTGTAGTAACT 
ApoA5* AAACAGTTGGAGCAAAGG ATTGTTCATATTGTAGAGGTCTT 
Apob* AACCAAGAACTCTGAAGA CAGGGTAAAGAACAATTTG 
Apobr * GGGCTACATCAGGCTTTG GGACTGTGTCTCCTACGA 
ApoC1*    TCCTGATTGTGGTCGTAG GTATGCTCTCCAATGTTC 
ApoC2* CGGTTCTTCCTGGCTCTA CGAGTCATCTTCCTGGTTC 
ApoC3* GAGTCCGATATAGCTGTG AGTAAACTTGCTCCAGTAG 
Arg1** GTGAAGAACCCACGGTCTGT CTGGTTGTCAGGGGAGTGTT 
Bax* GATGCGTCCACCAAGAAG CGTCAGCAATCATCCTCT 
B-myc  CATGGTGCAGGACTGTATGT AAGCTTACAGTCCAAAGCCC 
Casp12 AATCTTGGATACTCTGTGGTGTTA CTGAGGACTGGTGCTCTG 
Ccnd1 TCAAGTGCGTGCAGAAGG GCTCCTCACAGACCTCCA 
Ccr2 CTACTCCCTGGTATTCATC CCAAGTTGAGCAGATAGA 
Ces1d* TCTTGGCTCCTTGAGATT CATCCTGAGAGCACATAG 
Crbp1 ACGCTGAGCACTTTTCGGAA TGCACACACTGGAGTTTGTC 
Cyp26a1 CGGTTCAGCTTCATTCCATT GTGGGGCTTGTCTTCATTGT 
Cyp2c38 AACTTCAACCAATCCTTAACCAAT GCTCCTTCACTGCTTCATAC 
Ddit3* GGGGCACCTATATCTCATCC CTCCTCTGTCAGCCAAGC 
Eno1 GTCCACTGGCATCTACGA CCTGTGAGACACCCTTCC 
Enpp1 CCGCTGCTTTTGAAAGGAC TTGGTTCCACACAGGTCTC 
Fasn TTCCAAGACGAAAATGATGC AATTGTGGGATCAGGAGAGC 
Fizz** TGCTGGGATGACTGCTACTG AGCTGGGTTCTCCACCTCTT 
Gck TGGAGACCCATCAGGAGG TCCAACTTCTGAGCCTTCTG 
Glut2 CCAGTTCGGCTATGACATCG CCAGTGGAACACCCAAAACA 
Hprt TGGACTGATTATGGACAGGACTGA GCACACAGAGGCCCACAAT 
Hsp90aa1 ATCGGACGCTCTGGATAA CCTGTTTGCTGGGAATGA 
Icam1 CCGCAGGTCCAATTCACACT CAGAGCGGCAGAGCAAAAG 
IL-33 GTTGACACATTGAGCATCC CAGATTGGTCATTGTATGTACTC 
IL-4ra** CCTCACACTCCACACCAATG AGCCTGGGTTCCTTGTAGGT 
Irf9  TTCATCTATGGTGGCCGAGT ACGCCTCTGTCAAGCTGATT 
Irs1 AATAGCGTAACTGGACATC  CCTGGTTGTGAATTGTGA 
Irs2 ACTTCCTGTCCCATCACTTGA  GCTTCACTCTTTCACGACTGT 
Lcn13 GACGTCGGTGAATGAGCACT CCGATCTCTGGCACAAACAT 
Lpl AGG ACC CCT GAA GAC AC GGC ACC CAA CTC TCA TA 
Mcat* CTTCAGTGTGGGAGAGTTTG TTCACCGCATACAGACCTT 
Me1 CCGCATCTCAACAAGGAC GTCAGAGTTCAGTCGTTCG 
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*Primers designed by Shiming Jiang, PhD, **Primers designed by Huiyuan Zhang, 
MD/PhD 
 
 
 
 
 
 
 
 
 
  
Mbl2 CAGGTCAAGGGCTCAGAG CTCCTTTCGGTCCCACTG 
Mdh2 CATTGCCAACCCAGTGAA GTTCGCTCTGACGATGTC 
Mgl2** GGATCCCAAAATTCCCAGTT TCCCTCTTCTCCAGTGTGCT 
Mttp* TACCAACGAGGTAGATAT ATGTATCCAGAGCCTTAA 
Nox4* ACACCTCTGCCTGCTCAT ATGCTCTGCTTAAACACAATCCT 
Pdk1 GGTCAGTGAATGCTTGTG GGGTCCTGAGAAGATTGT 
Pgm2 TCATTCTGACAGCCAGCCATAATC GCTTCTGGAGCAGGACCC 
Plin2* AGCCACAAATTGCGGTTG TGGTTCAGAATAGGCAGTCTT 
Plin3* CAGCAGCCGACTGAGAAG CATTTCTTGAGCCCCAGACA 
Plin5* ACTAGACAAATTGGAAGAGAA CTGTATCCTTGGCTGATG 
Pnlip* CTTAACAATGTCCACCTGAT CCTGTGATCCTTCCAATG 
Pnliprp1* TCAACTACTCTGCTTCCA CTGTAATCCTGCCAAGAC 
Pnpla3* GTCCACCAACTTCTTCCA CCATCACCTTCACATCAGA 
Retn CAAGACTTCAACTCCCTGTTTCCA GGGCAGGAGGCCAACTTA 
Scd-1  TGG GTT GGC TGC TTG TG GCG TGG GCA GGA TGA AG 
Sc5d AAGAACCAAGTCTCGCGTGAG CAGTGAGACGGTGGGGATG 
Stra6 GGGACTGGAGTCACTGTGT GCCAGTGTGAGGAGAAGAGG 
Tgm2 AAGAACCCACTTTCCGATCC ACTTCAGCTTGTCACACTGG 
Tm7sf2 GGCTATGTGGCTGGTCAAT ATGGTGGTGAGGACAGACT 
Trim24-
3’UTR* 
AGAAGGAAGAGAAGGTAG ACATCCAGATCACACTAA 
Trim24-
E11/13* 
CCAGAGGTTGACTATGATTGT TCAGGCACAGTTAGAGGAA 
Trim24-
E2/3* ACACCACTGAAGTTCCTA TCAACACACTCTACACAAA 
Trim24-
E7/8* GCAAGCGGCTGATTACATACA TGGTCACAGGAGGAAGCATCAC 
Trim28* ACATGCCACACTTCAGAAAAAC ACACCTGGCGGATCGA 
Trim33* GAAAACTGCACAAGGCTTAAGC GGTAAAGCAGAAGACGTTCACA 
Vcam1* GAATGAACACTCTTACCT CACTGAATTGAATCTCTG 
Vldlr CGACGAGAAGAACTGTGTAA CACTGCCATCTGTTAGGAA 
Zfp445 GTGCAGTGTTTCCCATTCCT ACTCCATCGGAAGGCTTTTT 
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Table 4: Primers for ChIP PCR analysis 
 
Acacb*~(-3.6kb) CTTGGCATGGAGGT
CTTGA 
CCTTGAACTCAGAGATCACTTT
G 
ApoA1*~ (2.0kb) CTGGGGTCACAGGCTAT
G 
CAGCAAATGGCAAGTGTTCT 
ApoA1* ~ (-3.2kb) GGCTGGCACCATTG
AAGG 
GCACCAGAGACACCAAAC
ATT 
ApoC3* ~ (-0.15kb) CTTTGTCCTTCTCTC
ACTAATCC 
CACACTGACCTCCACCTG 
ApoC3* ~ (-2.9kb) ACTCACGTCTCTGTC
TGA 
CTACCAATCAGCCTTACT
AGC 
ApoD1*~ (1.1kb) GTGGCGAGGTGGTA
ACAATG 
TGTCTGAGAAGGGCACAG
G 
Bax *  ~(-3.1kb) CACACACCACAGAGAAGA
CAAGGA 
GCAATCCAGCCTGGCTCTCA 
Casp12* ~(-1.1kb) GGGTGGGAAGCAGAAAG
C 
TGGCAGAAGAGGAAGCAGAA 
Ccr2*    ~ (-0.5kb) CGTGAACTCATTGCT
GGCAGATAG 
ACCACGAGATGTTCTTACCACCT
T 
Ccr2*     ~(-1.0kb) ACTCCAGGCAATCTGAAG
C 
GGACACACCTTGGCATGA 
Cdkn1a CGAGGAGGTGACTCATT
GT  
 
CAGGGAAAGGGGCTTCTG  
 
Ddit3* ~ (-3.7kb) GCATTGAGTCTCTGG
CAC 
CTACCTCCTCAGCGATGG 
Gbe1 CCAGGGCGTGTGTGATT
T  
 
CAAGAGCAAACAGGAGGGT 
 
 Gck AAGCCAGAGGACCTGAA
TC 
 
AGGAAGGAAGGAAGCCAAG 
 
Icam*   ~(-4.9kb) AGATAGGCGCATCTC
TGAGTTCA 
CCCAGTGATTTCTTCGGTGGT
TT 
Icam*    ~ (3.7kb) ATCCGCAGAGCATTC
CTTAG 
TGCCCTGTACCTCAGTCT 
Il-1a*   ~(-4.0kb) TCTAGCCTGAACTAC
ATGAAACCT 
ACCACGCCCTGCTTACAT 
Jun CTACCAACGTGAGTGCT
A  
 
CGCTTCTGTAACAAAGTTTG  
 
Lpin1 GGCAGAATCCCTTGAGA
G 
 
ACCACGAACTTCCAATCC 
 
Mttp*  ~ (700bp) CACGCAACCACATTTTAA CTCGGCCTCGTGGTCAG 
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*Primers designed by Sabrina Stratton 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACACAA 
Nfe2l2/Nrf2 GGGCTGTGTGTTCTGAG
TA  
 
CCTCTGTGACTGCCAACT 
 
Pnpla* ~ (-3.5kb) CGGGGTCTGGGAAT
TGAG 
TTAGGTTTGAAACTATTTG
GGAC 
Saa1  CGGAGTAGAGGAGATGA
G  
 
CGATAAGGACGATAGATACA
TAT 
 
Vldlr* ~ (-2.4kb) GTCTGAACCTCTGAA
CCTGTAAGC 
CACAAGAGCCCTGCCTTA
GTTAG 
Non-specific (>5 
kb from TSS) 
GCAAGGGCAGTCAC
ATTCA 
GTCTCCATTTAGTTCCTGT
TTCCA 
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Table 5: Pathology report and diagnosis of aging Trim24-/- mice 
 
Genotype WT WT Null Null WT WT Null Null 
Sex M M M M F F F F 
Age 
 
12 
mo 
 
12 mo 
 
15 mo 
 
15 mo 
 
12 mo 
 
12 mo  13 mo 
 
13 mo 
Terminal body 
weight (g) 35.7 46.27 30.01 30.14 35.65 30.79 25.04 39.08 
Liver weight 1.61 2.24 2.22 3.94 1.63 1.5 2.41 2.83 
Kidney weight 0.55 0.78 1.09 0.54 0.43 0.39 0.32 0.49 
Spleen weight 0.36 0.12 0.08 0.15 0.2 0.12 0.09 0.1 
Tumor weight 
(g)/size (mm) N/A N/A   N/A N/A   
Gross 
observations N/A N/A 
Multiple 
hepatic 
lesions 
Multiple 
hepatic 
lesions 
N/A N/A 
Multipl
ehepa
tic 
lesion
s 
Multipl
e  
hepatic 
lesions 
Organ 
Morphologic 
Diagnosis 
Lesio
n  
Grad
e 
Lesio
n  
Grad
e 
Lesion  
Grade 
Lesion  
Grade 
Lesio
n  
Grade 
Lesio
n  
Grad
e 
Lesio
n  
Grade 
Lesion  
Grade 
Liver/Gall 
Bladder A N A A A N A A 
Hepatocellular 
Carcinoma 
(HCC)   
P      
Undifferentiate
d, invasive, 
malignant 
tumor, suspect 
Hepatoblasto
ma or HCC 
   P     
Hepatocellular 
Adenoma 
(HCA)    
P   P P 
Focal nodular 
hyperplasia 
(FNH)    
P    P 
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Foci of cellular 
alteration 
(FCA), 
eosinophilic 
  1 2   4 4 
Hepatic fatty 
change or 
lipidosis/steato
sis 
  1 1   1 3 
 
Hepatic 
necrosis, focal, 
acute 
   
 
 
 
2 
   
 
 
 
1 
Lipofuscin 
laden-
macrophages, 
multifocal 
  1 2   2 1 
Karyomegalic/
polyploid 
nuclei, 
hepatocytes 
  4 4   1 3 
Microgranulom
as and/or 
Kupffer cell 
hyperplasia, 
multifocal 
   2     
Large 
numbers of 
intravascular 
lymphocytes 
3        
Extramedullary 
hematopoiesis     1  2 1 
Inflammation, 
gall bladder 
(cholecystitis)    
3     
Kidneys A N A A A N A N 
Chronic 
Progressive 
Nephropathy 
1  4 4 1  1  
Vascular 
mineralization, 
multifocal   
2 1   1  
Hydronephrosi
s   4      
Atrophy, 
diffuse   4      
Lung A N A A N N A A 
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Bronchioalveol
ar Adenoma    P     
Increased 
number of 
intravascular 
lymphocytes 
2        
Mineralization/
calcification, 
multifocal, 
alveolar/vascul
ar 
  1 4   3 1 
Spleen A N N A A A N N 
Lymphoid 
hyperplasia 4    4 3   
Extramedullary 
hematopoiesis
, increased    
4     
Heart N N N A N N A N 
Mineralization/ 
calcification, 
multifocal, 
vascular, 
endocardium 
and/or 
myocardium 
   1   1  
Skeletal 
muscle N N N A N N N N 
Vascular 
mineralization/ 
calcification, 
multifocal 
   2     
Aorta 
(thoracic) 0 0 N N 0 N 0 0 
         Adrenal 
Glands N N N N N A A A 
Spindle cell 
hyperplasia, 
focal, 
subcapsular 
(incidental 
finding) 
     1 2 1 
Brain and 
head tissues N N A A N N A N 
Mineralization, 
multifocal,   1 2   1  
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neuropil 
Myodegenerati
on, focal, 
skeletal 
muscle of 
head 
   2     
Nose N N N N N N A N 
Osteoblasts 
hyperplasia 
and fibrosis, 
nasal/maxilary 
bones 
(consistent w/ 
fibrous 
osteodystroph
y) 
      2  
Mineralization 
of dentin, teeth       3  
Eyes, Ears N N N N N N A A 
Otitis, 
granulomatous
, chronic 
(clolesterol 
granuloma) 
with foci of 
mineralization, 
tympanic 
bulae 
      2 3 
Pituitary Gland N 0 N N N N N N 
         Sciatic Nerve N N N N N N N N 
         Spinal Column N N N A N N A N 
Mineralization/
saponification, 
multifocal, of 
subcutaneous 
and 
intermuscular 
brown fat 
   1   2  
Vascular 
mineralization, 
multifocal, 
skeletal 
muscle and 
brown fat 
   2     
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Stomach N N A A N N A A 
 
Squamous 
papilloma, 
forestomach 
      
 
P  
Hyperplasia 
and 
hyperkeratosis 
of squamous 
epithelium, 
forestomach 
  2 1    2 
Gastric polyp 
of glandular 
mucosa   
P P     
Hyperplasia, 
focal, 
glandular 
mucosa 
   2   1 1 
Duodenum N N N N N N N N 
         Pancreas N N N N N N N N 
         Jejunum N N N N N N N N 
         Ileum N N N N N N N N 
         Cecum N N N N N N N N 
         Colon/Rectum N N N N N N N N 
         Mesenteric 
Lymph Node 
and 
Mesenterium 
0 N 0 A A 0 N N 
Lymphocytic 
hyperplasia, 
paracortical     
3    
Plasmacytosis, 
medulla     1    
Vascular 
mineralization 
of blood 
vessels within 
the mesenteric 
adipose tissue 
   2     
Salivary N N N A N A A A 
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Glands 
Periductal 
and/or 
perivascular 
lymphocytic 
infiltration 
     2 3 1 
Chronic 
abscess, 
cervical/subma
ndibular region 
   4     
Mandibular 
Lymph Node 0 N N A A N N N 
Lymphocytic 
hyperplasia, 
lymphoid 
follicle and/or 
paracortical 
   3 2    
Thymus N N N  0 N N N 
         Tongue N N N N N N A A 
Mineralization/
calcification of 
tongue with 
granulomatous 
inflammation 
and fibrosis, 
focal 
      2 2 
Esophagus N N N N N N N N 
         Trachea N N N N 0 N N N 
         Thyroid Gland 0 N N N 0 N N N 
         Parathyroid 0 0 N 0 0 0 0 A 
Hyperplasia, 
diffuse        1 
Skin N N N N A N A A 
Focal 
subcutaneous 
neutrophilic 
panniculitis 
    1    
Superficial 
dermatitis, 
diffuse, 
minimal or 
mild 
      1 1 
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Mammary 
Gland 0 0 0 0 A N A A 
Vascular 
mineralization/
calcification, 
multifocal, 
small and 
medium 
arteries of 
subcutaneous 
and mammary 
gland tissue 
      1 2 
Prostate N N N N n/a n/a n/a n/a 
         Seminal 
Vesicles N N N N n/a n/a n/a n/a 
         Urinary 
Bladder N N 0 N 0 0 I N 
         Ureter 0 0 0 0 0 A 0 N 
Periureteral 
lymphocytic 
infiltration, 
unilateral 
     3   
Ovary n/a n/a n/a n/a N 0 N N 
         Uterus n/a n/a n/a n/a N N A A 
Endometrial 
cystic 
hyperplasia, 
endometrial 
mucosa 
      2 4 
Adenomyosis, 
focal        P 
Preputial 
Gland N N N N n/a n/a n/a n/a 
         Testes N N N N n/a n/a n/a n/a 
         Epididymides N N N N n/a n/a n/a n/a 
         Femur/Knee 
Joint N N A A N A N N 
Hemosiderin 
laden 
macrophages,      
2   
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LEGEND 
N = No lesion observed (Normal tissue) 
A = Abnormal tissue (Lesion present) 
0 = No tissue present on the slide 
P = The lesion is present, but not graded 
S = Suspected/Presumptive lesion or diagnosis (needs more tests to confirm 
PMA = Postmortem autolysis 
I = Inadequate section 
n/a = not applicable 
 
GRADING/SCORING OF HISTOLOGICAL LESIONS  
Grade 0 = no histologic change (or normal tissue) 
Grade 1 = minimal change, rare, occasional (or lesion affects less than 10% of the 
tissue) 
Grade 2 = mild, slight, infrequent, random, sporadic (or lesion affects 10-20% of 
tissue) 
Grade 3 = moderate, frequent, typical, common (or lesion affects 20-40% of tissue) 
Grade 4 = marked, extensive, numerous, severe (or lesion affects 40-100% of 
tissue)  
  
increased, 
bone marrow 
Erythroid 
hyperplasia, 
bone marrow   
2   2   
Granulocytic 
hyperplasia, 
bone marrow    
3     
 
 
Sternum 
 
 
A 
 
 
N 
 
 
A 
 
 
A 
 
 
N 
 
 
N 
 
 
N 
 
 
N 
Lymphocytic 
hyperplasia, 
multifocal, 
bone marrow 
1        
 
Erythroid 
hyperplasia, 
bone marrow 
  
 
 
1      
Granulocytic 
hyperplasia, 
bone marrow    
3     
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Table 6: Top up- and down-regulated categories from Trim24-/- vs. Trim24+/+ 
RNA-seq 
 
Trim24-/- vs. Trim24+/+  top 5 (by p-value) up-regulated categories with 
associated genes 
   
Protein folding: HSP90AB1, HSP90AA1, FKBP4, AARS, HSPH1, HSP90B1, 
DNAJC16, DNAJB9, DNAJB11, DNAJA1, HSPA4L, HSPE1, DNAJB1, DNAJB4, 
AHSA1 
 
Defense response: CXCL1, B4GALT1, PTPRC, MBL2, IFIH1, IRGM1, LYZ2, 
IL1R1, C4A, COLEC10, IFI47, B2M, DDX58, TNFRSF1A, SERPINA3N, SAA2, 
SAA1, BCL3, CLEC2H, MX2, ORM2, H47 
 
mRNA metabolic process: TXNL4B, APOBEC1, PRPF4B, CRNKL1, PNPT1, 
DDX5, WBP4, SF3B3, PNN, DNAJB11, SNRPA, HNRNPC, PRPF38B, RBM25, 
ADAR, TXNL4A 
 
Regulation of cell cycle: PTPRC, E2F4, ROCK2, ESR1, JUNB, CDKN1A, CCND1, 
YWHAH, CCND3, JUN, B230120H23RIK, MDM2, SIK1 
 
EndR-nuclear signaling pathway: CCND1, AARS, HSPA5, NFE2L2, EIF2AK3 
 
Trim24-/- vs. Trim24+/+  top 5 (by p-value) down-regulated categories with 
associated genes 
 
Oxidation Reduction: CYB5R3, ACOX2, TM7SF2, SC5D, D2HGDH, ALDH1L1, 
UQCRC1, HIBADH, TDO2, AKR1C6, SRD5A1, PDHA1, NQO2, HPD, CYP2C54, 
CYP2D22, CYP2C29, QDPR, DECR2, CYP1A2, CYP2E1, ACADL, CDO1, 
CYP27A1, ALDH9A1, PRODH, ME1, CYP51, HSD3B3, CYP3A25, HSD17B2, 
HSD3B7, FDX1, HSD3B5, CYP2C40, ALDH3A2, ALDH1A1, FASN, HAAO, NSDHL, 
NOX4, BCKDHA, SCD1, CYP2C37, IDO2, CRYZ, PHYH, RDH11, SDHB, 
AKR1C19, PRODH2, CYP8B1, RDH16, CYP2C38, CYP2C39  
 
Steroid Metabolic Process: CYB5R3, TM7SF2, CYP51, HSD3B3, SC5D, 
HSD17B2, HSD3B7, 0610007P14RIK, HSD3B5, STAT5B, SLC37A4, APOA2, 
INSIG2, AKR1C6, SRD5A1, SCARB1, NSDHL, SOAT2, FDPS, SCAP, EBPL, 
HMGCS2, SULT1B1, PON1, LIPC, SLC27A5  
 
Lipid biosynthetic process: TM7SF2, CYB5R3, CYP51, HSD3B3, SC5D, 
HSD17B2, SGMS2, HSD3B7, 0610007P14RIK, HSD3B5, ALDH1A1, INSIG2, 
ELOVL5, AKR1C6, ELOVL3, ELOVL2, FASN, SCARB1, SRD5A1, ETNK2, 
AGPAT2, NSDHL, SCD1, FDPS, ACACB, LPCAT3, CHPT1, ACSM3, HMGCS2, 
RDH16, GPAM  
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Table 6: Top up- and down-regulated categories from Trim24-/- vs. Trim24+/+ 
RNA-seq (continued)  
 
Fatty acid metabolic process: SCD1, ACOX2, HACL1, SC5D, ECH1, CYP2D22, 
STAT5B, ADIPOR2, ACACB, ACADL, PHYH, ACSM3, APOA2, ELOVL5, ELOVL3, 
ELOVL2, FASN, ACOT12, LIPC, AACS, ACAA1B, GPAM, SLC27A2, SLC27A5   
 
Steroid biosynthetic process: TM7SF2, CYB5R3, CYP51, HSD3B3, SC5D, 
HSD17B2, HSD3B7, 0610007P14RIK, HSD3B5, FDPS, HMGCS2, INSIG2, 
AKR1C6, SRD5A1, SCARB1 
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Table 7: Lipid and Inflammatory genes activated and repressed in Trim24-/- 
Repressed in Trim24-/-, Activated in Trim24-/-, No change = no significant change 
compared to WT, * Data not shown.  
Category Gene 
Fold change 
at 3 weeks 
Fold change 
at 10 weeks 3 weeks  10 week  
Lipases Lpl 2.86 fold 1.07 fold Activated No change 
 Pnpla3 2.03 fold  4.34 fold  Activated Activated 
 Pnlip 1.64 fold 8.31 fold Repressed Activated   Pnlprp1 1.55 fold 18.09 fold Activated Activated 
Lipid Transport 
Receptors Apobr 1.81 fold 1.83 fold Activated Activated 
Pro-inflammatory 
Factors Ccr2 2.76 fold 1.94 fold Activated Activated 
 Il-33 1.73 fold 2.14 fold Activated Activated  
  Icam1  Vcam1 
1.29 fold           
1.95 fold 
2.46 fold 
1.78 fold 
No change 
Activated 
Activated  
No change 
De Novo Lipid 
Synthesis Acaca 2.19 fold 1.09 fold Repressed Repressed 
 Acacb 10.71 fold 2.76 fold Repressed Repressed 
 Acss3 1.88 fold 2.28 fold Repressed Repressed 
 Fasn 38.17 fold 1.28 fold Repressed Repressed 
 Mcat 1.57 fold 1.41 fold Repressed Repressed 
 Me1 2.46 fold 2.28 fold Repressed Repressed 
  Scd1 22.39 fold 4.55 fold Repressed Repressed 
Lipid Storage Apoa1 1.26 fold 1.87 fold  Activated Repressed 
 Apoa5 1.67 fold 1.35 fold Repressed Repressed 
 
Apob 2.63 fold 1. fold Repressed Repressed 
 
Apoc1 .99 fold  1.36 fold No change Repressed 
 
Apoc2  1.38 fold 1.10 fold Repressed No change 
 
Apoc3 2.26 fold 1.50 fold Repressed Repressed 
  Apod 2.06 fold 3.33 fold Activated Repressed 
Lipid Secretion Plin2 2.20 fold 1.52 fold Repressed Repressed 
 
Plin3 2.31 fold 1.58 fold Repressed Repressed 
  Plin5 1.11 fold 2.59 fold No change Repressed 
Lipid 
Transport/Receptors Mttp 12.11 fold 1.66 fold Repressed Repressed 
 
Vldlr 1.79 fold 3.61 fold  Activated Repressed 
 
Ldlr 3.34 fold 2.19 fold Repressed No change 
  Ces1d 1.47 fold 2.75 fold Repressed Repressed 
β-oxidation* Acaa1 1.23 fold  2.01 fold  No change Repressed 
 
Acot1 4.08 fold  23.44 fold  Repressed Repressed 
 
Acox1 2.03 fold  1.93 fold Repressed No change 
 Hsd17b6 2.20 fold  2.91 fold  Repressed Activated 
 
Nox4 1.05 fold  2.34 fold  No change Repressed 
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Table 8: Comparison of phenotypic characteristics in DE4 and DE1 Trim24-/- 
mice 
                   Trim24dlE4/ dlE4 mice1            Trim24dlE1/ dlE1 mice 
 
1-5 wk  Alterations in retinoic 
responsive gene expression:Crbp1, 
Stra6, Tgm2 (3 wk – no change, 10 wk 
– upregulated), and Cyp26a1 (3 wk-
upregulated, 10 wk –upregulated). 
3 wk, 10 wk Alterations in retinoic 
responsive gene expression:  Crbp1 (3 
wk –downregulated, 10 wk – 
upregulated), Stra6 (3 wk and 10 wk – 
no significant change), Tgm2 (3 wk – 
no change, 10 wk – upregulated), and 
Cyp26a1 (3 wk, 10 wk – no significant 
change). 
2 wk No reported change in hepatic 
steatosis phenotype 
2 wk Phenotype observed -first 
evidence of hepatic steatosis 
14 wk Increased hepatocellular 
proliferation  
10 wk Increase in hepatocellular 
proliferation 
2M, 3M  No steatosis/damage 
reported, no changes in peripheral fat 
accumulation reported. No data 
regarding ALT/AST levels.  Changes in 
hepatic expression of inflammation 
pathway genes, controlled by RAR-α.   
Acot1 – lipid metabolism gene, 
downregulated in Trim24-/- , no other 
fat/lipid metabolism genes 
misregulated (RNA-seq) 
 
3 wk, 10 wk (2M) Misregulated gene 
expression in fat/lipid metabolism and 
transport pathways, evidence of 
hepatic steatosis and damage. 
Histological changes consistent with 
NASH, increased hepatocyte apoptosis 
and inflammation. ALT/AST levels 
indicative of liver damage. 
3M Abnormal hypertrophic 
hepatocytes, enlarged nuclei 
2M Abnormal hypertrophic hepatocytes 
with enlarged nuclei  
4-6M No reported hepatic lipid 
accumulation, peripheral fat 
accumulation, or persistent fibrosis. 
4-6 M Marked hepatic lipid 
accumulation, peripheral fat 
accumulation is less than WT. 
Persistent fibrosis. 
7-8M Clear cell foci of altered 
hepatocytes (FCA) 13% 
7-8 M Hepatic fibrotic changes with 
FCA 
9M 53% HCA, 12M 20% HCC, 13-19 M 
41% HCC, 19-29 M 80% HCC 
9-21M 26% HCA, 33% HCC with HCA, 
22% HCC without HCA, 19% Other 
9-29 M No change in pancreas, spleen, 
intestine, testis, uterus, 80% male have 
hepatic tumors, 69% female have hepatic 
tumors, Mets to the lung (n=2) 
(3M) Calcification reported 100% in kidney 
and tongue, 6% in brown fat, 13% in snout 
dermis, 20% in heart, 30% in retina, and 
65% in thyroid 
 
9-21M Abnormalities reported in lungs, 
kidneys, spleen, and heart.  No 
abnormalities reported in pancreas, 
intestine, testis.100% hepatic tumors. 
Hyperplasia reported in uterus. No mets(9-
21M)Calcification/mineralization reported 
in kidney, tongue, skeletal muscle, lung, 
heart, mammary gland 
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Table 9: Trim24 variants and predicted products upon deletion of E4 
 
Trim24 Variant 1  
 
1   ggtggtccaa ggggcccgag agaaaggctg ctaggcacgg gcgggcgcgc tgggcggaat        
 61  cgagcgtctc ggtggcggtt tgcctatcgg cccgcgcggc ggcgtcgcgg tgcgggaacc        
121 ggtccccgtt gacagctccg cgtcttccgg ccgcgccact cgggaggtgg cttcctccct        
181 gtgctccctc cgcgagtccg ttcggcctcg gagaagcggg aggcggcggc ggctgcggag        
241 gtcgtcgggg gcggcgggcg gtgagcgcgc tcccgcttcc ccggcggcgg ccgcaggaca        
301 atggaggtgg ctgtggagaa ggcggcggcg gcagcggctc cggccggagg ccccgcagcg        
361 gcggcgccga gcggggagaa tgaggccgag agccggcagg gcccggactc ggagagcggc        
421 ggcgaggcgt cccggctcaa cctgttggac acttgcgccg tgtgccacca gaacatccag        
481 agccgggtgc ccaagctgct gccctgcctg cactcgttct gccagcgctg tttgcccgcg        
541 ccgcagcgct atctcatgct gacggcgccc gcgctgggct cggcagagac ccctccaccc        
601 gctcccgccc ccgcccccgc cccgggctcc ccggccggtg gtccttcgcc attcgccacc        
661 caagttggag tcattcgatg cccagtttgc agtcaagagt gtgctgagag acacatcata        
721 gacaactttt ttgtgaagga caccactgaa gttcctagta gtacagtaga aaagtctaat        
781 caggtatgta caagctgtga agacaatgca gaagctaatg ggttttgtgt agagtgtgtt        
841 gaatggctct gcaagacatg tattagagct caccagaggg tgaagttcac aaaagaccac        
901 acagtcaggc agaaagaaga agtatctcca gaggcagttg gggtgaccag tcagcgacca       
 961 gtgttttgtc ccttccataa aaaggagcag ttgaaacttt actgtgaaac atgtgataaa       
1021 ctgacctgtc gagactgcca gctgctagaa cacaaagaac acaggtatca atttatagaa      
 1081 gaagcttttc agaatcaaaa agtgatcata gatactctaa tcaccaaact gatggaaaaa       
1141 acaaaatata taaagtatac aggaaatcag atccaaaata g   
 
Trim24 Variant 1 with E4 deletion  
 
1   ggtggtccaa ggggcccgag agaaaggctg ctaggcacgg gcgggcgcgc tgggcggaat         
61  cgagcgtctc ggtggcggtt tgcctatcgg cccgcgcggc ggcgtcgcgg tgcgggaacc       
 121 ggtccccgtt gacagctccg cgtcttccgg ccgcgccact cgggaggtgg cttcctccct        
181 gtgctccctc cgcgagtccg ttcggcctcg gagaagcggg aggcggcggc ggctgcggag        
241 gtcgtcgggg gcggcgggcg gtgagcgcgc tcccgcttcc ccggcggcgg ccgcaggaca        
301 atggaggtgg ctgtggagaa ggcggcggcg gcagcggctc cggccggagg ccccgcagcg        
361 gcggcgccga gcggggagaa tgaggccgag agccggcagg gcccggactc ggagagcggc        
421 ggcgaggcgt cccggctcaa cctgttggac acttgcgccg tgtgccacca gaacatccag        
481 agccgggtgc ccaagctgct gccctgcctg cactcgttct gccagcgctg tttgcccgcg       
 541 ccgcagcgct atctcatgct gacggcgccc gcgctgggct cggcagagac ccctccaccc        
601 gctcccgccc ccgcccccgc cccgggctcc ccggccggtg gtccttcgcc attcgccacc        
661 caagttggag tcattcgatg cccagtttgc agtcaagagt gtgctgagag acacatcata        
721 gacaactttt ttgtgaagga caccactgaa gttcctagta gtacagtaga aaagtctaat        
781 caggtatgta caagctgtga agacaatgca gaagctaatg ggttttgtgt agagtgtgtt        
841 gaatggctct gcaagacatg tattagagct caccagaggg tgaagttcac aaaagaccac        
901 acagtcaggc agaaagaaga agtatctcca gtatca atttatagaa       
1081 gaagcttttc agaatcaaaa agtgatcata gatactctaa tcaccaaact gatggaaaaa       
1141 acaaaatata taaagtatac aggaaatcag atccaaaata g  
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Table 9: Trim24 variants and predicted products upon deletion of E4 
(continued) 
 
Trim24 Variant 3  
 
1   gacctatcat gcagtctcac cacttggtag ttgtactttg gagacccagc ctttaacagg         
61  ggcaccttgg gggccactag ctattcaact atggcagata tttttgatta cacttttatc        
121 ggtgggtgtg gagatgcttg tcccacatgc gcatgtggaa gtcagaggat aacttggaaa        
181 agtcagttct ttccatcctg tgttcgtccc atggataaaa ctgctgtcac tggtgatgag        
241 caagttggag tcattcgatg cccagtttgc agtcaagagt gtgctgagag acacatcata       
 301 gacaactttt ttgtgaagga caccactgaa gttcctagta gtacagtaga aaagtctaat        
361 caggtatgta caagctgtga agacaatgca gaagctaatg ggttttgtgt agagtgtgtt       
 421 gaatggctct gcaagacatg tattagagct caccagaggg tgaagttcac aaaagaccac        
481 acagtcaggc agaaagaaga agtatctcca gaggcagttg gggtgaccag tcagcgacca       
 541 gtgttttgtc ccttccataa aaaggagcag ttgaaacttt actgtgaaac atgtgataaa       
 601 ctgacctgtc gagactgcca gctgctagaa cacaaagaac acaggtatca atttatagaa       
 661 gaagcttttc agaatcaaaa agtgatcata gatactctaa tcaccaaact gatggaaaaa        
721 acaaaatata taaagtatac aggaaatcag atccaaaata g    
 
 
 
Trim24 Variant 3 with E4 deletion  
 
1   gacctatcat gcagtctcac cacttggtag ttgtactttg gagacccagc ctttaacagg         
61  ggcaccttgg gggccactag ctattcaact atggcagata tttttgatta cacttttatc        
121 ggtgggtgtg gagatgcttg tcccacatgc gcatgtggaa gtcagaggat aacttggaaa        
181 agtcagttct ttccatcctg tgttcgtccc atggataaaa ctgctgtcac tggtgatgag        
241 caagttggag tcattcgatg cccagtttgc agtcaagagt gtgctgagag acacatcata       
 301 gacaactttt ttgtgaagga caccactgaa gttcctagta gtacagtaga aaagtctaat       
 361 caggtatgta caagctgtga agacaatgca gaagctaatg ggttttgtgt agagtgtgtt        
421 gaatggctct gcaagacatg tattagagct caccagaggg tgaagttcac aaaagaccac        
481 acagtcaggc agaaagaaga agtatctcca gtatca atttatagaa        
661 gaagcttttc agaatcaaaa agtgatcata gatactctaa tcaccaaact gatggaaaaa        
721 acaaaatata taaagtatac aggaaatcag atccaaaata g    
 
Key: 
 
Variant 1:      
E1 – 301-664 (from start site), E2 – 665-783, E3 – 784-931, E4 – 932-1064,  
E5 – 1065-1181 Splice site Stop codon  
 
Variant 3: 
E1 – 91-244  (from start site), E2 – 245-363, E3 – 364-511, E4 – 512-644,  
E5 – 645-761 Splice site Stop codon 
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Table 14. Flow Cytometry Antibodies 
 
 
Antibody/Cell Surface 
Marker 
 
Target 
 
Compnay 
CD45*- PB Hematopoietic cells eBioscience 
Ly6G (Gr1)- FITC Lymphoid lineage eBioscience 
F4/80- Precp Macrophages eBioscience 
Cd11b-PE Myeloid lineage eBioscience 
Cd11c-PE-Cy7 Dendritic cells eBioscience 
Cd3-APC-Cy7 T cells eBioscience 
B220 -APC B cells Becton Dickson 
 
*Not included in analysis of bone marrow cells  
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Table 15. CyTOF Antibodies  
 
*Currently validating for future experiments 
 
Antibody/Cell 
Surface Marker 
 
Target 
 
Company 
CD45 Hematopoietic cells DVS  
Ly6G (Gr1) Lymphoid lineage DVS  
Cd11b Myeloid lineage DVS  
Cd11c Dendritic cells DVS 
*F4/80 Macrophages Biolegend 
*Arg1 M2 Macrophages Biolegend 
*Cd14 Monocytes/Macrophages/Dendritic 
cells/Neutrophils 
Biolegend 
B220  B cells DVS  
Cd3 T cells eBioscience 
Cd45RA Lymphocyte DVS 
Cd117 Hematopoietic cells DVS 
Cyclin D Cell Cycle BD Biosciences 
IFNγ M2 Macrophages DVS 
pRB Cell Cycle BD Biosciences 
TRIM24/28 - Proteintech 
p53 - Biolegend 
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Appendix 1: Solutions for ChIP  
 
2X SM2 Buffer  
0.5M Sucrose/Dextrose (Sigma/Fisher) 
80mM KCl (Fisher) 
20mM HEPES (pH 7.9)  (Fisher) 
6mM CaCl (Sigma) 
H20 (to 5 mL)  
 
10X EDTA/EGTA Stop Solution 
0.5M EDTA (Fisher) 
0.1M EGTA (Sigma) 
H20 (to 1 mL) 
 
Cell Lysis buffer 
5mM PIPES pH 8.0 (Sigma) 
85mM KCl  (Fisher) 
0.5% NP40 (Fluka) 
PI’s (fresh) (Sigma) 
H2O (to 10 mL) 
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Appendix 1: Solutions for ChIP (continued)  
Nuclei Lysis Buffer 
50mM Tris-Cl pH 8.1 (Fisher) 
10mM EDTA (Fisher) 
1% SDS  (Bio Rad) 
PI’s (fresh) (Sigma) 
H20 (to 10 mL) 
 
Lysis Buffer  
150mM NaCl (Fisher) 
25mM Tris pH 7.5 (Fisher) 
5mM EDTA (Fisher) 
1% Triton X 100 (Fisher) 
0.1% SDS (Bio Rad) 
0.5% Deoxycholate (Fisher) 
PI’s (fresh) (Sigma) 
H2O (to 10 mL)  
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High Salt Buffer (see previous for manufacturers) 
50mM Tris pH 8.0  
500mM NaCl  
0.1% SDS  
0.5% Deoxycholate  
1% NP40 
1mM EDTA  
PI’s (fresh) 
H2O (to 10 mL) 
 
RIPA (see previous for manufacturers) 
50mM Tris pH 8.0  
150mM NaCl  
0.1% SDS  
0.5% Deoxycholate  
1% NP40  
1mM EDTA  
PI’s (fresh) 
H2O (to 10 mL) 
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LiCl Wash 
50mM Tris pH 8.0  
1mM EDTA  
250mM LiCl (Fisher) 
1% NP40 
0.5% Deoxycholate   
PI’s (fresh) 
H2O (to 10 mL) 
 
 
TE Buffer  
10 mM Tris-HCL pH 7.5  
1 mM EDTA pH 8.0  
H2O (to 500 mL) 
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